[go: up one dir, main page]

WO2024098180A1 - Compositions pharmaceutiques comprenant des anticorps anti-récepteur tslp humain et leurs procédés d'utilisation - Google Patents

Compositions pharmaceutiques comprenant des anticorps anti-récepteur tslp humain et leurs procédés d'utilisation Download PDF

Info

Publication number
WO2024098180A1
WO2024098180A1 PCT/CN2022/130252 CN2022130252W WO2024098180A1 WO 2024098180 A1 WO2024098180 A1 WO 2024098180A1 CN 2022130252 W CN2022130252 W CN 2022130252W WO 2024098180 A1 WO2024098180 A1 WO 2024098180A1
Authority
WO
WIPO (PCT)
Prior art keywords
mmol
pharmaceutical composition
seq
sequence
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2022/130252
Other languages
English (en)
Inventor
Parika PETAIPIMOL
Robert Patrick GEARING
Bingquan Wang
Geng Li
Jeremy GUO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wuxi Biologics Hong Kong Ltd
Upstream Bio Inc
Original Assignee
Wuxi Biologics Hong Kong Ltd
Upstream Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wuxi Biologics Hong Kong Ltd, Upstream Bio Inc filed Critical Wuxi Biologics Hong Kong Ltd
Priority to PCT/CN2022/130252 priority Critical patent/WO2024098180A1/fr
Priority to JP2025526206A priority patent/JP2025538151A/ja
Priority to PCT/US2023/078873 priority patent/WO2024102675A1/fr
Priority to AU2023375895A priority patent/AU2023375895A1/en
Priority to US18/503,245 priority patent/US12150991B2/en
Priority to EP23889566.8A priority patent/EP4615502A1/fr
Priority to TW112142818A priority patent/TW202432601A/zh
Priority to ARP230102991A priority patent/AR130993A1/es
Priority to KR1020257018074A priority patent/KR20250120995A/ko
Priority to CN202380090775.XA priority patent/CN120548195A/zh
Publication of WO2024098180A1 publication Critical patent/WO2024098180A1/fr
Priority to US18/916,566 priority patent/US20250064929A1/en
Priority to IL320555A priority patent/IL320555A/en
Priority to MX2025005271A priority patent/MX2025005271A/es
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Definitions

  • the embodiments provided herein relate to antibodies, and fragments thereof, that bind to the thymic stromal lymphopoietin receptor (TSLP-R) , and pharmaceutical compositions comprising the same.
  • TLP-R thymic stromal lymphopoietin receptor
  • Thymic stromal lymphopoietin is a cytokine derived from epithelium cells that is produced in response to pro-inflammatory stimuli, and it is involved in dendritic cell mediated Th2 cell activation and interacts with the TSLP receptor (TSLP-R) . It has been reported that TSLP-mediated activation of the dendritic cells through the TSLP-R is involved in various disease pathologies, including allergic inflammation and chronic obstructive pulmonary disease, autoimmune diseases and rheumatic diseases, cancer, coronary artery disease, and myocardial infarction.
  • a monoclonal antibody that specifically binds to human TSLP-R and inhibits the action of human TSLP through human TSLP-R is useful for preventing and treating various diseases in which human TSLP and human TSLP-R are involved in the disease pathology.
  • the disclosed embodiments are directed towards antibodies, or antibody fragments thereof, that specifically bind to TSLP-R, and pharmaceutical compositions that contain antibodies, and fragments thereof, that are specific for TSLP-R.
  • Embodiments provided herein are directed to pharmaceutical compositions comprising anti-TSLP-R antibodies, or antigen-binding fragments thereof.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) a pharmaceutically acceptable buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) an excipient at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) a pharmaceutically acceptable buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) a pharmaceutically acceptable buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) a pharmaceutically acceptable buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 150 mg/mL to about 250 mg/mL; (ii) histidine buffer at a concentration of about 10 mmol/L to about 30 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 200 mmol/L; and (iv) polysorbate 80 at a concentration of about 0.01-0.2% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 150 mg/mL to about 250 mg/mL; (ii) histidine buffer at a concentration of about 10 mmol/L to about 30 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 150 mmol/L; and (iv) polysorbate 80 at a concentration of about 0.01-0.2% (w/v) .
  • the pharmaceutical composition comprises: (i) anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 150 mg/mL to about 250 mg/mL; (ii) histidine buffer at a concentration of about 10 mmol/L to about 30 mmol/L; (iii) proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 220 mmol/L; and (iv) polysorbate 80 at a concentration of about 0.01-0.2% (w/v) .
  • the pharmaceutical composition comprises: (i) anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 180 mg/mL to about 220 mg/mL; (ii) histidine buffer at a concentration of about 18 mmol/L to about 22 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 160 mmol/L to about 200 mmol/L; (iv) polysorbate 80 at a concentration of about 0.01-0.05% (w/v) , and (v) a pH of about 5.6 to 5.8, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence
  • the pharmaceutical composition comprises: (i) anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 135 mg/mL to about 165 mg/mL; (ii) histidine buffer at a concentration of about 18 mmol/L to about 22 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 160 mmol/L to about 200 mmol/L; (iv) polysorbate 80 at a concentration of about 0.01-0.05% (w/v) , and (v) a pH of about 5.6 to 5.8, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3
  • the pharmaceutical composition comprises: (i) anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 180 mg/mL to about 220 mg/mL; (ii) histidine buffer at a concentration of about 18 mmol/L to about 22 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 105 mmol/L to 135 mmol/L; (iv) polysorbate 80 at a concentration of about 0.01-0.05% (w/v) , and (v) a pH of about 5.6 to 5.8, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3
  • the pharmaceutical composition comprises: (i) anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 135 mg/mL to about 165 mg/mL; (ii) histidine buffer at a concentration of about 18 mmol/L to about 22 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 105 mmol/L to 135 mmol/L; (iv) polysorbate 80 at a concentration of about 0.01-0.05% (w/v) , and (v) a pH of about 5.6 to 5.8, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR
  • the pharmaceutical composition comprises: (i) anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 180 mg/mL to about 220 mg/mL; (ii) histidine buffer at a concentration of about 18 mmol/L to about 22 mmol/L; (iii) proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 160 mmol/L to about 200 mmol/L; (iv) polysorbate 80 at a concentration of about 0.01-0.05% (w/v) , and (v) a pH of about 5.6 to 5.8, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the
  • the pharmaceutical composition comprises: (i) anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 135 mg/mL to about 165 mg/mL; (ii) histidine buffer at a concentration of about 18 mmol/L to about 22 mmol/L; (iii) proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 160 mmol/L to about 200 mmol/L; (iv) polysorbate 80 at a concentration of about 0.01-0.05% (w/v) , and (v) a pH of about 5.6 to 5.8, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 200 mg/mL; (ii) histidine buffer at a concentration of about 20 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 180 mmol/L; (iv) polysorbate 80 at a concentration of about 0.03% (w/v) ; and (v) a pH of about 5.7, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 200 mg/mL; (ii) histidine buffer at a concentration of about 20 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 180 mmol/L; (iv) polysorbate 80 at a concentration of about 0.02% (w/v) ; and (v) a pH of about 5.7, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 150 mg/mL; (ii) histidine buffer at a concentration of about 20 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 180 mmol/L; (iv) polysorbate 80 at a concentration of about 0.03% (w/v) ; and (v) a pH of about 5.7, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 150 mg/mL; (ii) histidine buffer at a concentration of about 20 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 180 mmol/L; (iv) polysorbate 80 at a concentration of about 0.02% (w/v) ; and (v) a pH of about 5.7, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 200 mg/mL; (ii) histidine buffer at a concentration of about 20 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 120 mmol/L; (iv) polysorbate 80 at a concentration of about 0.04% (w/v) ; and (v) a pH of about 5.7, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 200 mg/mL; (ii) histidine buffer at a concentration of about 20 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 120 mmol/L; (iv) polysorbate 80 at a concentration of about 0.03% (w/v) ; and (v) a pH of about 5.7, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 200 mg/mL; (ii) histidine buffer at a concentration of about 20 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 120 mmol/L; (iv) polysorbate 80 at a concentration of about 0.02% (w/v) ; and (v) a pH of about 5.7, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 150 mg/mL; (ii) histidine buffer at a concentration of about 20 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 130 mmol/L; (iv) polysorbate 80 at a concentration of about 0.02% (w/v) ; and (v) a pH of about 5.7, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 150 mg/mL; (ii) histidine buffer at a concentration of about 20 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 120 mmol/L; (iv) polysorbate 80 at a concentration of about 0.04% (w/v) ; and (v) a pH of about 5.7, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 150 mg/mL; (ii) histidine buffer at a concentration of about 20 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 120 mmol/L; (iv) polysorbate 80 at a concentration of about 0.03% (w/v) ; and (v) a pH of about 5.7, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 150 mg/mL; (ii) histidine buffer at a concentration of about 20 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 120 mmol/L; (iv) polysorbate 80 at a concentration of about 0.02% (w/v) ; and (v) a pH of about 5.7, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 200 mg/mL; (ii) histidine buffer at a concentration of about 20 mmol/L; (iii) proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 180 mmol/L; (iv) polysorbate 80 at a concentration of about 0.03% (w/v) ; and (v) a pH of about 5.7, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain CDR
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 200 mg/mL; (ii) histidine buffer at a concentration of about 20 mmol/L; (iii) proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 180 mmol/L; (iv) polysorbate 80 at a concentration of about 0.02% (w/v) ; and (v) a pH of about 5.7, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain CDR
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 150 mg/mL; (ii) histidine buffer at a concentration of about 20 mmol/L; (iii) proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 180 mmol/L; (iv) polysorbate 80 at a concentration of about 0.03% (w/v) ; and (v) a pH of about 5.7, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain CDR
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 150 mg/mL; (ii) histidine buffer at a concentration of about 20 mmol/L; (iii) proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 180 mmol/L; (iv) polysorbate 80 at a concentration of about 0.02% (w/v) ; and (v) a pH of about 5.7, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain CDR
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 150 mg/mL; (ii) histidine buffer at a concentration of about 20 mmol/L; (iii) proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 200 mmol/L; (iv) polysorbate 80 at a concentration of about 0.03% (w/v) ; and (v) a pH of about 5.7, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain CDR
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a dose of 0.03 mg/kg to 10 mg/kg; and optionally:
  • a pharmaceutically acceptable buffer at a concentration of about 5 mmol/L to about 100 mmol/L;
  • an excipient at a concentration of about 1 mmol/L to about 600 mmol/L; and
  • a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a dose of 0.03 mg/kg to 10 mg/kg; (ii) histidine buffer at a concentration of 18 mmol/L to 22 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of 160 mmol/L to 200 mmol/L; (iv) polysorbate 80 at a concentration of 0.01% (w/v) to 0.05% (w/v) ; and (v) a pH of about 5.6 to 5.8, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a dose of 0.03 mg/kg to 10 mg/kg; (ii) histidine buffer at a concentration of about 20 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 180 mmol/L; (iv) polysorbate 80 at a concentration of about 0.03% (w/v) ; and (v) a pH of about 5.7, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a dose of 0.03 mg/kg to 10 mg/kg; (ii) histidine buffer at a concentration of 18 mmol/L to 22 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of 105 mmol/L to 135 mmol/L; (iv) polysorbate 80 at a concentration of 0.01% (w/v) to 0.05% (w/v) ; and (v) a pH of about 5.6 to 5.8, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a dose of 0.03 mg/kg to 10 mg/kg; (ii) histidine buffer at a concentration of about 20 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 120 mmol/L; (iv) polysorbate 80 at a concentration of about 0.03% (w/v) ; and (v) a pH of about 5.7, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a dose of 0.03 mg/kg to 10 mg/kg; (ii) histidine buffer at a concentration of 18 mmol/L to 22 mmol/L; (iii) proline, or a pharmaceutically acceptable salt thereof, at a concentration of 160 mmol/L to 200 mmol/L; (iv) polysorbate 80 at a concentration of 0.01% (w/v) to 0.05% (w/v) ; and (v) a pH of about 5.6 to 5.8, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a dose of 0.03 mg/kg to 10 mg/kg; (ii) histidine buffer at a concentration of about 20 mmol/L; (iii) proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 180 mmol/L; (iv) polysorbate 80 at a concentration of about 0.03% (w/v) ; and (v) a pH of about 5.7, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising
  • a pharmaceutical dosage form of the pharmaceutical composition is provided herein.
  • the pharmaceutical dosage form comprises the pharmaceutical composition in a container.
  • kits are provided herein.
  • the kit comprises the pharmaceutical composition as disclosed herein and instructions for use.
  • the kit additionally comprises a pharmaceutical dosage form of the pharmaceutical composition, wherein the pharmaceutical dosage form comprises the pharmaceutical composition in a container.
  • the container is a pre-filled syringe, a plastic vial or a glass vial.
  • a method of treating a disease in a subject in need thereof comprises administering a therapeutically effective amount of the pharmaceutical composition or the pharmaceutical dosage form of the pharmaceutical composition as disclosed herein.
  • a method of treating and reducing the severity of a disease in a subject in need thereof comprises administering a therapeutically effective amount of the pharmaceutical composition or the pharmaceutical dosage form of the pharmaceutical composition.
  • a method of delaying the onset of a disease in a subject in need thereof comprises administering a therapeutically effective amount of the pharmaceutical composition or the pharmaceutical dosage form of the pharmaceutical composition.
  • a method of preventing a disease in a subject in need thereof comprises administering a therapeutically effective amount of the pharmaceutical composition or the pharmaceutical dosage form of the pharmaceutical composition.
  • a method of increasing the internalization of TSLP-R on a cell comprises contacting the cell with the pharmaceutical composition or the pharmaceutical dosage form of the pharmaceutical composition.
  • a method of inhibiting TSLP-R on a cell comprises contacting the cell with the pharmaceutical composition or the pharmaceutical dosage form of the pharmaceutical composition.
  • a method of inhibiting TSLP-R by at least 95%, 96%, 97%, 98%, or 99%or by 100%in a subject in need thereof comprises administering the pharmaceutical composition or the pharmaceutical dosage form of the pharmaceutical composition.
  • FIGs. 1A-1B Data depicting that TRAB-1 produces potent suppression of TSLP/TSLP-R-mediated responses in vitro.
  • FIG. 1A Chart depicting cell proliferation rates in Ba/F3 cells transfected with human TSLPR/IL-7R ⁇ and treated with either TRAB-1 antibody, tezepelumab antibody, or IgG antibody, plotted as a function of the concentration of the antibody concentration.
  • FIG. 1B Bar graph depicting CCL17 (ng/mL) production in dendritic cells treated with TRAB-1 antibody, tezepelumab antibody, or IgG antibody, plotted as a function of the concentration of the antibody concentration.
  • FIGs. 2A-2C Data depicting that single ascending dose (SAD) studies in healthy volunteers demonstrated sustained pharmacokinetics (PK) effect over 60 days.
  • FIG. 2B Graph depicting predicted mean serum concentration of TRAB-1 over time, as a function of dose of TRAB-1 administered subcutaneously every 4 weeks.
  • FIG. 2C Graph depicting predicted mean serum concentration of TRAB-1 over time, as a function of dose of TRAB-1 administered subcutaneously every 12 weeks.
  • FIGs. 3A-3B Data depicting that reduction of eosinophils was evident after a single dose of TRAB-1 in healthy volunteers.
  • FIG. 3A Graph depicting eosinophil concentrations in healthy volunteers treated with greater than or equal to 20 mg (0.3mg/kg) of TRAB-1, as a function of time. Groups were chosen based on eosinophil concentrations at day 0: ⁇ 150 cells/ ⁇ L; and >150 cells/ ⁇ L.
  • FIG. 3B Graph depicting eosinophil concentrations in healthy volunteers treated with greater than or equal to 20 mg (0.3mg/kg) of TRAB-1, as a function of time, compared to the placebo group.
  • FIGs. 4A-4B Data depicting an indication of pharmacokinetics/pharmacodynamics correlation in healthy volunteers treated with single ascending dose of TRAB-1.
  • FIG. 4A Pharmacokinetics curves depicting serum mean TRAB-1 as a function of time in healthy volunteers treated with 2 mg, 7mg, 20 mg, 70mg, 210mg, or 700 mg of TRAB-1.
  • FIG. 4B Pharmacodynamics curves depicting eosinophils as a function of time in healthy volunteers treated with 2 mg and 7mg, or 20 mg and 70mg of TRAB-1.
  • antibodies or antigen-binding fragments thereof, that bind and modulate the activity of TSLP-R.
  • an animal means one animal or more than one animal.
  • the term “including but not limited to” is inclusive or open-ended and does not exclude additional, unrecited elements or method steps. While various compositions, and methods are described in terms of “comprising” various components or steps (interpreted as meaning “including, but not limited to” ) , the compositions, methods, and devices can also “consist essentially of” or “consist of” the various components and steps, and such terminology should be interpreted as defining essentially closed-member groups.
  • antibody refers to any form of antibody that exhibits the desired biological activity. Thus, it is used in the broadest sense and specifically covers, but is not limited to, monoclonal antibodies (including full length monoclonal antibodies) , polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies) , humanized antibodies, fully human antibodies, chimeric antibodies, and camelized single domain antibodies. Another word for antibody is “immunoglobulin. ” An antibody can immunospecifically bind to one or more epitope or antigen-binding site. As used herein, the assignment of amino acids to each domain within an antibody is in accordance with the Kabat numbering system.
  • antibody fragment or “antigen-binding fragment” refers to antigen-binding fragments of antibodies, i.e. antibody fragments that retain the ability to bind specifically to the antigen bound by the full-length antibody, e.g. fragments that retain one or more CDR regions.
  • antibody binding fragments include, but are not limited to, Fab, Fab', F (ab') 2, and Fv fragments; diabodies; linear antibodies; single-chain antibody molecules, e.g., sc-Fv; nanobodies and multispecific antibody fragments.
  • antigen means any molecule that has the ability to generate antibodies either directly or indirectly.
  • An “antigen” can also refer to the binding partner of an antibody, or fragment thereof. Included within the definition of “antigen” is a protein-encoding nucleic acid.
  • epitopes and “antigen-binding site” are meant to refer to that portion of any molecule capable of being recognized by and bound by an antibody, or fragment thereof, at one or more of the Ab’s antigen-binding regions.
  • Epitopes usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and have specific three dimensional structural characteristics as well as specific charge characteristics. Examples of epitopes include, but are not limited to, the residues described herein that form TSLP-R epitopes.
  • telomere binding As used herein, the terms “specific binding, ” “immunospecific binding, ” “binds immune-specifically, ” and the like are used interchangeably to refer to an antibody, or fragment thereof, binding to a predetermined antigen (e.g. TSLP-R) or epitope present on the antigen.
  • a predetermined antigen e.g. TSLP-R
  • the extent of specific binding between an antibody, or fragment thereof, and its antigen can be quantified by a dissociation constant (KD) , which is an equilibrium constant that measures the propensity of a complex to dissociate into smaller components.
  • KD dissociation constant
  • a typical KD for an antibody bound to an antigen is between about 10-9 M and about 10-6 M or less.
  • An antibody can be defined as “specific for” a predetermined antigen if the KD between said antibody and said predetermined antigen is at least two-fold the KD between said antibody to a non-specific antigen (e.g., BSA, casein, or another non-specific polypeptide) . If the KD between an antibody and a predetermined antigen is at about 10-9 M or greater, then the antibody can be said to have “high specific binding” the predetermined antigen.
  • a non-specific antigen e.g., BSA, casein, or another non-specific polypeptide
  • purified or “isolated” means altered or removed from the natural state.
  • the terms refer to an antibody, or fragment thereof, that is substantially free of other material that associates with the molecule in its natural environment.
  • a purified protein is substantially free of the cellular material or other proteins from the cell or tissue from which it is derived.
  • the term refers to preparations where the isolated protein is sufficiently pure to be analyzed, or at least 70%to 80% (w/w) pure, at least 80-90% (w/w) pure, 90-95%pure; and, at least 95%, 96%, 97%, 98%, 99%, or 100% (w/w) pure.
  • the term “encoding” refers to the inherent property of specific sequences of nucleotides in a polynucleotide, such as a gene, a cDNA, or an mRNA or viral RNA, to serve as templates for synthesis of other polymers and macromolecules in biological processes having either a defined sequence of nucleotides (i.e., rRNA, tRNA and mRNA) or a defined sequence of amino acids and the biological properties resulting therefrom.
  • a gene encodes a protein if transcription and translation of mRNA corresponding to that gene produces the protein in a cell or other biological system.
  • Both the coding strand the nucleotide sequence of which is identical to the mRNA sequence and is usually provided in sequence listings, and the non-coding strand, used as the template for transcription of a gene or cDNA, can be referred to as encoding the protein or other product of that gene or cDNA.
  • homolog means protein sequences having between 40%and 100%sequence homology or identity to a reference sequence. Percent identity between two peptide chains can be determined by pair wise alignment using the default settings of the AlignX module of Vector NTI v. 9.0.0 (Invitrogen Corp., Carslbad, Calif. ) .
  • TSLP cytokine receptor like factor 2
  • CRLF2 cytokine receptor like factor 2
  • TSLP is a cytokine produced in and secreted from epithelium cells in response to pro-inflammatory stimuli. Without wishing to be bound to a particular theory, TSLP enhances the allergic inflammatory response through the activation of dendritic cells and mast cells.
  • TSLP activates dendritic cells by binding to TSLP-R/IL7R- ⁇ hereodimers composed of one TSLP-R and one IL-7 receptor ⁇ -chain (IL7R- ⁇ ) .
  • the dendritic cells activated by TSLP express inflammatory cytokines that induce the differentiation of naive T cells into Th2 cells and additionally attract Th2 cells to inflammation sites (Nat. Immunol., 2002, Vol. 7, p. 673 to 680; Int.
  • TSLP-activated dendritic cells The inflammatory responses mediated by TSLP-activated dendritic cells are reported to be involved with multiple disease pathologies, including allergic inflammatory diseases such as asthma and systemic sclerosis (Nat. Immunol., 2005, Vol. 6, p. 1047 to 1053) .
  • Loss of TSLP-R has been associated with suppression of Th2 cytokines and suppression of IgE production in the blood in a TSLP-R knockout mouse model, and the usage of anti-TSLP-R antibodies in a mouse model of asthma has additionally been associated with improvement of respiratory function (J. Exp. Med., 2005, Vol. 202, p. 829 to 839, and Clin.
  • antibodies, and antibody fragments thereof, that specifically bind to and inhibit TSLP-R are hypothesized to be useful for preventing and treating various diseases in which TSLP and TSLP-R are involved in disease pathology.
  • the basic antibody structural unit comprises a tetramer.
  • Each tetramer includes two identical pairs of polypeptide chains, each pair having one “light” (about 25 kDa) and one “heavy” chain (about 50-70 kDa) .
  • human light chains are classified as kappa and lambda light chains.
  • human heavy chains are typically classified as mu, delta, gamma, alpha, or epsilon, and define the antibody's isotype as IgM, IgD, IgG, IgA, and IgE, respectively.
  • each chain includes a variable region of about 100 to 110 or more amino acids that is primarily responsible for antigen recognition.
  • the variable regions of a light chain and a heavy chain are abbreviated as V L and V H , respectively.
  • variable regions of each chain are followed by one or more constant region of about 100 to 110 or more amino acids per constant region.
  • the constant regions are identical in all antibodies, or antigen-binding fragments thereof, of the same isotype, but differ between different isotypes.
  • the light chain contains one constant region, which is abbreviated as C L .
  • Heavy chains contain multiple constant regions that can be abbreviated as C H 1, C H 2, C H 3, etc.
  • the carboxy-terminal portion of the heavy chain may define a constant region primarily responsible for effector function.
  • variable and constant regions are joined by a “J” region of about 12 or more amino acids, with the heavy chain also including a “D” region of about 10 more amino acids.
  • variable regions of each light/heavy chain pair form the antigen-binding domain or site.
  • an intact antibody has two binding sites. Except in bifunctional or bispecific antibodies, the two binding sites are, in general, the same.
  • CDR complementarity determining region
  • a CDR can comprise a “hypervariable loop” within a folded antibody, or fragment thereof.
  • variable domains of both the heavy and light chains comprise three CDRs, located within relatively conserved framework regions (FR) .
  • FR framework regions
  • framework or FR residues refers to those variable domain residues other than the hypervariable region residues defined herein as CDR residues.
  • variable domains comprise FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4.
  • CDRL1, CDRL2, and CDRL3 three CDRs within a light chain are abbreviated as CDRL1, CDRL2, and CDRL3, with CDRL1 representing the CDR closest to the N terminal of the light chain and CDRL3 representing the CDR closest to the C terminal of the light chain.
  • CDRs provide the majority of contact residues for the binding of the anti-TSLP-R antibody, or antigen-binding fragment thereof, to the antigen or epitope.
  • CDRs of interest can be derived from variable heavy and light chain sequences from a donor antibody, or fragment thereof, and include analogs of the naturally occurring CDRs, which analogs also share or retain the same antigen-binding specificity and/or neutralizing ability as the donor antibody, or fragment thereof, from which they were derived.
  • the “Fv region” comprises the variable regions from both the light and heavy chains, i.e. the Fv region comprises VL and VH.
  • the term “Fv domain” is used interchangeably with “Fv region” .
  • the Fv region further comprises a polypeptide linker between the VH and VL domains which enables the scFv to form the desired structure for antigen-binding.
  • single-chain Fv or “scFv” antibody refers to antibody fragments comprising the VH and VL domains of an antibody, or fragment thereof, wherein these domains are present in a single polypeptide chain.
  • Fab region or “Fab domain” is used to refer to the region of an antibody, or fragment thereof, that is comprised of one light chain and the variable regions and C H 1 of one heavy chain.
  • the Fab region typically comprises V L , C L , V H , and C H 1.
  • a “Fab fragment” is an antibody fragment that is comprised of one light chain and the C H 1 and variable regions of one heavy chain. The heavy chain of a Fab region cannot form a disulfide bond with another heavy chain molecule.
  • a “Fab' fragment” contains one Fab region (V L , C L , V H , and C H 1) , wherein the heavy chain also contains the region between the C H 1 and C H 2 domains, such that an interchain disulfide bond can be formed between the two heavy chains of two Fab' fragments to form a F (ab') 2 molecule.
  • a “F (ab') 2 fragment” contains two Fab’ fragments (two light chains and two heavy chains containing a portion of the constant region between the C H 1 and C H 2 domains) , wherein an interchain disulfide bond is formed between the two heavy chains.
  • a F (ab') 2 fragment thus is composed of two Fab' fragments that are held together by a disulfide bond between the two heavy chains.
  • Fc region is used interchangeably with “Fc domain, ” which is defined as the region of an antibody, or fragment thereof, that contains two heavy chains held together by two or more disulfide bonds and hydrophobic interactions.
  • An Fc domain typically comprises the C H 2 and C H 3 domains for each heavy chain. The two heavy chain fragments are held together by two or more disulfide bonds and by hydrophobic interactions of the C H 3 domains.
  • a “domain antibody” is an immunologically functional immunoglobulin fragment containing only the variable region of a heavy chain or the variable region of a light chain.
  • two or more VH regions are covalently joined with a peptide linker to create a bivalent domain antibody.
  • the two VH regions of a bivalent domain antibody may target the same or different antigens.
  • the term “diabodies” refers to small antibody fragments with two antigen-binding domains, wherein the fragments comprise a heavy chain variable domain (VH) connected to a light chain variable domain (VL) in the same polypeptide chain (VH-VL or VL-VH) .
  • Diabodies are described more fully in, e.g., EP 404, 097; WO 93/11161; and Holliger et al. (1993) Proc. Natl. Acad. Sci. USA 90: 6444-6448.
  • engineered antibody, or fragment thereof variants generally see Holliger and Hudson (2005) Nat. Biotechnol. 23: 1126-1136.
  • a “bivalent antibody” comprises two antigen-binding sites. In some instances, the two binding sites have the same antigen specificities. In some instances, the two binding sites have different antigen specificities, in which case the antibody is a bispecific antibody.
  • the terms “bispecific antibody” and “multispecific antibody” refers to any antibody that binds immunospecifically to two or more different binding sites that have different antigen specificities.
  • Fully human antibody refers to an antibody that comprises human immunoglobulin protein sequences only.
  • a fully human antibody may contain murine carbohydrate chains if produced in a mouse, in a mouse cell, or in a hybridoma derived from a mouse cell.
  • mouse antibody refers to an antibody that comprises mouse immunoglobulin sequences only.
  • a fully human antibody may contain rat carbohydrate chains if produced in a rat, in a rat cell, or in a hybridoma derived from a rat cell.
  • rat antibody refers to an antibody that comprises rat immunoglobulin sequences only.
  • a “chimeric antibody” is an antibody having the variable domain from a first antibody and constant domain from a second antibody, where the first and second antibodies are from different species.
  • the variable domains are obtained from an antibody from an experimental animal (the “parental antibody” ) , such as a rodent, and the constant domain sequences are obtained from human antibodies, so that the resulting chimeric antibody is less likely to elicit an adverse immune response in a human subject than the parental (e.g. rodent) antibody.
  • humanized antibody refers to forms of antibodies that contain sequences from both human and non-human (e.g., murine, rat) antibodies.
  • a humanized antibody, or fragment thereof will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin, and all or substantially all of the framework (FR) regions are those of a human immunoglobulin sequence.
  • the humanized antibody, or fragment thereof may optionally comprise at least a portion of a human immunoglobulin constant region (Fc) .
  • Parental antibodies are antibodies obtained by exposure of an immune system to an antigen prior to modification of the antibodies for an intended use, such as humanization of an antibody for use as a human therapeutic antibody, or fragment thereof.
  • the term “monoclonal antibody” refers to population of substantially homogeneous antibodies, i.e., the antibody molecules comprising the population are identical in amino acid sequence except for possible naturally occurring mutations that may be present in minor amounts.
  • conventional (polyclonal) antibody preparations typically include a multitude of different antibodies, or antigen-binding fragments thereof, having different amino acid sequences in their variable domains, particularly their CDRs, that are often specific for different epitopes.
  • the modifier “monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method.
  • monoclonal antibodies to be used in accordance with the present invention may be made by the hybridoma method first described by Kohler et al. (1975) Nature 256: 495, or may be made by recombinant DNA methods (see, e.g., U.S. Pat. No. 4,816,567) .
  • the monoclonal antibodies may also be isolated from phage antibody libraries using the techniques described in Clackson et al. (1991) Nature 352: 624-628 and Marks et al. (1991) J. Mol. Biol. 222: 581-597, for example. See also Presta (2005) J. Allergy Clin. Immunol. 116: 731.
  • a monoclonal antibody to a polypeptide may be identified and isolated by screening a recombinant combinatorial immunoglobulin library (e.g., an antibody phage display library) with a polypeptide described herein to thereby isolate immunoglobulin library members that bind to the polypeptide.
  • a recombinant combinatorial immunoglobulin library e.g., an antibody phage display library
  • Techniques and commercially available kits for generating and screening phage display libraries are well known to those skilled in the art. Additionally, examples of methods and reagents particularly amenable for use in generating and screening antibody display libraries or antigen-binding protein display libraries can be found in the literature.
  • the epitopes described herein can be used to screen for other antibodies that can be used therapeutically, diagnostically, or as research tools.
  • an antibody recognizing TSLP-R and “an antibody specific for TSLP-R” are used interchangeably herein with the term “an antibody which binds specifically to TSLP-R. ”
  • the term also includes antibodies that are specific for CRLF2.
  • the pharmaceutical composition comprising the anti-TSLP-R antibody is designated TRAB-1.
  • an antibody, or antigen-binding fragment thereof is provided, wherein the antibody, or antigen-binding fragment thereof, is specific for TSLP-R.
  • the anti-TSLP-R antibody, or antigen-binding fragment thereof is used to detect the presence of an antigen.
  • the antigen is TSLP-R.
  • the antibody, or fragment thereof contains a variable region that binds specifically to TSLP-R.
  • antibody, or fragment thereof binds specifically to one or more antigen-binding site within TSLP-R.
  • the antibody, or fragment thereof binds to amino acids of an epitope of the TSLP-R.
  • the antibody, or fragment thereof binds to the one or more epitope, wherein the one or more epitope is an antigen-binding site within TSLP-R.
  • the present anti-TSLP-R antibody, or antigen-binding fragment thereof can be used in any device or method to detect the presence of the antigen.
  • the anti-TSLP-R antibody, or antigen-binding fragment thereof binds specifically to one or more TSLP-R binding site wherein the KD between the antibody, or fragment thereof, and the one or more TSLP-R binding site is at least twice the KD between the antibody, or fragment thereof, and a non-specific antigen.
  • the non-specific antigen can include, but is not limited to, BSA, casein, or any other polypeptide that binds to the anti-TSLP-R antibody, or antigen-binding fragment thereof, in a non-specific manner.
  • the antibody, or fragment thereof binds to its antigen (TSLP-R) with an affinity that is at least two fold greater, at least ten times greater, at least 20-times greater, or at least 100-times greater than the affinity with any other antigen.
  • TLP-R its antigen
  • the degree of specificity necessary for an anti-TSLP-R antibody, or antigen-binding fragment thereof, may depend on the intended use of the antibody, or fragment thereof, and at any rate is defined by its suitability for use for an intended purpose.
  • the anti-TSLP-R antibody, or antigen-binding fragment thereof binds specifically to one or more TSLP-R binding site wherein the KD between the anti-TSLP-R antibody, or antigen-binding fragment thereof, and the one or more TSLP-R binding site is at least 10 -6 , 10 -7 , 10 -8 , 10 -9 , 10 -10 , 10 -11 , 10 -12 , or 10 -13 M.
  • the anti-TSLP-R antibody, or antigen-binding fragment thereof is highly specific for one or more TSLP-R binding site, wherein the KD is at least about 10 -9 M.
  • the anti-TSLP-R antibody, or antigen-binding fragment thereof is highly specific for one or more TSLP-R binding site, wherein the KD is at least about 10 -12 M.
  • the antigen is the TSLP-R protein expressed on the surface of a cell.
  • the cell is an intact cell.
  • the cell is not an intact cell.
  • An intact cell is a cell that has not been lysed or broken open with the use of detergents or other reagents.
  • a cell that has been treated with detergents or other reagents that breaks up the cellular membrane or punches holes in a cellular membrane is not an intact cell.
  • methods are provided herein for generating an antibody, or fragment thereof, that binds to a TSLP-R protein, the method comprising culturing a cell comprising a nucleic acid molecule encoding the TSLP-R antibody, or fragment thereof.
  • the anti-TSLP-R antibody comprises at least two light chains and at least two heavy chains. In some embodiments, the anti-TSLP-R antibody comprises a tetramer. In some embodiments, the tetramer comprises two light chains and two heavy chains. In some embodiments, the anti-TSLP-R antibody comprises one or more tetramers. In some embodiments, the anti-TSLP-R antibody comprises two, five, or more tetramers. In some embodiments, the anti-TSLP-R antibody, or antigen-binding fragment thereof, is of IgM, IgD, IgG, IgA, or IgE isotype, or any combination thereof.
  • the anti-TSLP-R antibody fragment comprises a monomer or an oligomer.
  • the oligomer comprises two, three, four, five, or more monomers.
  • the monomer comprises an intact light chain or portion thereof, or an intact heavy chain or portion thereof.
  • the oligomer comprises two or more monomers, wherein the two or more monomers comprise one or more intact light chain, light chain portion, intact heavy chain, heavy chain portion, or a combination thereof.
  • the anti-TSLP-R antibody, or antigen-binding fragment thereof comprises one or more chains comprising a kappa light chain, lambda light chain, mu heavy chain, delta heavy chain, gamma heavy chain, alpha heavy chain, epsilon heavy chain, or a combination thereof.
  • the anti-TSLP-R antibody fragment comprises intact chains, portions of chains, or a combination of intact chains and chain portions.
  • the one or more intact heavy chains, or portion thereof comprises 1, 2, 3, or 4 constant regions.
  • the constant region comprises a C H 1, C H 2, C H 3, or C H 4 constant region, or any combination thereof.
  • the anti-TSLP-R antibody, or antigen-binding fragment thereof comprises one or more antibody region, wherein the one or more antibody region is V L , V H , C L , C H 1, C H 2, C H 3, or C H 4, or any combination thereof.
  • the anti-TSLP-R antibody, or antigen-binding fragment thereof comprises one or more linker, wherein the N-terminus of the linker is covalently bound to a V L , V H , C L , C H 1, C H 2, C H 3, or C H 4, and the C-terminus of the linker is covalently bound to a V L , V H , C L , C H 1, C H 2, C H 3, or C H 4.
  • the anti-TSLP-R antibody, or antigen-binding fragment thereof additionally comprises a “J” region. In some embodiments, the anti-TSLP-R antibody, or antigen-binding fragment thereof, additionally comprises a “D” region.
  • the anti-TSLP-R antibody, or antigen-binding fragment thereof comprises one or more amino acid sequences as provided herein. In some embodiments, the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises an antigen-binding domain that comprises one or more amino acid sequences as provided herein. In some embodiments, the anti-TSLP-R antibody, or fragment thereof, or antigenic binding fragment thereof, has, at least 50, 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99%homology or identity to a sequence described herein.
  • the antibody comprises one or more peptides having the sequences as listed in Table 1, or a variant thereof.
  • the anti-TSLP-R antibody, or antigen-binding fragment thereof comprises one or more heavy chain (HC) .
  • the anti-TSLP-R antibody, or antigen-binding fragment thereof comprises one or more heavy chain having the amino acid sequence of SEQ ID NO: 1.
  • the anti-TSLP-R antibody, or antigen-binding fragment thereof comprises two heavy chains having the amino acid sequence of SEQ ID NO: 1.
  • the anti-TSLP-R antibody, or antigen-binding fragment thereof comprises a heavy chain encoded by the nucleotide sequence of SEQ ID NO: 2:
  • the anti-TSLP-R antibody, or antigen-binding fragment thereof comprises a heavy chain having the amino acid sequence of SEQ ID NO: 1, encoded by the nucleotide sequence of SEQ ID NO: 2.
  • the anti-TSLP-R antibody, or antigen-binding fragment thereof comprises one or more light chain (LC) . In some embodiments, the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises one or more light chain having the amino acid sequence of SEQ ID NO: 3. In some embodiments, the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises two light chains having the amino acid sequence of SEQ ID NO: 3.
  • the anti-TSLP-R antibody, or antigen-binding fragment thereof comprises a light chain encoded by the nucleotide sequence of SEQ ID NO: 4:
  • the anti-TSLP-R antibody, or antigen-binding fragment thereof comprises one or more heavy chain having the amino acid sequence of SEQ ID NO: 1 encoded by the nucleotide sequence of SEQ ID NO: 2, and one or more light chain having the amino acid sequence of SEQ ID NO: 3 encoded by the nucleotide sequence of SEQ ID NO: 4.
  • the anti-TSLP-R antibody, or antigen-binding fragment thereof comprises two heavy chains having the amino acid sequence of SEQ ID NO: 1 encoded by the nucleotide sequence of SEQ ID NO: 2, and two light chains having the amino acid sequence of SEQ ID NO: 3 encoded by the nucleotide sequence of SEQ ID NO: 4.
  • the anti-TSLP-R antibody, or antigen-binding fragment thereof comprises a light chain having the amino acid sequence of SEQ ID NO: 3, encoded by the nucleotide sequence of SEQ ID NO: 4.
  • the anti-TSLP-R antibody, or antigen-binding fragment thereof comprises a heavy chain polypeptide having an amino acid sequence that is is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%identical to SEQ ID NO: 1.
  • the anti-TSLP-R antibody, or antigen-binding fragment thereof comprises a light chain polypeptide having an amino acid sequence that is is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%identical to SEQ ID NO: 3.
  • the anti-TSLP-R antibody, or antigen-binding fragment thereof comprises a heavy chain polypeptide having an amino acid sequence that is is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%identical to SEQ ID NO: 1; and a light chain polypeptide having an amino acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%identical to SEQ ID NO: 3.
  • the anti-TSLP-R antibody, or antigen-binding fragment thereof comprises one or more variable heavy chain (VH) polypeptide. In some embodiments, the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises one or more variable light chain (VL) polypeptide. In some embodiments, the antibody heavy chain sequence comprises the variable heavy chain of the antibody, and the antibody light chain sequence comprises the variable light chain of the antibody. In some embodiments, the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide VH and the variable light chain polypeptide VL, having the sequences shown in Table 2.
  • the anti-TSLP-R antibody, or antigen-binding fragment thereof comprises a variable heavy chain polypeptide having an amino acid sequence of SEQ ID NO: 5.
  • the anti-TSLP-R antibody, or antigen-binding fragment thereof comprises a variable light chain polypeptide having the amino acid sequence of SEQ ID NO: 6.
  • the anti-TSLP-R antibody or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having the amino acid sequence of SEQ ID NO: 5, and a variable light chain polypeptide having the amino acid sequence of SEQ ID NO: 6.
  • the anti-TSLP-R antibody, or antigen-binding fragment thereof comprises a variable heavy chain polypeptide having an amino acid sequence that is is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%identical to SEQ ID NO: 5.
  • the anti-TSLP-R antibody, or antigen-binding fragment thereof comprises a variable light chain polypeptide having an amino acid sequence that is is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%identical to SEQ ID NO: 6.
  • the anti-TSLP-R antibody, or antigen-binding fragment thereof comprises a variable heavy chain polypeptide having an amino acid sequence that is is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%identical to SEQ ID NO: 5; and a variable light chain polypeptide having an amino acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%identical to SEQ ID NO: 6.
  • an antibody, or antigen-binding fragment thereof is provided, wherein the antibody, or antibody fragment comprises a CDR polypeptide selected from Table 3.
  • the terms LCDR1, LCDR2, and LCDR3 refer to the CDR1, CDR2, and CDR3 of the light chain.
  • the terms HCDR1, HCDR2, and HCDR3 refer to the CDR1, CDR2, and CDR3 of the heavy chain.
  • the anti-TSLP-R antibody, or the anti-TSLP-R antibody fragment thereof contains one or more CDR regions.
  • the anti-TSLP-R antibody, or anti-TSLP-R antibody fragment thereof contains one or more CDR region with a sequence chosen from Table 3.
  • the anti-TSLP-R antibody, or the antigen-binding fragment thereof comprises a heavy chain HCDR1, HCDR2, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 7, 8, and 9, respectively.
  • the anti-TSLP-R antibody, or the fragment thereof comprises a heavy chain comprising a HCDR1 amino acid sequence of SEQ ID NO: 7; a HCDR2 amino acid sequence of SEQ ID NO: 8; and a HCDR3 amino acid sequence of SEQ ID NO: 9.
  • the anti-TSLP-R antibody comprises a heavy chain comprising a HCDR1 amino acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%identical SEQ ID NO: 7; a HCDR2 amino acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%identical to SEQ ID NO: 8; and a HCDR3 amino acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least
  • the anti-TSLP-R antibody, or antigen-binding fragment thereof comprises a heavy chain polypeptide having an amino acid sequence that is is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%identical to SEQ ID NO: 1, provided that the heavy chain polypeptide comprises a HCDR1 amino acid sequence of SEQ ID NO: 7; a HCDR2 amino acid sequence of SEQ ID NO: 8; and a HCDR3 amino acid sequence of SEQ ID NO: 9.
  • the anti-TSLP-R antibody, or the antigen-binding fragment thereof comprises a variable heavy chain HCDR1, HCDR2, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 7, 8, and 9, respectively.
  • the anti-TSLP-R antibody, or the fragment thereof comprises a variable heavy chain comprising a HCDR1 amino acid sequence of SEQ ID NO: 7; a HCDR2 amino acid sequence of SEQ ID NO: 8; and a HCDR3 amino acid sequence of SEQ ID NO: 9.
  • the anti-TSLP-R antibody comprises a variable heavy chain comprising a HCDR1 amino acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%identical SEQ ID NO: 7; a HCDR2 amino acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%identical to SEQ ID NO: 8; and a HCDR3 amino acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at
  • the anti-TSLP-R antibody, or the antigen-binding fragment thereof comprises a light chain LCDR1, LCDR2, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 10, 11, and 12, respectively.
  • the anti-TSLP-R antibody, or the fragment thereof comprises a light chain comprising a LCDR1 amino acid sequence of SEQ ID NO: 10; a LCDR2 amino acid sequence of SEQ ID NO: 11; and a LCDR3 amino acid sequence of SEQ ID NO: 12.
  • the anti-TSLP-R antibody comprises a light chain comprising a LCDR1 amino acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%identical SEQ ID NO: 10; a LCDR2 amino acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%identical to SEQ ID NO: 11; and a LCDR3 amino acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%,
  • the anti-TSLP-R antibody, or antigen-binding fragment thereof comprises a light chain polypeptide having an amino acid sequence that is is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%identical to SEQ ID NO: 3, provided that the light chain polypeptide comprises a LCDR1 amino acid sequence of SEQ ID NO: 10; a LCDR2 amino acid sequence of SEQ ID NO: 11; and a LCDR3 amino acid sequence of SEQ ID NO: 12.
  • the anti-TSLP-R antibody, or the antigen-binding fragment thereof comprises a variable light chain LCDR1, LCDR2, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 10, 11, and 12, respectively.
  • the anti-TSLP-R antibody, or the fragment thereof comprises a variable light chain comprising a LCDR1 amino acid sequence of SEQ ID NO: 10; a LCDR2 amino acid sequence of SEQ ID NO: 11; and a LCDR3 amino acid sequence of SEQ ID NO: 12.
  • the anti-TSLP-R antibody comprises a variable light chain comprising a LCDR1 amino acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%identical SEQ ID NO: 10; a LCDR2 amino acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%identical to SEQ ID NO: 11; and a LCDR3 amino acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%
  • the anti-TSLP-R antibody or the antigen-binding fragment thereof, comprises a heavy chain HCDR1, HCDR2, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 7, 8, and 9, respectively; and a light chain LCDR1, LCDR2, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 10, 11, and 12, respectively.
  • the anti-TSLP-R antibody comprises a heavy chain comprising a HCDR1 amino acid sequence of SEQ ID NO: 7; a HCDR2 amino acid sequence of SEQ ID NO: 8; and a HCDR3 amino acid sequence of SEQ ID NO: 9; and a light chain comprising a LCDR1 amino acid sequence of SEQ ID NO: 10; a LCDR2 amino acid sequence of SEQ ID NO: 11; and a LCDR3 amino acid sequence of SEQ ID NO: 12.
  • the anti-TSLP-R antibody comprises a heavy chain comprising a HCDR1 amino acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%identical SEQ ID NO: 7; a HCDR2 amino acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%identical to SEQ ID NO: 8; and a HCDR3 amino acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least
  • the anti-TSLP-R antibody, or antigen-binding fragment thereof comprises a heavy chain polypeptide having an amino acid sequence that is is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%identical to SEQ ID NO: 1, provided that the heavy chain polypeptide comprises a HCDR1 amino acid sequence of SEQ ID NO: 7; a HCDR2 amino acid sequence of SEQ ID NO: 8; and a HCDR3 amino acid sequence of SEQ ID NO: 9; and a light chain polypeptide having an amino acid sequence that is is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%
  • the anti-TSLP-R antibody or the antigen-binding fragment thereof, comprises a variable heavy chain HCDR1, HCDR2, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 7, 8, and 9, respectively; and a variable light chain LCDR1, LCDR2, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 10, 11, and 12, respectively.
  • the anti-TSLP-R antibody comprises a variable heavy chain comprising a HCDR1 amino acid sequence of SEQ ID NO: 7; a HCDR2 amino acid sequence of SEQ ID NO: 8; and a HCDR3 amino acid sequence of SEQ ID NO: 9; and a variable light chain comprising a LCDR1 amino acid sequence of SEQ ID NO: 10; a LCDR2 amino acid sequence of SEQ ID NO: 11; and a LCDR3 amino acid sequence of SEQ ID NO: 12.
  • the anti-TSLP-R antibody comprises a variable heavy chain comprising a HCDR1 amino acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%identical SEQ ID NO: 7; a HCDR2 amino acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%identical to SEQ ID NO: 8; and a HCDR3 amino acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at
  • the anti-TSLP-R antibody, or antigen-binding fragment thereof has conservative substitutions as compared to a sequence described herein.
  • Exemplary conservative substitutions are illustrated in Table 4 and are encompassed within the scope of the disclosed subject matter.
  • the conservative substitution may reside in the framework regions, or in antigen-binding sites, as long they do not adversely affect the properties of the antibody, or fragment thereof.
  • substitutions may be made to improve the properties or the antibody, or fragment thereof, for example the stability or affinity.
  • conservative substitutions will produce molecules having functional and chemical characteristics similar to those molecules into which such modifications are made. Exemplary amino acid substitutions are shown in the table below.
  • variants of the proteins and peptides provided herein are provided.
  • a variant comprises a substitution, deletions, or insertion.
  • the variant comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 (e.g., 1-10) substitutions.
  • the substitutions can be conservative substitutions.
  • the substitution is non-conservative.
  • the variant comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 (e.g., 1-10) deletions.
  • the variant comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 (e.g., 1-10) insertions.
  • the substitutions, deletions, or insertions are present in the CDRs provided for herein. In some embodiments, the substitutions, deletions, or insertions are not present in the CDRs provided for herein.
  • “derivatives” of the antibodies are provided.
  • the term “derivatives” includes those proteins encoded by truncated or modified genes to yield molecular species functionally resembling the immunoglobulin or immunoglobulin fragments.
  • the modifications can include, but are not limited to, addition of genetic sequences coding for cytotoxic proteins such as plant and bacterial toxins.
  • the modification can also include a reporter protein, such as a fluorescent or chemiluminescent tag.
  • the fragments and derivatives can be produced in any manner.
  • the anti-TSLP-R antibody, or antigen-binding fragment thereof can include, but is not limited to, a monoclonal, polyclonal, bispecific, humanized, fully human, chimeric, or a single-domain antibody, or fragment thereof, or any combination thereof.
  • the anti-TSLP-R antibody fragment can include, but is not limited to, a Fab, Fab’, F (ab’) 2, Fv fragment, diabody, linear antibody, single chain antibody, sc-Fv, nanobody, or multispecific antibody fragment, or any combination thereof.
  • the anti-TSLP-R antibody, or fragment thereof is isolated. In some embodiments, the anti-TSLP-R antibody, or fragment thereof, is at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9%, or 100% (w/w) pure. In some embodiments, the anti-TSLP-R antibody, or fragment thereof, is at least 70%-80%, 75%-80%, 75%-85%, 80%-85%, 80%-90%, 85%-90%, 85%-95%, or 90%-95%pure. In some embodiments, the anti-TSLP-R antibody, or fragment thereof, is at least 70%to at least 80%pure.
  • the anti-TSLP-R antibody, or fragment thereof is at least 75%to at least 80%pure. In some embodiments, the anti-TSLP-R antibody, or fragment thereof, is at least 75%to at least 85%pure. In some embodiments, the anti-TSLP-R antibody, or fragment thereof, is at least 80%to at least 85%pure. In some embodiments, the anti-TSLP-R antibody, or fragment thereof, is at least 80%to at least 90%pure. In some embodiments, the anti-TSLP-R antibody, or fragment thereof, is at least85%to at least 90%pure. In some embodiments, the anti-TSLP-R antibody, or fragment thereof, is at least 85%to at least 95%pure. In some embodiments, the anti-TSLP-R antibody, or fragment thereof, is at least 90%to at least 95%pure. In some embodiments, the anti-TSLP-R antibody, or fragment thereof, is at least 95%to at least 99%pure.
  • the anti-TSLP-R antibody, or fragment thereof binds specifically to one or more TSLP-R protein, wherein the one or more TSLP-R protein can include, but is not limited to primates such as humans or monkeys, mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, or horses, or any combination thereof.
  • the anti-TSLP-R antibody, or fragment thereof binds specifically to human TSLP-R.
  • the anti-TSLP-R antibody, or fragment thereof binds specifically to murine TSLP-R.
  • the anti-TSLP-R antibody, or fragment thereof binds specifically to one TSLP-R protein that is human in origin, and at least one additional TSLP-R protein that is another species in origin, wherein the another species of origin can include, but are not limited to, primates such as monkeys, mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, or horses, or any combination thereof.
  • the anti-TSLP-R antibody, or fragment thereof binds specifically to one TSLP-R protein that is murine in origin, and at least one additional TSLP-R protein that is another species in origin, wherein the another species of origin can include, but are not limited to, primates such as humans or monkeys, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, or horses, or any combination thereof.
  • the anti-TSLP-R antibody, or antigen-binding fragment thereof is a MAb which binds to TSLP-R.
  • the anti-TSLP-R antibody, or antigen-binding fragment thereof is a human IgG.
  • the anti-TSLP-R antibody, or antigen-binding fragment thereof is a variant of human IgG.
  • a “variant of human IgG” refers to an antibody that has been modified to be a human IgG or fragment thereof, when the starting antibody is not a human IgG antibody, or fragment thereof.
  • the sequences of the antibodies, or antigen-binding fragments thereof can be modified to yield human IgG antibodies, or antigen-binding fragments thereof.
  • the conversion of the sequences provided herein can be modified to yield other types of antibodies, or antigen-binding fragments thereof.
  • the CDRs can also be linked to other antibodies, or antigen-binding fragments thereof, that bind to TSLP-R.
  • the CDRs can also be linked to other proteins or molecules to create an antibody, or fragment thereof, that binds to TSLP-R.
  • variable regions of the anti-TSLP-R antibody, or antigen-binding fragment thereof, as described herein can be combined with any type of constant region including a human constant region or murine constant region.
  • the constant region comprises a mutation at position at an amino acid residue relative to a wild-type human IgG constant domain, numbered according to the EU numbering index of Kabat.
  • the mutation increases the half-life of the anti-TSLP-R antibody, or antigen-binding fragment thereof, as compared to the half-life of an IgG having the wild-type human IgG constant domain.
  • the antibodies, or fragments thereof comprise an Fc region.
  • the Fc region comprises a mutation that extends the half-life of the anti-TSLP-R antibody, or antigen-binding fragment thereof, when linked to the Fc region.
  • the Fc domain comprises a mutation such as those described in US2007041972A1, EP2235059B1, U.S. Patent No. 7,670,600, U.S. Patent No. 8,394,925, and Mueller et al, Mol Immunol 1997 Apr; 34 (6) : 441-52, each of which is incorporated by reference in its entirety.
  • the numbering referenced herein refers to the Kabat numbering system for the Fc region.
  • an antibody, or fragment thereof, of the invention can include conservative or non-conservative amino acid substitutions, which can also be referred to as “conservative variants” or “function conserved variants” of the antibody, or fragment thereof, that do not substantially alter its biological activity.
  • a variant antibody, or fragment thereof, or antigen-binding fragment of the antibodies, thereof, provided herein retains at least 10%of its TSLP-R binding activity (when compared to a parental antibody, or fragment thereof, that is modified) when that activity is expressed on a molar basis.
  • a variant antibody, or fragment thereof, provided herein retains at least 20%, 50%, 70%, 80%, 90%, 95%or 100%or more of the TSLP-R binding affinity as the parental antibody, or fragment thereof.
  • a variant antibody, or fragment thereof, provided herein retains at least 20%or more of the TSLP-R binding affinity as the parental antibody, or fragment thereof. In some embodiments, a variant antibody, or fragment thereof, provided herein, retains at least 50%or more of the TSLP-R binding affinity as the parental antibody, or fragment thereof. In some embodiments, a variant antibody, or fragment thereof, provided herein, retains at least 70%or more of the TSLP-R binding affinity as the parental antibody, or fragment thereof. In some embodiments, a variant antibody, or fragment thereof, provided herein, retains at least 80%or more of the TSLP-R binding affinity as the parental antibody, or fragment thereof.
  • a variant antibody, or fragment thereof, provided herein retains at least 90%or more of the TSLP-R binding affinity as the parental antibody, or fragment thereof. In some embodiments, a variant antibody, or fragment thereof, provided herein, retains at least 95%or more of the TSLP-R binding affinity as the parental antibody, or fragment thereof. In some embodiments, a variant antibody, or fragment thereof, provided herein, retains at least 100%of the TSLP-R binding affinity as the parental antibody, or fragment thereof.
  • the antibodies provided for herein may also be conjugated to a chemical moiety.
  • the chemical moiety may be, inter alia, a polymer, a radionuclide or a cytotoxic factor. In some embodiments, this can be referred to as an antibody drug conjugate.
  • the chemical moiety is a polymer which increases the half-life of the antibody molecule in the body of a subject.
  • Suitable polymers include, but are not limited to, polyethylene glycol (PEG) (e.g., PEG with a molecular weight of 2kDa, 5 kDa, 10 kDa, 12kDa, 20 kDa, 30kDa or 40kDa) , dextran and monomethoxypolyethylene glycol (mPEG) .
  • PEG polyethylene glycol
  • mPEG monomethoxypolyethylene glycol
  • DTPA diethylenetriaminpentaacetic acid
  • chemical moieties include, but are not limited to, anti-mitotics, such as calicheamicins (e.g. ozogamicin) , monomethyl auristatin E, mertansine, and the like.
  • Other examples include, but are not limited to, biologically active anti-microtubule agents, alkylating agents and DNA minor groove binding agents. Other examples of are provided herein and below.
  • the chemical moiety can be linked to the antibody through a linking group (maleimide) , a cleavable linker, such as a cathepsin cleavable linkers (valine- citrulline) , and in some embodiments, one or more spacers (e.g. para-aminobenzylcarbamate) .
  • a linking group maleimide
  • a cleavable linker such as a cathepsin cleavable linkers (valine- citrulline)
  • one or more spacers e.g. para-aminobenzylcarbamate
  • the antibodies and antigen-binding fragments of the invention may also be conjugated with labels such as 99 Tc, 90 Y, 111 In, 32 P, 14 C, 125 I, 3 H, 131 I, 11 C, 15 O, 13 N, 18 F, 35 S, 51 Cr, 57 To, 226 Ra, 60 Co, 59 Fe, 57 Se, 152 Eu, 67 CU, 217 Ci, 211 At, 212 Pb, 47 Sc, 109 Pd, 234 Th, and 40 K, 157 Gd, 55 Mn, 52 Tr and 56 Fe.
  • labels such as 99 Tc, 90 Y, 111 In, 32 P, 14 C, 125 I, 3 H, 131 I, 11 C, 15 O, 13 N, 18 F, 35 S, 51 Cr, 57 To, 226 Ra, 60 Co, 59 Fe, 57 Se, 152 Eu, 67 CU, 217 Ci, 211 At, 212 Pb, 47 Sc, 109 Pd, 234 Th, and 40 K, 157 Gd
  • the antibodies, and antibody fragments thereof may also be conjugated with fluorescent or chemiluminescent labels, including fluorophores such as rare earth chelates, fluorescein and its derivatives, rhodamine and its derivatives, isothiocyanate, phycoerythrin, phycocyanin, allophycocyanin, o-phthaladehyde, fluorescamine, 152Eu, dansyl, umbelliferone, luciferin, luminal label, isoluminal label, an aromatic acridinium ester label, an imidazole label, an acridimium salt label, an oxalate ester label, an aequorin label, 2, 3-dihydrophthalazinediones, biotin/avidin, spin labels and stable free radicals.
  • fluorophores such as rare earth chelates, fluorescein and its derivatives, rhodamine and its derivatives, isothiocyanate, phycoerythr
  • the antibody molecules may also be conjugated to a cytotoxic factor such as diptheria toxin, Pseudomonas aeruginosa exotoxin A chain, ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins and compounds (e.g., fatty acids) , dianthin proteins, Phytoiacca americana proteins PAPI, PAPII, and PAP-S, momordica charantia inhibitor, curcin, crotin, saponaria officinalis inhibitor, mitogellin, restrictocin, phenomycin, and enomycin.
  • a cytotoxic factor such as diptheria toxin, Pseudomonas aeruginosa exotoxin A chain, ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins and compounds (e.g., fatty acids)
  • any method known in the art for conjugating the antibody molecules of the invention to the various moieties may be employed, including those methods described by Hunter, et al., (1962) Nature 144: 945; David, et al., (1974) Biochemistry 13: 1014; Pain, et al., (1981) J. Immunol. Meth. 40: 219; and Nygren, J., (1982) Histochem. and Cytochem. 30: 407. Methods for conjugating antibodies are conventional and very well known in the art.
  • composition means a product which results from the mixing or combining of more than one element or ingredient.
  • carrier encompasses carriers, excipients, and diluents, meaning a material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material involved in carrying or transporting a pharmaceutical, cosmetic or other agent across a tissue layer.
  • pharmaceutically acceptable is employed herein to refer to those agents of interest/compounds, salts, compositions, pharmaceutical dosage forms, etc., which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and/or other mammals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • pharmaceutically acceptable means approved by a regulatory agency of the federal or a state government, or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals (e.g., mammals) , and more particularly, in humans.
  • stable means to have stability against, for example, heat, light, temperature, and/or humidity.
  • excipient refers to a pharmacologically inactive substance formulated with an antibody, or antigen-binding fragment thereof, as described herein.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) a pharmaceutically acceptable buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) an excipient at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • a pharmaceutical composition comprising anti-TSLP-R antibody, or one or more antigen-binding fragment thereof. In some embodiments, a pharmaceutical composition is provided, wherein the pharmaceutical composition comprises the anti-TSLP-R antibody, or one or more antigen-binding fragment thereof, as disclosed herein.
  • the pharmaceutical composition comprises an anti-TSLP-R antibody, or fragment thereof, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (i) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7; the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8; and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; or variants of any of the foregoing; and (ii) a light chain variable region comprising light chain CDR1, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence has the amino acid sequence SEQ ID NO: 10; the light chain CDR2 sequence has the amino acid sequence of SEQ ID NO: 11; and the light chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 12; or variants of any of the foregoing.
  • a heavy chain variable region comprising heavy chain CDR
  • the pharmaceutical composition comprises an anti-TSLP-R antibody, or fragment thereof, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%identical to the sequence of SEQ ID NO: 5.
  • the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%identical to the sequence of SEQ ID NO: 5, provided that the heavy chain polypeptide comprises the amino acid sequences of SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9.
  • the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the anti-TSLP-R antibody, or fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%identical to the sequence of SEQ ID NO: 6.
  • the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%identical to the sequence of SEQ ID NO: 6, provided that the light chain polypeptide comprises the amino acid sequences of SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12.
  • the pharmaceutical composition comprises the anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the anti-TSLP-R antibody, or fragment thereof, comprises: (i) a variable heavy chain polypeptide having a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%identical to the sequence of SEQ ID NO: 5; and (ii) a variable light chain polypeptide having a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%identical to the sequence of SEQ ID NO: 6.
  • the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (i) a variable heavy chain polypeptide having a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%identical to the sequence of SEQ ID NO: 5, provided that the heavy chain polypeptide comprises the amino acid sequences of SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9; and (ii) a variable light chain polypeptide having a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%identical to the sequence of SEQ ID NO: 6, provided that the light chain polypeptide comprises the amino acid sequences of SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12.
  • the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the anti-TSLP-R antibody, or fragment thereof, comprises a variable heavy chain polypeptide having a sequence of SEQ ID NO: 5.
  • the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the anti-TSLP-R antibody, or fragment thereof, comprises a variable light chain polypeptide having a sequence of SEQ ID NO: 6.
  • the pharmaceutical composition comprises the anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the anti-TSLP-R antibody, or fragment thereof, comprises: (i) a variable heavy chain polypeptide having a sequence of SEQ ID NO: 5; and (ii) a variable light chain polypeptide having a sequence of SEQ ID NO: 6.
  • the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a concentration from about 1 mg/mL to about 1000 mg/mL. In some embodiments, the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a concentration from about 1 mg/mL to about 900 mg/mL. In some embodiments, the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a concentration from about 1 mg/mL to about 800 mg/mL.
  • the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a concentration from about 1 mg/mL to about 700 mg/mL. In some embodiments, the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a concentration from about 1 mg/mL to about 600 mg/mL. In some embodiments, the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a concentration from about 1 mg/mL to about 500 mg/mL.
  • the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a concentration from about 1 mg/mL to about 400 mg/mL. In some embodiments, the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a concentration from about 1 mg/mL to about 300 mg/mL. In some embodiments, the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a concentration from about 50 mg/mL to about 250 mg/mL.
  • the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a concentration from about 100 mg/mL to about 200 mg/mL. In some embodiments, the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a concentration from about 150 mg/mL to about 200 mg/mL.
  • the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a concentration of about 25 mg/mL. In some embodiments, the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a concentration of about 50 mg/mL. In some embodiments, the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a concentration of about 100 mg/mL.
  • the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a concentration of about 125 mg/mL. In some embodiments, the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a concentration of about 150 mg/mL. In some embodiments, the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a concentration of about 155 mg/mL.
  • the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a concentration of about 160 mg/mL. In some embodiments, the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a concentration of about 165 mg/mL. In some embodiments, the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a concentration of about 170 mg/mL.
  • the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a concentration of about 175 mg/mL. In some embodiments, the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a concentration of about 180 mg/mL. In some embodiments, the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a concentration of about 185 mg/mL.
  • the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a concentration of about 190 mg/mL. In some embodiments, the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a concentration of about 195 mg/mL. In some embodiments, the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a concentration of about 200 mg/mL.
  • the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a concentration of about 205 mg/mL. In some embodiments, the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a concentration of about 210 mg/mL. In some embodiments, the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a concentration of about 215 mg/mL.
  • the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a concentration of about 220 mg/mL. In some embodiments, the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a concentration of about 225 mg/mL. In some embodiments, the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a concentration of about 230 mg/mL.
  • the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a concentration of about 235 mg/mL. In some embodiments, the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a concentration of about 240 mg/mL. In some embodiments, the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a concentration of about 245 mg/mL.
  • the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a concentration of about 250 mg/mL. In some embodiments, the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a concentration of about 255 mg/mL. In some embodiments, the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a concentration of about 260 mg/mL.
  • the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a concentration of about 265 mg/mL. In some embodiments, the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a concentration of about 270 mg/mL. In some embodiments, the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a concentration of about 275 mg/mL.
  • the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a concentration of about 280 mg/mL. In some embodiments, the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a concentration of about 285 mg/mL. In some embodiments, the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a concentration of about 290 mg/mL.
  • the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a concentration of about 300 mg/mL. In some embodiments, the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a concentration of about 325 mg/mL. In some embodiments, the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a concentration of about 350 mg/mL.
  • the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a concentration of about 375 mg/mL. In some embodiments, the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a concentration of about 400 mg/mL. In some embodiments, the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a concentration of about 425 mg/mL.
  • the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a concentration of about 450 mg/mL. In some embodiments, the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a concentration of about 475 mg/mL. In some embodiments, the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a concentration of about 500 mg/mL.
  • the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a concentration of about 525 mg/mL. In some embodiments, the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a concentration of about 550 mg/mL. In some embodiments, the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a concentration of about 575 mg/mL.
  • the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a concentration of about 600 mg/mL. In some embodiments, the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a concentration of about 700 mg/mL. In some embodiments, the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a concentration of about 800 mg/mL.
  • the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a concentration of about 900 mg/mL. In some embodiments, the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a concentration of about 1000 mg/mL.
  • the pharmaceutical composition comprises an anti-TSLP-R antibody, or the antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a concentration of about 200 mg/mL or less.
  • the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a dose of about 0.01 mg/kg to about 15 mg/kg. In some embodiments, the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a dose of about 0.02 mg/kg to about 15 mg/kg. In some embodiments, the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a dose of about 0.03 mg/kg to about 10 mg/kg.
  • the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a dose of 0.01 mg/kg to 15 mg/kg.
  • the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a dose of 0.02 mg/kg to 15 mg/kg.
  • the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a dose of 0.03 mg/kg to 10 mg/kg.
  • the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present in an amout of about 10 mg to about 700 mg. In some embodiments, the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present in an amout of about 25 mg to about 600 mg.
  • the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present in an amout of 10 mg to 700 mg. In some embodiments, the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present in an amout of 25 mg to 600 mg.
  • the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a dose of about 0.01 mg/kg, about 0.02 mg/kg, about 0.03 mg/kg, about 0.04 mg/kg, about 0.05 mg/kg, about 0.06 mg/kg, about 0.07 mg/kg, about 0.08 mg/kg, about 0.09 mg/kg, about 0.1 mg/kg, about 0.2 mg/kg, about 0.3 mg/kg, about 0.4 mg/kg, about 0.5 mg/kg, about 0.6 mg/kg, about 0.7 mg/kg, about 0.8 mg/kg, about 0.9 mg/kg, about 1.0 mg/kg, about 1.1 mg/kg, about 1.2 mg/kg, about 1.3 mg/kg, about 1.4 mg/kg, about 1.5 mg/kg, about 1.6 mg/kg, about 1.7 mg/kg, about 1.8 mg/kg, about 1.9 mg/kg, about 2.0 mg/kg, about 2.1 mg/
  • the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present at a dose of 0.01 mg/kg, 0.02 mg/kg, 0.03 mg/kg, 0.04 mg/kg, 0.05 mg/kg, 0.06 mg/kg, 0.07 mg/kg, 0.08 mg/kg, 0.09 mg/kg, 0.1 mg/kg, 0.2 mg/kg, 0.3 mg/kg, 0.4 mg/kg, 0.5 mg/kg, 0.6 mg/kg, 0.7 mg/kg, 0.8 mg/kg, 0.9 mg/kg, 1.0 mg/kg, 1.1 mg/kg, 1.2 mg/kg, 1.3 mg/kg, 1.4 mg/kg, 1.5 mg/kg, 1.6 mg/kg, 1.7 mg/kg, 1.8 mg/kg, 1.9 mg/kg, 2.0 mg/kg, 2.1 mg/kg, 2.2 mg/kg, 2.3 mg/kg, 2.4 mg/kg, 2.5 mg/kg, 2.6 mg/kg, 2.0 mg/kg
  • the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present in an amout of about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85 mg, about 90 mg, about 95 mg, about 100 mg, 110 mg, about 115 mg, about 120 mg, about 125 mg, about 130 mg, about 135 mg, about 140 mg, about 145 mg, about 150 mg, about 155 mg, about 160 mg, about 165 mg, about 170 mg, about 175 mg, about 180 mg, about 185 mg, about 190 mg, about 195 mg, about 200 mg, about 210 mg, about 215 mg, about 220 mg, about 225 mg, about 230 mg, about 235 mg, about 240 mg, about 245 mg, about 250 mg, about
  • the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present in an amout of 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 110 mg, 115 mg, 120 mg, 125 mg, 130 mg, 135 mg, 140 mg, 145 mg, 150 mg, 155 mg, 160 mg, 165 mg, 170 mg, 175 mg, 180 mg, 185 mg, 190 mg, 195 mg, 200 mg, 210 mg, 215 mg, 220 mg, 225 mg, 230 mg, 235 mg, 240 mg, 245 mg, 250 mg, 255 mg, 260 mg, 265 mg, 270 mg, 275 mg, 280 mg, 285 mg, 290 mg, 295 mg, 300 mg, 310 mg, 315 mg,
  • the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present in an amout of 25 mg, 50 mg, 100 mg, 150 mg, 200 mg, 250 mg, or 300 mg.
  • the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the antibody, or antigen-binding fragment thereof, is present in an amout of 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 500 mg, or 600 mg.
  • the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, present at a dose of about 0.03 mg/kg to about 10 mg/kg, is present in an amount of 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 110 mg, 115 mg, 120 mg, 125 mg, 130 mg, 135 mg, 140 mg, 145 mg, 150 mg, 155 mg, 160 mg, 165 mg, 170 mg, 175 mg, 180 mg, 185 mg, 190 mg, 195 mg, 200 mg, 210 mg, 215 mg, 220 mg, 225 mg, 230 mg, 235 mg, 240 mg, 245 mg, 250 mg, 255 mg, 260 mg, 265 mg, 270 mg, 275 mg, 280 mg, 285 mg, 290 mg, 295 mg, 300 mg, 310 mg,
  • the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, present at a dose of about 0.03 mg/kg to about 10 mg/kg, is present in an amount of 25 mg, 50 mg, 100 mg, 150 mg, 200 mg, 250 mg, or 300 mg.
  • the pharmaceutical composition comprises an anti-TSLP-R antibody, or antigen-binding fragment thereof, present at a dose of about 0.03 mg/kg to about 10 mg/kg, is present in an amount of 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 500 mg, or 600 mg.
  • the antibody, or antigen-binding fragment thereof, provided herein are admixed with a pharmaceutically acceptable carrier or excipient. See, e.g., Remington's Pharmaceutical Sciences and U.S. Pharmacopeia: National Formulary, Mack Publishing Company, Easton, PA (1984) .
  • Formulations of therapeutic and diagnostic agents may be prepared by mixing with acceptable carriers, excipients, or stabilizers in the form of, e.g., lyophilized powders, slurries, aqueous solutions or suspensions (see, e.g., Hardman, et al. (2001) Goodman and Gilman's The Pharmacological Basis of Therapeutics, McGraw-Hill, New York, NY; Gennaro (2000) Remington: The Science and Practice of Pharmacy, Lippincott, Williams, and Wilkins, New York, NY; Avis, et al. (eds. ) (1993) Pharmaceutical Dosage Forms: Parenteral Medications, Marcel Dekker, NY; Lieberman, et al. (eds.
  • NaCl or sucrose is added to the anti-TSLP-R antibody composition for tonicity. Additional agents, such as polysorbate 20 or polysorbate 80, may be added to enhance stability.
  • the pharmaceutical compositions can further comprise one or more pharmaceutically acceptable carriers, including, e.g., ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, acetates, succinates, sucrose, glycine, arginine, proline, histidine, glutamate, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, sodium acetate, sodium succinate, sodium phosphate, histidine hydrochloride, glycine hydrochloride, arginine hydrochloride, proline hydrochloride, glutamate hydrochloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene
  • the pharmaceutical compositions described herein comprise a buffer (e.g., histidine, acetate, phosphate or citrate buffer) and/or a stabilizer agent (e.g. human albumin) , etc., or a combination thereof.
  • the buffer is used to buffer the pH.
  • the pH of the pharmaceutical composition is from about 4.4 to about 7.6.
  • the pH of the pharmaceutical composition is from about 5.0 to about 6.5.
  • the pH of the pharmaceutical composition if about 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, or 6.5.
  • the pH of the pharmaceutical composition is about 5.0. In some embodiments, the pH of the pharmaceutical composition is about 5.1. In some embodiments, the pH of the pharmaceutical composition is about 5.2. In some embodiments, the pH of the pharmaceutical composition is about 5.3. In some embodiments, the pH of the pharmaceutical composition is about 5.4. In some embodiments, the pH of the pharmaceutical composition is about 5.5. In some embodiments, the pH of the pharmaceutical composition is about 5.6. In some embodiments, the pH of the pharmaceutical composition is about 5.7. In some embodiments, the pH of the pharmaceutical composition is about 5.8. In some embodiments, the pH of the pharmaceutical composition is about 5.9. In some embodiments, the pH of the pharmaceutical composition is about 6.0. In some embodiments, the pH of the pharmaceutical composition is about 6.1.
  • the pH of the pharmaceutical composition is about 6.2. In some embodiments, the pH of the pharmaceutical composition is about 6.3. In some embodiments, the pH of the pharmaceutical composition is about 6.4. In some embodiments, the pH of the pharmaceutical composition is about 6.5.
  • the pharmaceutical composition comprises a pharmaceutically acceptable buffer, wherein the pharmaceutically acceptable buffer is phosphoric acid buffer, citric acid buffer, acetic acid buffer, succinic acid buffer, citrate buffer, ascorbic acid buffer, glutamic acid buffer, lactic acid buffer, maleic acid buffer, trometamol buffer, and gluconic acid buffer, acetate buffer, succinate buffer, phosphate buffer, histidine buffer or any combination thereof.
  • the pharmaceutically acceptable buffer is phosphoric acid buffer, citric acid buffer, acetic acid buffer, succinic acid buffer, citrate buffer, ascorbic acid buffer, glutamic acid buffer, lactic acid buffer, maleic acid buffer, trometamol buffer, and gluconic acid buffer, acetate buffer, succinate buffer, phosphate buffer, histidine buffer or any combination thereof.
  • the pharmaceutical composition comprises a citric acid buffer. In some embodiments, the pharmaceutical composition comprises an acetic acid buffer. In some embodiments, the pharmaceutical composition comprises a succinic acid buffer. In some embodiments, the pharmaceutical composition comprises a citrate buffer. In some embodiments, the pharmaceutical composition comprises an ascorbic acid buffer. In some embodiments, the pharmaceutical composition comprises a glutamic acid buffer. In some embodiments, the pharmaceutical composition comprises a lactic acid buffer. In some embodiments, the pharmaceutical composition comprises a maleic acid buffer. In some embodiments, the pharmaceutical composition comprises a trometamol acid buffer. In some embodiments, the pharmaceutical composition comprises a gluconic acid buffer. In some embodiments, the pharmaceutical composition comprises an acetate buffer. In some embodiments, the pharmaceutical composition comprises a succinate buffer. In some embodiments, the pharmaceutical composition comprises a phosphate buffer. In some embodiments, the pharmaceutical composition comprises a histidine buffer.
  • the pharmaceutically acceptable buffer is about 5 mmol/L phosphoric acid buffer to about 100 mmol/L phosphoric acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L to about 70 mmol/L phosphoric acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L to about 50 mmol/L phosphoric acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 5 mmol/L to about 60 mmol/L phosphoric acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L to about 40 mmol/L phosphoric acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 15 mmol/L to about 30 mmol/L phosphoric acid buffer. In some embodiments, 15 mmol/L to about 25 mmol/L phosphoric acid buffer.
  • the pharmaceutically acceptable buffer is about 5 mmol/L phosphoric acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L phosphoric acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 15 mmol/L phosphoric acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 20 mmol/L phosphoric acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 25 mmol/L phosphoric acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 30 mmol/L phosphoric acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 35 mmol/L phosphoric acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 40 mmol/L phosphoric acid buffer.
  • the pharmaceutically acceptable buffer is about 45 mmol/L phosphoric acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 50 mmol/L phosphoric acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 55 mmol/L phosphoric acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 60 mmol/L phosphoric acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 75 mmol/L phosphoric acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 80 mmol/L phosphoric acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 85 mmol/L phosphoric acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 90 mmol/L phosphoric acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 95 mmol/L phosphoric acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 100 mmol/L phosphoric acid buffer.
  • the pharmaceutically acceptable buffer is about 5 mmol/L citric acid buffer to about 100 mmol/L citric acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L to about 70 mmol/L citric acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L to about 50 mmol/L citric acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 5 mmol/L to about 60 mmol/L citric acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L to about 40 mmol/L citric acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 15 mmol/L to about 30 mmol/L citric acid buffer. In some embodiments, 15 mmol/L to about 25 mmol/L citric acid buffer.
  • the pharmaceutically acceptable buffer is about 5 mmol/L citric acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L citric acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 15 mmol/L citric acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 20 mmol/L citric acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 25 mmol/L citric acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 30 mmol/L citric acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 35 mmol/L citric acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 40 mmol/L citric acid buffer.
  • the pharmaceutically acceptable buffer is about 45 mmol/L citric acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 50 mmol/L citric acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 55 mmol/L citric acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 60 mmol/L citric acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 75 mmol/L citric acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 80 mmol/L citric acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 85 mmol/L citric acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 90 mmol/L citric acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 95 mmol/L citric acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 100 mmol/L citric acid buffer.
  • the pharmaceutically acceptable buffer is about 5 mmol/L acetic acid buffer to about 100 mmol/L acetic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L to about 70 mmol/L acetic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L to about 50 mmol/L acetic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 5 mmol/L to about 60 mmol/L acetic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L to about 40 mmol/L acetic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 15 mmol/L to about 30 mmol/L acetic acid buffer. In some embodiments, 15 mmol/L to about 25 mmol/L acetic acid buffer.
  • the pharmaceutically acceptable buffer is about 5 mmol/L acetic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L acetic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 15 mmol/L acetic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 20 mmol/L acetic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 25 mmol/L acetic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 30 mmol/L acetic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 35 mmol/L acetic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 40 mmol/L acetic acid buffer.
  • the pharmaceutically acceptable buffer is about 45 mmol/L acetic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 50 mmol/L acetic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 55 mmol/L acetic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 60 mmol/L acetic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 75 mmol/L acetic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 80 mmol/L acetic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 85 mmol/L acetic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 90 mmol/L acetic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 95 mmol/L acetic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 100 mmol/L acetic acid buffer.
  • the pharmaceutically acceptable buffer is about 5 mmol/L succinic acid buffer to about 100 mmol/L succinic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L to about 70 mmol/L succinic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L to about 50 mmol/L succinic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 5 mmol/L to about 60 mmol/L succinic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L to about 40 mmol/L succinic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 15 mmol/L to about 30 mmol/L succinic acid buffer. In some embodiments, 15 mmol/L to about 25 mmol/L succinic acid buffer.
  • the pharmaceutically acceptable buffer is about 5 mmol/L succinic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L succinic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 15 mmol/L succinic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 20 mmol/L succinic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 25 mmol/L succinic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 30 mmol/L succinic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 35 mmol/L succinic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 40 mmol/L succinic acid buffer.
  • the pharmaceutically acceptable buffer is about 45 mmol/L succinic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 50 mmol/L succinic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 55 mmol/L succinic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 60 mmol/L succinic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 75 mmol/L succinic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 80 mmol/L succinic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 85 mmol/L succinic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 90 mmol/L succinic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 95 mmol/L succinic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 100 mmol/L succinic acid buffer.
  • the pharmaceutically acceptable buffer about 5 mmol/L citrate buffer to about 100 mmol/L citrate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L to about 70 mmol/L citrate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L to about 50 mmol/L citrate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 5 mmol/L to about 60 mmol/L citrate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L to about 40 mmol/L citrate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 15 mmol/L to about 30 mmol/L citrate buffer. In some embodiments, 15 mmol/L to about 25 mmol/L citrate buffer.
  • the pharmaceutically acceptable buffer is about 5 mmol/L citrate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L citrate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 15 mmol/L citrate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 20 mmol/L citrate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 25 mmol/L citrate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 30 mmol/L citrate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 35 mmol/L citrate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 40 mmol/L citrate buffer.
  • the pharmaceutically acceptable buffer is about 45 mmol/L citrate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 50 mmol/L citrate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 55 mmol/L citrate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 60 mmol/L citrate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 75 mmol/L citrate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 80 mmol/L citrate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 85 mmol/L citrate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 90 mmol/L citrate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 95 mmol/L citrate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 100 mmol/L citrate buffer.
  • the pharmaceutically acceptable buffer is about 5 mmol/L ascorbic acid buffer to about 100 mmol/L ascorbic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L to about 70 mmol/L ascorbic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L to about 50 mmol/L ascorbic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 5 mmol/L to about 60 mmol/L ascorbic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L to about 40 mmol/L ascorbic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 15 mmol/L to about 30 mmol/L ascorbic acid buffer. In some embodiments, 15 mmol/L to about 25 mmol/L ascorbic acid buffer.
  • the pharmaceutically acceptable buffer is about 5 mmol/L ascorbic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L ascorbic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 15 mmol/L ascorbic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 20 mmol/L ascorbic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 25 mmol/L ascorbic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 30 mmol/L ascorbic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 35 mmol/L ascorbic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 40 mmol/L ascorbic acid buffer.
  • the pharmaceutically acceptable buffer is about 45 mmol/L ascorbic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 50 mmol/L ascorbic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 55 mmol/L ascorbic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 60 mmol/L ascorbic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 75 mmol/L ascorbic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 80 mmol/L ascorbic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 85 mmol/L ascorbic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 90 mmol/L ascorbic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 95 mmol/L ascorbic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 100 mmol/L ascorbic acid buffer.
  • the pharmaceutically acceptable buffer is about 5 mmol/L glutamic acid buffer to about 100 mmol/L glutamic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L to about 70 mmol/L glutamic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L to about 50 mmol/L glutamic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 5 mmol/L to about 60 mmol/L glutamic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L to about 40 mmol/L glutamic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 15 mmol/L to about 30 mmol/L glutamic acid buffer. In some embodiments, 15 mmol/L to about 25 mmol/L glutamic acid buffer.
  • the pharmaceutically acceptable buffer is about 5 mmol/L glutamic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L glutamic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 15 mmol/L glutamic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 20 mmol/L glutamic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 25 mmol/L glutamic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 30 mmol/L glutamic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 35 mmol/L glutamic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 40 mmol/L glutamic acid buffer.
  • the pharmaceutically acceptable buffer is about 45 mmol/L glutamic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 50 mmol/L glutamic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 55 mmol/L glutamic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 60 mmol/L glutamic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 75 mmol/L glutamic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 80 mmol/L glutamic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 85 mmol/L glutamic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 90 mmol/L glutamic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 95 mmol/L glutamic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 100 mmol/L glutamic acid buffer.
  • the pharmaceutically acceptable buffer is about 5 mmol/L lactic acid buffer to about 100 mmol/L lactic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L to about 70 mmol/L lactic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L to about 50 mmol/L lactic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 5 mmol/L to about 60 mmol/L lactic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L to about 40 mmol/L lactic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 15 mmol/L to about 30 mmol/L lactic acid buffer. In some embodiments, 15 mmol/L to about 25 mmol/L lactic acid buffer.
  • the pharmaceutically acceptable buffer is about 5 mmol/L lactic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L lactic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 15 mmol/L lactic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 20 mmol/L lactic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 25 mmol/L lactic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 30 mmol/L lactic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 35 mmol/L lactic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 40 mmol/L lactic acid buffer.
  • the pharmaceutically acceptable buffer is about 45 mmol/L lactic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 50 mmol/L lactic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 55 mmol/L lactic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 60 mmol/L lactic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 75 mmol/L lactic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 80 mmol/L lactic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 85 mmol/L lactic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 90 mmol/L lactic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 95 mmol/L lactic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 100 mmol/L lactic acid buffer.
  • the pharmaceutically acceptable buffer is about 5 mmol/L maleic acid buffer to about 100 mmol/L maleic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L to about 70 mmol/L maleic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L to about 50 mmol/L maleic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 5 mmol/L to about 60 mmol/L maleic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L to about 40 mmol/L maleic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 15 mmol/L to about 30 mmol/L maleic acid buffer. In some embodiments, 15 mmol/L to about 25 mmol/L maleic acid buffer.
  • the pharmaceutically acceptable buffer is about 5 mmol/L maleic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L maleic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 15 mmol/L maleic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 20 mmol/L maleic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 25 mmol/L maleic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 30 mmol/L maleic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 35 mmol/L maleic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 40 mmol/L maleic acid buffer.
  • the pharmaceutically acceptable buffer is about 45 mmol/L maleic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 50 mmol/L maleic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 55 mmol/L maleic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 60 mmol/L maleic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 75 mmol/L maleic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 80 mmol/L maleic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 85 mmol/L maleic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 90 mmol/L maleic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 95 mmol/L maleic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 100 mmol/L maleic acid buffer.
  • the pharmaceutically acceptable buffer is about 5 mmol/L trometamol buffer to about 100 mmol/L trometamol buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L to about 70 mmol/L trometamol buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L to about 50 mmol/L trometamol buffer. In some embodiments, the pharmaceutically acceptable buffer is about 5 mmol/L to about 60 mmol/L trometamol buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L to about 40 mmol/L trometamol buffer. In some embodiments, the pharmaceutically acceptable buffer is about 15 mmol/L to about 30 mmol/L trometamol buffer. In some embodiments, 15 mmol/L to about 25 mmol/L trometamol buffer.
  • the pharmaceutically acceptable buffer is about 5 mmol/L trometamol buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L trometamol buffer. In some embodiments, the pharmaceutically acceptable buffer is about 15 mmol/L trometamol buffer. In some embodiments, the pharmaceutically acceptable buffer is about 20 mmol/L trometamol buffer. In some embodiments, the pharmaceutically acceptable buffer is about 25 mmol/L trometamol buffer. In some embodiments, the pharmaceutically acceptable buffer is about 30 mmol/L trometamol buffer. In some embodiments, the pharmaceutically acceptable buffer is about 35 mmol/L trometamol buffer. In some embodiments, the pharmaceutically acceptable buffer is about 40 mmol/L trometamol buffer.
  • the pharmaceutically acceptable buffer is about 45 mmol/L trometamol buffer. In some embodiments, the pharmaceutically acceptable buffer is about 50 mmol/L trometamol buffer. In some embodiments, the pharmaceutically acceptable buffer is about 55 mmol/L trometamol buffer. In some embodiments, the pharmaceutically acceptable buffer is about 60 mmol/L trometamol buffer. In some embodiments, the pharmaceutically acceptable buffer is about 75 mmol/L trometamol buffer. In some embodiments, the pharmaceutically acceptable buffer is about 80 mmol/L trometamol buffer. In some embodiments, the pharmaceutically acceptable buffer is about 85 mmol/L trometamol buffer. In some embodiments, the pharmaceutically acceptable buffer is about 90 mmol/L trometamol buffer. In some embodiments, the pharmaceutically acceptable buffer is about 95 mmol/L trometamol buffer. In some embodiments, the pharmaceutically acceptable buffer is about 100 mmol/L trometamol buffer.
  • the pharmaceutically acceptable buffer is about 5 mmol/L gluconic acid buffer to about 100 mmol/L gluconic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L to about 70 mmol/L gluconic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L to about 50 mmol/L gluconic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 5 mmol/L to about 60 mmol/L gluconic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L to about 40 mmol/L gluconic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 15 mmol/L to about 30 mmol/L gluconic acid buffer. In some embodiments, 15 mmol/L to about 25 mmol/L gluconic acid buffer.
  • the pharmaceutically acceptable buffer is about 5 mmol/L gluconic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L gluconic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 15 mmol/L gluconic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 20 mmol/L gluconic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 25 mmol/L gluconic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 30 mmol/L gluconic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 35 mmol/L gluconic acid buffer.
  • the pharmaceutically acceptable buffer is about 40 mmol/L gluconic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 45 mmol/L gluconic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 50 mmol/L gluconic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 55 mmol/L gluconic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 60 mmol/L gluconic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 75 mmol/L gluconic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 80 mmol/L gluconic acid buffer.
  • the pharmaceutically acceptable buffer is about 85 mmol/L gluconic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 90 mmol/L gluconic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 95 mmol/L gluconic acid buffer. In some embodiments, the pharmaceutically acceptable buffer is about 100 mmol/L gluconic acid buffer.
  • the pharmaceutically acceptable buffer is about 5 mmol/L acetate buffer to about 100 mmol/L acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L to about 70 mmol/L acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L to about 50 mmol/L acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 5 mmol/L to about 60 mmol/L acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L to about 40 mmol/L acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 15 mmol/L to about 30 mmol/L acetate buffer. In some embodiments, 15 mmol/L to about 25 mmol/L acetate buffer.
  • the pharmaceutically acceptable buffer is about 5 mmol/L acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 15 mmol/L acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 20 mmol/L acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 25 mmol/L acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 30 mmol/L acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 35 mmol/L acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 40 mmol/L acetate buffer.
  • the pharmaceutically acceptable buffer is about 45 mmol/L acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 50 mmol/L acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 55 mmol/L acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 60 mmol/L acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 75 mmol/L acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 80 mmol/L acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 85 mmol/L acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 90 mmol/L acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 95 mmol/L acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 100 mmol/L acetate buffer.
  • the pharmaceutical composition comprises a pharmaceutically acceptable buffer, wherein the pharmaceutically acceptable buffer is an acetate buffer, wherein the acetate buffer can be, but is not limited to, sodium acetate, potassium acetate, or magnesium acetate, or any combination thereof.
  • the pharmaceutical composition comprises a sodium acetate buffer.
  • the pharmaceutical composition comprises a potassium acetate buffer.
  • the pharmaceutical composition comprises a magnesium acetate buffer.
  • the pharmaceutically acceptable buffer is about 5 mmol/L potassium acetate buffer to about 100 mmol/L potassium acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L to about 70 mmol/L potassium acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L to about 50 mmol/L potassium acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 5 mmol/L to about 60 mmol/L potassium acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L to about 40 mmol/L potassium acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 15 mmol/L to about 30 mmol/L potassium acetate buffer. In some embodiments, 15 mmol/L to about 25 mmol/L potassium acetate buffer.
  • the pharmaceutically acceptable buffer is about 5 mmol/L potassium acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L potassium acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 15 mmol/L potassium acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 20 mmol/L potassium acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 25 mmol/L potassium acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 30 mmol/L potassium acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 35 mmol/L potassium acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 40 mmol/L potassium acetate buffer.
  • the pharmaceutically acceptable buffer is about 45 mmol/L potassium acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 50 mmol/L potassium acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 55 mmol/L potassium acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 60 mmol/L potassium acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 75 mmol/L potassium acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 80 mmol/L potassium acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 85 mmol/L potassium acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 90 mmol/L potassium acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 95 mmol/L potassium acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 100 mmol/L potassium acetate buffer.
  • the pharmaceutically acceptable buffer is about 5 mmol/L magnesium acetate buffer to about 100 mmol/L magnesium acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L to about 70 mmol/L magnesium acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L to about 50 mmol/L magnesium acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 5 mmol/L to about 60 mmol/L magnesium acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L to about 40 mmol/L magnesium acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 15 mmol/L to about 30 mmol/L magnesium acetate buffer. In some embodiments, 15 mmol/L to about 25 mmol/L magnesium acetate buffer.
  • the pharmaceutically acceptable buffer is about 5 mmol/L magnesium acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L magnesium acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 15 mmol/L magnesium acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 20 mmol/L magnesium acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 25 mmol/L magnesium acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 30 mmol/L magnesium acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 35 mmol/L magnesium acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 40 mmol/L magnesium acetate buffer.
  • the pharmaceutically acceptable buffer is about 45 mmol/L magnesium acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 50 mmol/L magnesium acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 55 mmol/L magnesium acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 60 mmol/L magnesium acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 75 mmol/L magnesium acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 80 mmol/L magnesium acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 85 mmol/L magnesium acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 90 mmol/L magnesium acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 95 mmol/L magnesium acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 100 mmol/L magnesium acetate buffer.
  • the pharmaceutically acceptable buffer is about 5 mmol/L sodium acetate buffer to about 100 mmol/L sodium acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L to about 70 mmol/L sodium acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L to about 50 mmol/L sodium acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 5 mmol/L to about 60 mmol/L sodium acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L to about 40 mmol/L sodium acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 15 mmol/L to about 30 mmol/L sodium acetate buffer. In some embodiments, 15 mmol/L to about 25 mmol/L sodium acetate buffer.
  • the pharmaceutically acceptable buffer is about 5 mmol/L sodium acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L sodium acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 15 mmol/L sodium acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 20 mmol/L sodium acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 25 mmol/L sodium acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 30 mmol/L sodium acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 35 mmol/L sodium acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 40 mmol/L sodium acetate buffer.
  • the pharmaceutically acceptable buffer is about 45 mmol/L sodium acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 50 mmol/L sodium acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 55 mmol/L sodium acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 60 mmol/L sodium acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 75 mmol/L sodium acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 80 mmol/L sodium acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 85 mmol/L sodium acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 90 mmol/L sodium acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 95 mmol/L sodium acetate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 100 mmol/L sodium acetate buffer.
  • the pharmaceutically acceptable buffer is about 5 mmol/L succinate buffer to about 100 mmol/L succinate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L to about 70 mmol/L succinate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L to about 50 mmol/L succinate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 5 mmol/L to about 60 mmol/L succinate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L to about 40 mmol/L succinate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 15 mmol/L to about 30 mmol/L succinate buffer. In some embodiments, 15 mmol/L to about 25 mmol/L succinate buffer.
  • the pharmaceutically acceptable buffer is about 5 mmol/L succinate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L succinate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 15 mmol/L succinate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 20 mmol/L succinate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 25 mmol/L succinate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 30 mmol/L succinate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 35 mmol/L succinate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 40 mmol/L succinate buffer.
  • the pharmaceutically acceptable buffer is about 45 mmol/L succinate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 50 mmol/L succinate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 55 mmol/L succinate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 60 mmol/L succinate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 75 mmol/L succinate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 80 mmol/L succinate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 85 mmol/L succinate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 90 mmol/L succinate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 95 mmol/L succinate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 100 mmol/L succinate buffer.
  • the succinate buffer is about 5 mmol/L sodium succinate buffer to about 100 mmol/L sodium succinate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L to about 70 mmol/L sodium succinate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L to about 50 mmol/L sodium succinate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 5 mmol/L to about 60 mmol/L sodium succinate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L to about 40 mmol/L sodium succinate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 15 mmol/L to about 30 mmol/L sodium succinate buffer. In some embodiments, 15 mmol/L to about 25 mmol/L sodium succinate buffer.
  • the pharmaceutically acceptable buffer is about 5 mmol/L sodium succinate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L sodium succinate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 15 mmol/L sodium succinate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 20 mmol/L sodium succinate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 25 mmol/L sodium succinate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 30 mmol/L sodium succinate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 35 mmol/L sodium succinate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 40 mmol/L sodium succinate buffer.
  • the pharmaceutically acceptable buffer is about 45 mmol/L sodium succinate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 50 mmol/L sodium succinate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 55 mmol/L sodium succinate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 60 mmol/L sodium succinate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 75 mmol/L sodium succinate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 80 mmol/L sodium succinate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 85 mmol/L sodium succinate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 90 mmol/L sodium succinate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 95 mmol/L sodium succinate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 100 mmol/L sodium succinate buffer.
  • the pharmaceutically acceptable buffer is about 5 mmol/L phosphate buffer to about 100 mmol/L phosphate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L to about 70 mmol/L phosphate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L to about 50 mmol/L phosphate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 5 mmol/L to about 60 mmol/L phosphate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L to about 40 mmol/L phosphate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 15 mmol/L to about 30 mmol/L phosphate buffer. In some embodiments, 15 mmol/L to about 25 mmol/L phosphate buffer.
  • the pharmaceutically acceptable buffer is about 5 mmol/L phosphate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L phosphate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 15 mmol/L phosphate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 20 mmol/L phosphate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 25 mmol/L phosphate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 30 mmol/L phosphate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 35 mmol/L phosphate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 40 mmol/L phosphate buffer.
  • the pharmaceutically acceptable buffer is about 45 mmol/L phosphate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 50 mmol/L phosphate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 55 mmol/L phosphate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 60 mmol/L phosphate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 75 mmol/L phosphate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 80 mmol/L phosphate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 85 mmol/L phosphate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 90 mmol/L phosphate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 95 mmol/L phosphate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 100 mmol/L phosphate buffer.
  • the phosphate buffer is sodium phosphate. In some embodiments, the pharmaceutically acceptable buffer is about 5 mmol/L sodium phosphate buffer to about 100 mmol/L sodium phosphate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L to about 70 mmol/L sodium phosphate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L to about 50 mmol/L sodium phosphate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 5 mmol/L to about 60 mmol/L sodium phosphate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L to about 40 mmol/L sodium phosphate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 15 mmol/L to about 30 mmol/L sodium phosphate buffer. In some embodiments, 15 mmol/L to about 25 mmol/L sodium phosphate buffer.
  • the pharmaceutically acceptable buffer is about 5 mmol/L sodium phosphate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L sodium phosphate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 15 mmol/L sodium phosphate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 20 mmol/L sodium phosphate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 25 mmol/L sodium phosphate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 30 mmol/L sodium phosphate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 35 mmol/L sodium phosphate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 40 mmol/L sodium phosphate buffer.
  • the pharmaceutically acceptable buffer is about 45 mmol/L sodium phosphate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 50 mmol/L sodium phosphate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 55 mmol/L sodium phosphate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 60 mmol/L sodium phosphate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 75 mmol/L sodium phosphate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 80 mmol/L sodium phosphate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 85 mmol/L sodium phosphate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 90 mmol/L sodium phosphate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 95 mmol/L sodium phosphate buffer. In some embodiments, the pharmaceutically acceptable buffer is about 100 mmol/L sodium phosphate buffer.
  • the pharmaceutically acceptable buffer is about 5 mmol/L to about 100 mmol/L histidine buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L to about 70 mmol/L histidine buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L to about 50 mmol/L histidine buffer. In some embodiments, the pharmaceutically acceptable buffer is about 5 mmol/L to about 60 mmol/L histidine buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L to about 40 mmol/L histidine buffer. In some embodiments, the pharmaceutically acceptable buffer is about 15 mmol/L to about 30 mmol/L histidine buffer. In some embodiments, 15 mmol/L to about 25 mmol/L histidine buffer.
  • the pharmaceutically acceptable buffer is about 5 mmol/L histidine buffer. In some embodiments, the pharmaceutically acceptable buffer is about 10 mmol/L histidine buffer. In some embodiments, the pharmaceutically acceptable buffer is about 15 mmol/L histidine buffer. In some embodiments, the pharmaceutically acceptable buffer is about 20 mmol/L histidine buffer. In some embodiments, the pharmaceutically acceptable buffer is about 25 mmol/L histidine buffer. In some embodiments, the pharmaceutically acceptable buffer is about 30 mmol/L histidine buffer. In some embodiments, the pharmaceutically acceptable buffer is about 35 mmol/L histidine buffer. In some embodiments, the pharmaceutically acceptable buffer is about 40 mmol/L histidine buffer.
  • the pharmaceutically acceptable buffer is about 45 mmol/L histidine buffer. In some embodiments, the pharmaceutically acceptable buffer is about 50 mmol/L histidine buffer. In some embodiments, the pharmaceutically acceptable buffer is about 55 mmol/L histidine buffer. In some embodiments, the pharmaceutically acceptable buffer is about 60 mmol/L histidine buffer. In some embodiments, the pharmaceutically acceptable buffer is about 75 mmol/L histidine buffer. In some embodiments, the pharmaceutically acceptable buffer is about 80 mmol/L histidine buffer. In some embodiments, the pharmaceutically acceptable buffer is about 85 mmol/L histidine buffer. In some embodiments, the pharmaceutically acceptable buffer is about 90 mmol/L histidine buffer. In some embodiments, the pharmaceutically acceptable buffer is about 95 mmol/L histidine buffer. In some embodiments, the pharmaceutically acceptable buffer is about 100 mmol/L histidine buffer.
  • interfacial stress e.g., from air/water interfaces in liquid compositions, or ice/water interfaces during freezing/thawing.
  • Surfactants are typically used to stabilize proteins in biopharmaceutical compositions while under stress or long-term storage to prevent or minimize aggregation and/or particle formation.
  • a surfactant examples include, but are not limited to, anionic surfactants (e.g., ammonium lauryl sulfate, sodium lauryl sulfate, sodium laureth sulfate, sodium myreth sulfate, diocytl sodium sulfosuccinate, perfluorooctanesulfonate, perfluorobutanesulfonate, alkyl-aryl ether phosphates, alkyl ether phosphates, carboxylates, sodium lauroyl sarcosinate, perfluorononanoate, perfluorooctanoate) ; cationic surfactants (e.g., octenidine dihydrochloride, cetrimonium bromide, cetylpyridinium chloride, benzalkonium chloride, benzethonium chloride, dimethyldioctadecylammonium chloride, and dioctade
  • the pharmaceutical composition comprises a surfactant, wherein the surfactant is a polysorbate or a poloxamer.
  • the pharmaceutical composition comprises a polysorbate, wherein the polysorbate is polysorbate 20 (PS20) or polysorbate 80 (PS80) .
  • PS80 is also known as polyoxyethylene (20) sorbitan monooleate, and is represented by the formula:
  • PS20 is also known as polyoxyethylene (20) sorbitan monolaurate, and is represented by the formula:
  • the surfactant is a poloxamer.
  • Poloxamers are nonionic triblock copolymers composed of a central hydrophobic chain of polyoxypropylene (polypropylene oxide) flanked by two hydrophilic chains of polyoxyethylene (poly (ethylene oxide) ) .
  • the pharmaceutical composition comprises a poloxamer, wherein the poloxamer is poloxamer 188, poloxamer 407, poloxamer 184, poloxamer 124, or a combination thereof.
  • the pharmaceutical composition comprises poloxamer 188.
  • the pharmaceutical composition comprises poloxamer 407.
  • the pharmaceutical composition comprises poloxamer 184.
  • the pharmaceutical composition comprises poloxamer 124.
  • the pharmaceutical composition comprises a surfactant, wherein the surfactant is present at a concentration of about 0.001% (w/v) to about 1% (w/v) . In some embodiments, the pharmaceutical composition comprises a surfactant, wherein the surfactant is present at a concentration of about 0.01% (w/v) to about 0.5% (w/v) . In some embodiments, the pharmaceutical composition comprises a surfactant, wherein the surfactant is present at a concentration of about 0.01% (w/v) to about 0.1% (w/v) . In some embodiments, the pharmaceutical composition comprises a surfactant, wherein the surfactant is present at a concentration of about 0.02% (w/v) to about 0.05% (w/v) .
  • the pharmaceutical composition comprises a surfactant, wherein the surfactant is present at a concentration of about 0.01% (w/v) . In some embodiments, the pharmaceutical composition comprises a surfactant, wherein the surfactant is present at a concentration of about 0.02% (w/v) . In some embodiments, the pharmaceutical composition comprises a surfactant, wherein the surfactant is present at a concentration of about 0.03% (w/v) . In some embodiments, the pharmaceutical composition comprises a surfactant, wherein the surfactant is present at a concentration of about 0.04% (w/v) .
  • the pharmaceutical composition comprises a surfactant, wherein the surfactant is present at a concentration of about 0.05% (w/v) . In some embodiments, the pharmaceutical composition comprises a surfactant, wherein the surfactant is present at a concentration of about 0.1% (w/v) . In some embodiments, the pharmaceutical composition comprises a surfactant, wherein the surfactant is present at a concentration of about 0.15% (w/v) . In some embodiments, the pharmaceutical composition comprises a surfactant, wherein the surfactant is present at a concentration of about 0.2% (w/v) .
  • PS20 is present at a concentration of about 0.01% (w/v) . In some embodiments, PS20 is present at a concentration of about 0.02% (w/v) . In some embodiments, PS20 is present at a concentration of about 0.03% (w/v) . In some embodiments, PS20 is present at a concentration of about 0.04% (w/v) . In some embodiments, PS20 is present at a concentration of about 0.05% (w/v) . In some embodiments, PS20 is present at a concentration of about 0.05% (w/v) . In some embodiments, PS20 is present at a concentration of about 0.1% (w/v) . In some embodiments, PS20 is present at a concentration of about 0.15% (w/v) . In some embodiments, PS20 is present at a concentration of about 0.2% (w/v) .
  • PS80 is present at a concentration of about 0.01% (w/v) . In some embodiments, PS80 is present at a concentration of about 0.02% (w/v) . In some embodiments, PS80 is present at a concentration of about 0.03% (w/v) . In some embodiments, PS80 is present at a concentration of about 0.04% (w/v) . In some embodiments, PS80 is present at a concentration of about 0.05% (w/v) . In some embodiments, PS80 is present at a concentration of about 0.1% (w/v) . In some embodiments, PS80 is present at a concentration of about 0.15% (w/v) . In some embodiments, PS80 is present at a concentration of about 0.2% (w/v) .
  • poloxamer 188 is present at a concentration of about 0.01% (w/v) . In some embodiments, poloxamer 188 is present at a concentration of about 0.02% (w/v) . In some embodiments, poloxamer 188 is present at a concentration of about 0.03% (w/v) . In some embodiments, poloxamer 188 is present at a concentration of about 0.04% (w/v) . In some embodiments, poloxamer 188 is present at a concentration of about 0.05% (w/v) . In some embodiments, poloxamer 188 is present at a concentration of about 0.05% (w/v) .
  • poloxamer 188 is present at a concentration of about 0.1% (w/v) . In some embodiments, poloxamer 188 is present at a concentration of about 0.15% (w/v) . In some embodiments, poloxamer 188 is present at a concentration of about 0.2% (w/v) .
  • poloxamer 407 is present at a concentration of about 0.01% (w/v) . In some embodiments, poloxamer 407 is present at a concentration of about 0.02% (w/v) . In some embodiments, poloxamer 407 is present at a concentration of about 0.03% (w/v) . In some embodiments, poloxamer 407 is present at a concentration of about 0.04% (w/v) . In some embodiments, poloxamer 407 is present at a concentration of about 0.05% (w/v) . In some embodiments, poloxamer 407 is present at a concentration of about 0.05% (w/v) .
  • poloxamer 407 is present at a concentration of about 0.1% (w/v) . In some embodiments, poloxamer 407 is present at a concentration of about 0.15% (w/v) . In some embodiments, poloxamer 407 is present at a concentration of about 0.2% (w/v) .
  • poloxamer 184 is present at a concentration of about 0.01% (w/v) . In some embodiments, poloxamer 184 is present at a concentration of about 0.02% (w/v) . In some embodiments, poloxamer 184 is present at a concentration of about 0.03% (w/v) . In some embodiments, poloxamer 184 is present at a concentration of about 0.04% (w/v) . In some embodiments, poloxamer 184 is present at a concentration of about 0.05% (w/v) . In some embodiments, poloxamer 184 is present at a concentration of about 0.05% (w/v) .
  • poloxamer 184 is present at a concentration of about 0.1% (w/v) . In some embodiments, poloxamer 184 is present at a concentration of about 0.15% (w/v) . In some embodiments, poloxamer 184 is present at a concentration of about 0.2% (w/v) .
  • poloxamer 124 is present at a concentration of about 0.01% (w/v) . In some embodiments, poloxamer 124 is present at a concentration of about 0.02% (w/v) . In some embodiments, poloxamer 124 is present at a concentration of about 0.03% (w/v) . In some embodiments, poloxamer 124 is present at a concentration of about 0.04% (w/v) . In some embodiments, poloxamer 124 is present at a concentration of about 0.05% (w/v) . In some embodiments, poloxamer 124 is present at a concentration of about 0.05% (w/v) .
  • poloxamer 124 is present at a concentration of about 0.1% (w/v) . In some embodiments, poloxamer 124 is present at a concentration of about 0.15% (w/v) . In some embodiments, poloxamer 124 is present at a concentration of about 0.2% (w/v) .
  • the pharmaceutical composition comprises an excipient. In some embodiments, the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 1 mmol/L to about 600 mmol/L. In some embodiments, the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 1 mmol/L to about 300 mmol/L. In some embodiments, the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 50 mmol/L to about 300 mmol/L. In some embodiments, the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 100 mmol/L to about 300 mmol/L.
  • the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 100 mmol/L to about 250 mmol/L. In some embodiments, the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 100 mmol/L to about 220 mmol/L. In some embodiments, the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 110 mmol/L to about 220 mmol/L. In some embodiments, the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 120 mmol/L to about 220 mmol/L.
  • the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 130 mmol/L to about 220 mmol/L. In some embodiments, the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 140 mmol/L to about 220 mmol/L. In some embodiments, the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 150 mmol/L to about 220 mmol/L. In some embodiments, the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 160 mmol/L to about 220 mmol/L.
  • the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 170 mmol/L to about 220 mmol/L. In some embodiments, the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 180 mmol/L to about 220 mmol/L. In some embodiments, the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 190 mmol/L to about 210 mmol/L. In some embodiments, the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 200 mmol/L.
  • the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 100 mmol/L to about 200 mmol/L. In some embodiments, the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 110 mmol/L to about 200 mmol/L. In some embodiments, the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 120 mmol/L to about 200 mmol/L. In some embodiments, the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 130 mmol/L to about 200 mmol/L.
  • the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 140 mmol/L to about 200 mmol/L. In some embodiments, the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 150 mmol/L to about 200 mmol/L. In some embodiments, the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 160 mmol/L to about 200 mmol/L. In some embodiments, the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 170 mmol/L to about 200 mmol/L.
  • the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 180 mmol/L to about 200 mmol/L. In some embodiments, the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 170 mmol/L to about 190 mmol/L. In some embodiments, the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 180 mmol/L.
  • the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 100 mmol/L to about 190 mmol/L. In some embodiments, the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 100 mmol/L to about 180 mmol/L. In some embodiments, the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 100 mmol/L to about 170 mmol/L. In some embodiments, the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 100 mmol/L to about 160 mmol/L.
  • the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 120 mmol/L to about 160 mmol/L. In some embodiments, the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 130 mmol/L to about 150 mmol/L. In some embodiments, the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 140 mmol/L.
  • the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 100 mmol/L to about 150 mmol/L. In some embodiments, the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 110 mmol/L to about 150 mmol/L. In some embodiments, the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 120 mmol/L to about 140 mmol/L. In some embodiments, the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 130 mmol/L.
  • the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 100 mmol/L to about 150 mmol/L. In some embodiments, the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 100 mmol/L to about 140 mmol/L. In some embodiments, the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 110 mmol/L to about 130 mmol/L. In some embodiments, the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 120 mmol/L.
  • the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 1 mmol/L to about 100 mmol/L. In some embodiments, the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 1 mmol/L to about 90 mmol/L. In some embodiments, the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 1 mmol/L to about 80 mmol/L. In some embodiments, the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 1 mmol/L to about 70 mmol/L.
  • the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 30 mmol/L to about 70 mmol/L. In some embodiments, the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 40 mmol/L to about 60 mmol/L. In some embodiments, the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 50 mmol/L.
  • the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 1 mmol/L to about 40 mmol/L. In some embodiments, the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 10 mmol/L to about 30 mmol/L. In some embodiments, the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 20 mmol/L.
  • the excipient is present at a concentration of about 600 mmol/L or less. In some embodiments, the excipient is present at a concentration of about 500 mmol/L or less. In some embodiments, the excipient is present at a concentration of about 400 mmol/L or less. In some embodiments, the excipient is present at a concentration of about 300 mmol/L or less. In some embodiments, the excipient is present at a concentration of about 250 mmol/L or less. In some embodiments, the excipient is present at a concentration of about 220 mmol/L or less. In some embodiments, the excipient is present at a concentration of about 200 mmol/L or less.
  • the excipient is present at a concentration of about 180 mmol/L or less. In some embodiments, the excipient is present at a concentration of about 160 mmol/L or less. In some embodiments, the excipient is present at a concentration of about 140 mmol/L or less. In some embodiments, the excipient is present at a concentration of about 120 mmol/L or less. In some embodiments, the excipient is present at a concentration of about 100 mmol/L or less. In some embodiments, the excipient is present at a concentration of about 50 mmol/L or less. In some embodiments, the excipient is present at a concentration of about 20 mmol/L or less.
  • the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 10 mmol/L. In some embodiments, the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 20 mmol/L. In some embodiments, the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 30 mmol/L. In some embodiments, the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 40 mmol/L. In some embodiments, the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 50 mmol/L.
  • the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 75 mmol/L. In some embodiments, the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 100 mmol/L. In some embodiments, the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 110 mmol/L. In some embodiments, the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 120 mmol/L. In some embodiments, the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 130 mmol/L.
  • the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 140 mmol/L. In some embodiments, the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 150 mmol/L. In some embodiments, the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 160 mmol/L. In some embodiments, the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 170 mmol/L. In some embodiments, the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 180 mmol/L.
  • the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 190 mmol/L. In some embodiments, the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 200 mmol/L. In some embodiments, the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 210 mmol/L. In some embodiments, the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 220 mmol/L. In some embodiments, the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 250 mmol/L.
  • the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 300 mmol/L. In some embodiments, the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 400 mmol/L. In some embodiments, the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 500 mmol/L. In some embodiments, the pharmaceutical composition comprises an excipient, wherein the excipient is present at a concentration of about 600 mmol/L.
  • the pharmaceutical composition comprises an excipient, wherein the excipient is an amino acid.
  • the excipient is histidine, glycine, arginine, proline, or glutamate, or a pharmaceutically acceptable salt thereof, or any combination thereof.
  • the excipient is a combination of any two or more of histidine, glycine, arginine, proline, or glutamate, or pharmaceutically acceptable salts thereof.
  • the pharmaceutical composition comprises an excipient, wherein the excipient is glycine, arginine, or proline, or a pharmaceutically acceptable salt thereof.
  • the excipient is glycine, or a pharmaceutically acceptable salt thereof.
  • the excipient is glutamate, or a pharmaceutically acceptable salt thereof.
  • the excipient is arginine, or a pharmaceutically acceptable salt thereof.
  • the excipient is histidine, or a pharmaceutically acceptable salt thereof.
  • the excipient is proline, or a pharmaceutically acceptable salt thereof.
  • the excipient is a buffering agent.
  • the buffering agent is histidine.
  • the excipient is a viscosity reducing agent.
  • the viscosity reducing agent is histidine, glycine, arginine, proline, or glutamate, or a pharmaceutically acceptable salt thereof, or any combination thereof.
  • the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof.
  • Histidine is an essential amino acid that can be represented by the formula:
  • Histidine includes the free base form of histidine, as well as any and all salts thereof.
  • histidine includes a pharmaceutically acceptable salt thereof, e.g., histidine hydrochloride.
  • the pharmaceutically acceptable salt of histidine is histidine hydrochloride.
  • Histidine, as used herein also includes all enantiomers (e.g., L-histidine and S-histidine) , and any combination of enantiomers (e.g., 50%L-histidine and 50%S-histidine; 90%-100%L-histidine and 10%-0%S-histidine, etc. ) .
  • the term “histidine” includes greater than 99%L-histidine and less than 1%S-histidine. In some embodiments, the term “histidine” includes an enantomerically pure L-histidine. In some embodiments, histidine is a pharmaceutical grade histidine.
  • the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L. In some embodiments, the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 300 mmol/L. In some embodiments, the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 50 mmol/L to about 300 mmol/L.
  • the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 300 mmol/L. In some embodiments, the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 250 mmol/L. In some embodiments, the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 220 mmol/L. In some embodiments, the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 110 mmol/L to about 220 mmol/L.
  • the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 120 mmol/L to about 220 mmol/L. In some embodiments, the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 130 mmol/L to about 220 mmol/L. In some embodiments, the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 140 mmol/L to about 220 mmol/L. In some embodiments, the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 150 mmol/L to about 220 mmol/L.
  • the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 160 mmol/L to about 220 mmol/L. In some embodiments, the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 170 mmol/L to about 220 mmol/L. In some embodiments, the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 180 mmol/L to about 220 mmol/L. In some embodiments, the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 190 mmol/L to about 210 mmol/L. In some embodiments, the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 200 mmol/L.
  • the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 200 mmol/L. In some embodiments, the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 110 mmol/L to about 200 mmol/L. In some embodiments, the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 120 mmol/L to about 200 mmol/L. In some embodiments, the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 130 mmol/L to about 200 mmol/L.
  • the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 140 mmol/L to about 200 mmol/L. In some embodiments, the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 150 mmol/L to about 200 mmol/L. In some embodiments, the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 160 mmol/L to about 200 mmol/L. In some embodiments, the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 170 mmol/L to about 190 mmol/L. In some embodiments, the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 180 mmol/L.
  • the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 190 mmol/L. In some embodiments, the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 180 mmol/L. In some embodiments, the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 170 mmol/L. In some embodiments, the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 160 mmol/L.
  • the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 120 mmol/L to about 160 mmol/L. In some embodiments, the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 130 mmol/L to about 150 mmol/L. In some embodiments, the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 140 mmol/L.
  • the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 150 mmol/L. In some embodiments, the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 110 mmol/L to about 150 mmol/L. In some embodiments, the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 120 mmol/L to about 140 mmol/L. In some embodiments, the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 130 mmol/L.
  • the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 150 mmol/L. In some embodiments, the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 140 mmol/L. In some embodiments, the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 110 mmol/L to about 130 mmol/L. In some embodiments, the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 120 mmol/L.
  • the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 100 mmol/L. In some embodiments, the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 90 mmol/L. In some embodiments, the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 80 mmol/L. In some embodiments, the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 70 mmol/L.
  • the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 30 mmol/L to about 70 mmol/L. In some embodiments, the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 40 mmol/L to about 60 mmol/L. In some embodiments, the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 50 mmol/L.
  • the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 40 mmol/L. In some embodiments, the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 10 mmol/L to about 30 mmol/L. In some embodiments, the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 20 mmol/L.
  • the histidine, or a pharmaceutically acceptable salt thereof is present at a concentration of about 600 mmol/L or less. In some embodiments, the histidine, or a pharmaceutically acceptable salt thereof, is present at a concentration of about 500 mmol/L or less. In some embodiments, the histidine, or a pharmaceutically acceptable salt thereof, is present at a concentration of about 400 mmol/L or less. In some embodiments, the histidine, or a pharmaceutically acceptable salt thereof, is present at a concentration of about 300 mmol/L or less. In some embodiments, the histidine, or a pharmaceutically acceptable salt thereof, is present at a concentration of about 250 mmol/L or less.
  • the histidine, or a pharmaceutically acceptable salt thereof is present at a concentration of about 220 mmol/L or less. In some embodiments, the histidine, or a pharmaceutically acceptable salt thereof, is present at a concentration of about 200 mmol/L or less. In some embodiments, the histidine, or a pharmaceutically acceptable salt thereof, is present at a concentration of about 180 mmol/L or less. In some embodiments, the histidine, or a pharmaceutically acceptable salt thereof, is present at a concentration of about 160 mmol/L or less. In some embodiments, the histidine, or a pharmaceutically acceptable salt thereof, is present at a concentration of about 140 mmol/L or less.
  • the histidine, or a pharmaceutically acceptable salt thereof is present at a concentration of about 120 mmol/L or less. In some embodiments, the histidine, or a pharmaceutically acceptable salt thereof, is present at a concentration of about 100 mmol/L or less. In some embodiments, the histidine, or a pharmaceutically acceptable salt thereof, is present at a concentration of about 50 mmol/L or less. In some embodiments, the histidine, or a pharmaceutically acceptable salt thereof, is present at a concentration of about 20 mmol/L or less.
  • the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 10 mmol/L. In some embodiments, the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 20 mmol/L. In some embodiments, the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 30 mmol/L. In some embodiments, the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 40 mmol/L. In some embodiments, the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 50 mmol/L.
  • the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 75 mmol/L. In some embodiments, the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L. In some embodiments, the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 110 mmol/L. In some embodiments, the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 120 mmol/L. In some embodiments, the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 130 mmol/L.
  • the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 140 mmol/L. In some embodiments, the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 150 mmol/L. In some embodiments, the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 160 mmol/L. In some embodiments, the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 170 mmol/L. In some embodiments, the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 180 mmol/L.
  • the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 190 mmol/L. In some embodiments, the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 200 mmol/L. In some embodiments, the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 210 mmol/L. In some embodiments, the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 220 mmol/L. In some embodiments, the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 250 mmol/L.
  • the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 300 mmol/L. In some embodiments, the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 400 mmol/L. In some embodiments, the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 500 mmol/L. In some embodiments, the pharmaceutical composition comprises histidine, or a pharmaceutically acceptable salt thereof, at a concentration of about 600 mmol/L.
  • composition comprises glycine, or a pharmaceutically acceptable salt thereof.
  • Glycine is an amino acid that can be represented by the formula:
  • Glycine includes the free base form of glycine, as well as any and all salts thereof.
  • glycine includes a pharmaceutically acceptable salt thereof, e.g., glycine hydrochloride.
  • the pharmaceutically acceptable salt of glycine is glycine hydrochloride.
  • Glycine, as used herein also includes all enantiomers (e.g., L-glycine and S-glycine) , and any combination of enantiomers (e.g., 50%L-glycine and 50%S-glycine; 90%-100%L-glycine and 10%-0%S-glycine, etc. ) .
  • the term “glycine” includes greater than 99%L-glycine and less than 1%S-glycine. In some embodiments, the term “glycine” includes an enantomerically pure L-glycine. In some embodiments, glycine is a pharmaceutical grade glycine.
  • the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L. In some embodiments, the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 300 mmol/L. In some embodiments, the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 50 mmol/L to about 300 mmol/L.
  • the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 300 mmol/L. In some embodiments, the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 250 mmol/L. In some embodiments, the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 220 mmol/L. In some embodiments, the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 110 mmol/L to about 220 mmol/L.
  • the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 120 mmol/L to about 220 mmol/L. In some embodiments, the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 130 mmol/L to about 220 mmol/L. In some embodiments, the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 140 mmol/L to about 220 mmol/L. In some embodiments, the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 150 mmol/L to about 220 mmol/L.
  • the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 160 mmol/L to about 220 mmol/L. In some embodiments, the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 170 mmol/L to about 220 mmol/L. In some embodiments, the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 180 mmol/L to about 220 mmol/L. In some embodiments, the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 190 mmol/L to about 210 mmol/L. In some embodiments, the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 200 mmol/L.
  • the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 200 mmol/L. In some embodiments, the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 110 mmol/L to about 200 mmol/L. In some embodiments, the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 120 mmol/L to about 200 mmol/L. In some embodiments, the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 130 mmol/L to about 200 mmol/L.
  • the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 140 mmol/L to about 200 mmol/L. In some embodiments, the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 150 mmol/L to about 200 mmol/L. In some embodiments, the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 160 mmol/L to about 200 mmol/L. In some embodiments, the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 170 mmol/L to about 190 mmol/L. In some embodiments, the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 180 mmol/L.
  • the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 190 mmol/L. In some embodiments, the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 180 mmol/L. In some embodiments, the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 170 mmol/L. In some embodiments, the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 160 mmol/L.
  • the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 120 mmol/L to about 160 mmol/L. In some embodiments, the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 130 mmol/L to about 150 mmol/L. In some embodiments, the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 140 mmol/L.
  • the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 150 mmol/L. In some embodiments, the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 110 mmol/L to about 150 mmol/L. In some embodiments, the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 120 mmol/L to about 140 mmol/L. In some embodiments, the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 130 mmol/L.
  • the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 150 mmol/L. In some embodiments, the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 140 mmol/L. In some embodiments, the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 110 mmol/L to about 130 mmol/L. In some embodiments, the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 120 mmol/L.
  • the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 100 mmol/L. In some embodiments, the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 90 mmol/L. In some embodiments, the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 80 mmol/L. In some embodiments, the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 70 mmol/L.
  • the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 30 mmol/L to about 70 mmol/L. In some embodiments, the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 40 mmol/L to about 60 mmol/L. In some embodiments, the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 50 mmol/L.
  • the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 40 mmol/L. In some embodiments, the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 10 mmol/L to about 30 mmol/L. In some embodiments, the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 20 mmol/L.
  • the glycine, or a pharmaceutically acceptable salt thereof is present at a concentration of about 600 mmol/L or less. In some embodiments, the glycine, or a pharmaceutically acceptable salt thereof, is present at a concentration of about 500 mmol/L or less. In some embodiments, the glycine, or a pharmaceutically acceptable salt thereof, is present at a concentration of about 400 mmol/L or less. In some embodiments, the glycine, or a pharmaceutically acceptable salt thereof, is present at a concentration of about 300 mmol/L or less. In some embodiments, the glycine, or a pharmaceutically acceptable salt thereof, is present at a concentration of about 250 mmol/L or less.
  • the glycine, or a pharmaceutically acceptable salt thereof is present at a concentration of about 220 mmol/L or less. In some embodiments, the glycine, or a pharmaceutically acceptable salt thereof, is present at a concentration of about 200 mmol/L or less. In some embodiments, the glycine, or a pharmaceutically acceptable salt thereof, is present at a concentration of about 180 mmol/L or less. In some embodiments, the glycine, or a pharmaceutically acceptable salt thereof, is present at a concentration of about 160 mmol/L or less. In some embodiments, the glycine, or a pharmaceutically acceptable salt thereof, is present at a concentration of about 140 mmol/L or less.
  • the glycine, or a pharmaceutically acceptable salt thereof is present at a concentration of about 120 mmol/L or less. In some embodiments, the glycine, or a pharmaceutically acceptable salt thereof, is present at a concentration of about 100 mmol/L or less. In some embodiments, the glycine, or a pharmaceutically acceptable salt thereof, is present at a concentration of about 50 mmol/L or less. In some embodiments, the glycine, or a pharmaceutically acceptable salt thereof, is present at a concentration of about 20 mmol/L or less.
  • the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 10 mmol/L. In some embodiments, the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 20 mmol/L. In some embodiments, the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 30 mmol/L. In some embodiments, the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 40 mmol/L. In some embodiments, the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 50 mmol/L.
  • the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 75 mmol/L. In some embodiments, the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L. In some embodiments, the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 110 mmol/L. In some embodiments, the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 120 mmol/L. In some embodiments, the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 130 mmol/L.
  • the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 140 mmol/L. In some embodiments, the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 150 mmol/L. In some embodiments, the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 160 mmol/L. In some embodiments, the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 170 mmol/L. In some embodiments, the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 180 mmol/L.
  • the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 190 mmol/L. In some embodiments, the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 200 mmol/L. In some embodiments, the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 210 mmol/L. In some embodiments, the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 220 mmol/L. In some embodiments, the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 250 mmol/L.
  • the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 300 mmol/L. In some embodiments, the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 400 mmol/L. In some embodiments, the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 500 mmol/L. In some embodiments, the pharmaceutical composition comprises glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 600 mmol/L.
  • the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof.
  • Arginine is a conditionally non-essential amino acid that can be represented by the formula:
  • Arginine includes the free base form of arginine, as well as any and all salts thereof.
  • arginine includes a pharmaceutically acceptable salt thereof, e.g., arginine hydrochloride.
  • the pharmaceutically acceptable salt of arginine is arginine hydrochloride.
  • Arginine also includes all enantiomers (e.g., L-arginine and S-arginine) , and any combination of enantiomers (e.g., 50%L-arginine and 50%S-arginine; 90%-100%L-arginine and 10%-0%S-arginine, etc. ) .
  • the term "arginine” includes greater than 99%L-arginine and less than 1%S-arginine.
  • the term “arginine” includes an enantomerically pure L-arginine.
  • arginine is a pharmaceutical grade arginine.
  • the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L. In some embodiments, the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 300 mmol/L. In some embodiments, the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 50 mmol/L to about 300 mmol/L.
  • the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 300 mmol/L. In some embodiments, the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 250 mmol/L. In some embodiments, the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 220 mmol/L. In some embodiments, the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 110 mmol/L to about 220 mmol/L.
  • the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 120 mmol/L to about 220 mmol/L. In some embodiments, the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 130 mmol/L to about 220 mmol/L. In some embodiments, the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 140 mmol/L to about 220 mmol/L. In some embodiments, the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 150 mmol/L to about 220 mmol/L.
  • the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 160 mmol/L to about 220 mmol/L. In some embodiments, the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 170 mmol/L to about 220 mmol/L. In some embodiments, the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 180 mmol/L to about 220 mmol/L. In some embodiments, the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 190 mmol/L to about 210 mmol/L. In some embodiments, the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 200 mmol/L.
  • the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 200 mmol/L. In some embodiments, the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 110 mmol/L to about 200 mmol/L. In some embodiments, the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 120 mmol/L to about 200 mmol/L. In some embodiments, the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 130 mmol/L to about 200 mmol/L.
  • the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 140 mmol/L to about 200 mmol/L. In some embodiments, the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 150 mmol/L to about 200 mmol/L. In some embodiments, the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 160 mmol/L to about 200 mmol/L. In some embodiments, the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 170 mmol/L to about 190 mmol/L. In some embodiments, the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 180 mmol/L.
  • the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 190 mmol/L. In some embodiments, the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 180 mmol/L. In some embodiments, the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 170 mmol/L. In some embodiments, the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 160 mmol/L.
  • the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 120 mmol/L to about 160 mmol/L. In some embodiments, the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 130 mmol/L to about 150 mmol/L. In some embodiments, the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 140 mmol/L.
  • the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 150 mmol/L. In some embodiments, the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 110 mmol/L to about 150 mmol/L. In some embodiments, the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 120 mmol/L to about 140 mmol/L. In some embodiments, the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 130 mmol/L.
  • the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 150 mmol/L. In some embodiments, the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 140 mmol/L. In some embodiments, the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 110 mmol/L to about 130 mmol/L. In some embodiments, the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 120 mmol/L.
  • the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 100 mmol/L. In some embodiments, the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 90 mmol/L. In some embodiments, the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 80 mmol/L. In some embodiments, the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 70 mmol/L.
  • the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 30 mmol/L to about 70 mmol/L. In some embodiments, the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 40 mmol/L to about 60 mmol/L. In some embodiments, the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 50 mmol/L.
  • the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 40 mmol/L. In some embodiments, the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 10 mmol/L to about 30 mmol/L. In some embodiments, the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 20 mmol/L.
  • the arginine, or a pharmaceutically acceptable salt thereof is present at a concentration of about 600 mmol/L or less. In some embodiments, the arginine, or a pharmaceutically acceptable salt thereof, is present at a concentration of about 500 mmol/L or less. In some embodiments, the arginine, or a pharmaceutically acceptable salt thereof, is present at a concentration of about 400 mmol/L or less. In some embodiments, the arginine, or a pharmaceutically acceptable salt thereof, is present at a concentration of about 300 mmol/L or less. In some embodiments, the arginine, or a pharmaceutically acceptable salt thereof, is present at a concentration of about 250 mmol/L or less.
  • the arginine, or a pharmaceutically acceptable salt thereof is present at a concentration of about 220 mmol/L or less. In some embodiments, the arginine, or a pharmaceutically acceptable salt thereof, is present at a concentration of about 200 mmol/L or less. In some embodiments, the arginine, or a pharmaceutically acceptable salt thereof, is present at a concentration of about 180 mmol/L or less. In some embodiments, the arginine, or a pharmaceutically acceptable salt thereof, is present at a concentration of about 160 mmol/L or less. In some embodiments, the arginine, or a pharmaceutically acceptable salt thereof, is present at a concentration of about 140 mmol/L or less.
  • the arginine, or a pharmaceutically acceptable salt thereof is present at a concentration of about 120 mmol/L or less. In some embodiments, the arginine, or a pharmaceutically acceptable salt thereof, is present at a concentration of about 100 mmol/L or less. In some embodiments, the arginine, or a pharmaceutically acceptable salt thereof, is present at a concentration of about 50 mmol/L or less. In some embodiments, the arginine, or a pharmaceutically acceptable salt thereof, is present at a concentration of about 20 mmol/L or less.
  • the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 10 mmol/L. In some embodiments, the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 20 mmol/L. In some embodiments, the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 30 mmol/L. In some embodiments, the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 40 mmol/L. In some embodiments, the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 50 mmol/L.
  • the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 75 mmol/L. In some embodiments, the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L. In some embodiments, the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 110 mmol/L. In some embodiments, the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 120 mmol/L. In some embodiments, the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 130 mmol/L.
  • the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 140 mmol/L. In some embodiments, the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 150 mmol/L. In some embodiments, the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 160 mmol/L. In some embodiments, the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 170 mmol/L. In some embodiments, the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 180 mmol/L.
  • the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 190 mmol/L. In some embodiments, the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 200 mmol/L. In some embodiments, the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 210 mmol/L. In some embodiments, the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 220 mmol/L. In some embodiments, the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 250 mmol/L.
  • the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 300 mmol/L. In some embodiments, the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 400 mmol/L. In some embodiments, the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 500 mmol/L. In some embodiments, the pharmaceutical composition comprises arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 600 mmol/L.
  • the viscosity reducing agent is proline, or a pharmaceutically acceptable salt thereof.
  • Proline is an amino acid that can be represented by the formula:
  • Proline includes the free base form of proline, as well as any and all salts thereof.
  • proline includes a pharmaceutically acceptable salt thereof, e.g., proline hydrochloride.
  • the pharmaceutically acceptable salt of proline is proline hydrochloride.
  • Proline also includes all enantiomers (e.g., L-proline and S-proline) , and any combination of enantiomers (e.g., 50%L-proline and 50%S-proline; 90%-100%L-proline and 10%-0%S-proline, etc. ) .
  • the term "proline” includes greater than 99%L-proline and less than 1%S-proline.
  • the term "proline” includes an enantomerically pure L-proline.
  • proline is a pharmaceutical grade proline.
  • the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L. In some embodiments, the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 300 mmol/L. In some embodiments, the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 50 mmol/L to about 300 mmol/L. In some embodiments, the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 300 mmol/L.
  • the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 250 mmol/L. In some embodiments, the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 220 mmol/L. In some embodiments, the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 110 mmol/L to about 220 mmol/L. In some embodiments, the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 120 mmol/L to about 220 mmol/L.
  • the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 130 mmol/L to about 220 mmol/L. In some embodiments, the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 140 mmol/L to about 220 mmol/L. In some embodiments, the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 150 mmol/L to about 220 mmol/L. In some embodiments, the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 160 mmol/L to about 220 mmol/L.
  • the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 170 mmol/L to about 220 mmol/L. In some embodiments, the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 180 mmol/L to about 220 mmol/L. In some embodiments, the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 190 mmol/L to about 210 mmol/L. In some embodiments, the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 200 mmol/L.
  • the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 200 mmol/L. In some embodiments, the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 110 mmol/L to about 200 mmol/L. In some embodiments, the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 120 mmol/L to about 200 mmol/L. In some embodiments, the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 130 mmol/L to about 200 mmol/L.
  • the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 140 mmol/L to about 200 mmol/L. In some embodiments, the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 150 mmol/L to about 200 mmol/L. In some embodiments, the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 160 mmol/L to about 200 mmol/L. In some embodiments, the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 170 mmol/L to about 190 mmol/L. In some embodiments, the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 180 mmol/L.
  • the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 190 mmol/L. In some embodiments, the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 180 mmol/L. In some embodiments, the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 170 mmol/L. In some embodiments, the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 160 mmol/L.
  • the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 120 mmol/L to about 160 mmol/L. In some embodiments, the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 130 mmol/L to about 150 mmol/L. In some embodiments, the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 140 mmol/L.
  • the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 150 mmol/L. In some embodiments, the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 110 mmol/L to about 150 mmol/L. In some embodiments, the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 120 mmol/L to about 140 mmol/L. In some embodiments, the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 130 mmol/L.
  • the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 150 mmol/L. In some embodiments, the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 140 mmol/L. In some embodiments, the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 110 mmol/L to about 130 mmol/L. In some embodiments, the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 120 mmol/L.
  • the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 100 mmol/L. In some embodiments, the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 90 mmol/L. In some embodiments, the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 80 mmol/L. In some embodiments, the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 70 mmol/L.
  • the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 30 mmol/L to about 70 mmol/L. In some embodiments, the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 40 mmol/L to about 60 mmol/L. In some embodiments, the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 50 mmol/L.
  • the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 40 mmol/L. In some embodiments, the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 10 mmol/L to about 30 mmol/L. In some embodiments, the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 20 mmol/L.
  • the proline, or a pharmaceutically acceptable salt thereof is present at a concentration of about 600 mmol/L or less. In some embodiments, the proline, or a pharmaceutically acceptable salt thereof, is present at a concentration of about 500 mmol/L or less. In some embodiments, the proline, or a pharmaceutically acceptable salt thereof, is present at a concentration of about 400 mmol/L or less. In some embodiments, the proline, or a pharmaceutically acceptable salt thereof, is present at a concentration of about 300 mmol/L or less. In some embodiments, the proline, or a pharmaceutically acceptable salt thereof, is present at a concentration of about 250 mmol/L or less.
  • the proline, or a pharmaceutically acceptable salt thereof is present at a concentration of about 220 mmol/L or less. In some embodiments, the proline, or a pharmaceutically acceptable salt thereof, is present at a concentration of about 200 mmol/L or less. In some embodiments, the proline, or a pharmaceutically acceptable salt thereof, is present at a concentration of about 180 mmol/L or less. In some embodiments, the proline, or a pharmaceutically acceptable salt thereof, is present at a concentration of about 160 mmol/L or less. In some embodiments, the proline, or a pharmaceutically acceptable salt thereof, is present at a concentration of about 140 mmol/L or less.
  • the proline, or a pharmaceutically acceptable salt thereof is present at a concentration of about 120 mmol/L or less. In some embodiments, the proline, or a pharmaceutically acceptable salt thereof, is present at a concentration of about 100 mmol/L or less. In some embodiments, the proline, or a pharmaceutically acceptable salt thereof, is present at a concentration of about 50 mmol/L or less. In some embodiments, the proline, or a pharmaceutically acceptable salt thereof, is present at a concentration of about 20 mmol/L or less.
  • the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 10 mmol/L. In some embodiments, the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 20 mmol/L. In some embodiments, the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 30 mmol/L. In some embodiments, the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 40 mmol/L. In some embodiments, the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 50 mmol/L.
  • the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 75 mmol/L. In some embodiments, the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L. In some embodiments, the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 110 mmol/L. In some embodiments, the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 120 mmol/L. In some embodiments, the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 130 mmol/L.
  • the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 140 mmol/L. In some embodiments, the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 150 mmol/L. In some embodiments, the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 160 mmol/L. In some embodiments, the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 170 mmol/L. In some embodiments, the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 180 mmol/L.
  • the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 190 mmol/L. In some embodiments, the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 200 mmol/L. In some embodiments, the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 210 mmol/L. In some embodiments, the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 220 mmol/L. In some embodiments, the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 250 mmol/L.
  • the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 300 mmol/L. In some embodiments, the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 400 mmol/L. In some embodiments, the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 500 mmol/L. In some embodiments, the pharmaceutical composition comprises proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 600 mmol/L.
  • the pharmaceutical composition comprises histidine buffer, and additionally comprises proline.
  • the excipient is glutamate, or a pharmaceutically acceptable salt thereof.
  • Glutamate is an amino acid that can be represented by the formula:
  • Glutamate includes the free base form of glutamate, as well as any and all salts thereof.
  • glutamate includes a pharmaceutically acceptable salt thereof, e.g., glutamate hydrochloride.
  • the pharmaceutically acceptable salt of glutamate is glutamate hydrochloride.
  • Glutamate, as used herein also includes all enantiomers (e.g., L-glutamate and S-glutamate) , and any combination of enantiomers (e.g., 50%L-glutamate and 50%S-glutamate; 90%-100%L-glutamate and 10%-0%S-glutamate, etc. ) .
  • the term “glutamate” includes greater than 99%L-glutamate and less than 1%S-glutamate. In some embodiments, the term “glutamate” includes an enantomerically pure L-glutamate. In some embodiments, glutamate is a pharmaceutical grade glutamate.
  • the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L. In some embodiments, the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 300 mmol/L. In some embodiments, the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 50 mmol/L to about 300 mmol/L.
  • the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 300 mmol/L. In some embodiments, the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 250 mmol/L. In some embodiments, the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 220 mmol/L. In some embodiments, the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 110 mmol/L to about 220 mmol/L.
  • the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 120 mmol/L to about 220 mmol/L. In some embodiments, the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 130 mmol/L to about 220 mmol/L. In some embodiments, the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 140 mmol/L to about 220 mmol/L. In some embodiments, the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 150 mmol/L to about 220 mmol/L.
  • the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 160 mmol/L to about 220 mmol/L. In some embodiments, the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 170 mmol/L to about 220 mmol/L. In some embodiments, the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 180 mmol/L to about 220 mmol/L. In some embodiments, the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 190 mmol/L to about 210 mmol/L. In some embodiments, the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 200 mmol/L.
  • the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 200 mmol/L. In some embodiments, the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 110 mmol/L to about 200 mmol/L. In some embodiments, the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 120 mmol/L to about 200 mmol/L. In some embodiments, the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 130 mmol/L to about 200 mmol/L.
  • the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 140 mmol/L to about 200 mmol/L. In some embodiments, the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 150 mmol/L to about 200 mmol/L. In some embodiments, the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 160 mmol/L to about 200 mmol/L. In some embodiments, the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 170 mmol/L to about 190 mmol/L. In some embodiments, the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 180 mmol/L.
  • the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 190 mmol/L. In some embodiments, the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 180 mmol/L. In some embodiments, the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 170 mmol/L. In some embodiments, the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 160 mmol/L.
  • the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 120 mmol/L to about 160 mmol/L. In some embodiments, the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 130 mmol/L to about 150 mmol/L. In some embodiments, the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 140 mmol/L.
  • the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 150 mmol/L. In some embodiments, the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 110 mmol/L to about 150 mmol/L. In some embodiments, the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 120 mmol/L to about 140 mmol/L. In some embodiments, the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 130 mmol/L.
  • the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 150 mmol/L. In some embodiments, the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 140 mmol/L. In some embodiments, the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 110 mmol/L to about 130 mmol/L. In some embodiments, the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 120 mmol/L.
  • the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 100 mmol/L. In some embodiments, the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 90 mmol/L. In some embodiments, the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 80 mmol/L. In some embodiments, the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 70 mmol/L.
  • the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 30 mmol/L to about 70 mmol/L. In some embodiments, the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 40 mmol/L to about 60 mmol/L. In some embodiments, the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 50 mmol/L.
  • the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 40 mmol/L. In some embodiments, the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 10 mmol/L to about 30 mmol/L. In some embodiments, the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 20 mmol/L.
  • the glutamate, or a pharmaceutically acceptable salt thereof is present at a concentration of about 600 mmol/L or less. In some embodiments, the glutamate, or a pharmaceutically acceptable salt thereof, is present at a concentration of about 500 mmol/L or less. In some embodiments, the glutamate, or a pharmaceutically acceptable salt thereof, is present at a concentration of about 400 mmol/L or less. In some embodiments, the glutamate, or a pharmaceutically acceptable salt thereof, is present at a concentration of about 300 mmol/L or less. In some embodiments, the glutamate, or a pharmaceutically acceptable salt thereof, is present at a concentration of about 250 mmol/L or less.
  • the glutamate, or a pharmaceutically acceptable salt thereof is present at a concentration of about 220 mmol/L or less. In some embodiments, the glutamate, or a pharmaceutically acceptable salt thereof, is present at a concentration of about 200 mmol/L or less. In some embodiments, the glutamate, or a pharmaceutically acceptable salt thereof, is present at a concentration of about 180 mmol/L or less. In some embodiments, the glutamate, or a pharmaceutically acceptable salt thereof, is present at a concentration of about 160 mmol/L or less. In some embodiments, the glutamate, or a pharmaceutically acceptable salt thereof, is present at a concentration of about 140 mmol/L or less.
  • the glutamate, or a pharmaceutically acceptable salt thereof is present at a concentration of about 120 mmol/L or less. In some embodiments, the glutamate, or a pharmaceutically acceptable salt thereof, is present at a concentration of about 100 mmol/L or less. In some embodiments, the glutamate, or a pharmaceutically acceptable salt thereof, is present at a concentration of about 50 mmol/L or less. In some embodiments, the glutamate, or a pharmaceutically acceptable salt thereof, is present at a concentration of about 20 mmol/L or less.
  • the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 10 mmol/L. In some embodiments, the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 20 mmol/L. In some embodiments, the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 30 mmol/L. In some embodiments, the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 40 mmol/L. In some embodiments, the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 50 mmol/L.
  • the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 75 mmol/L. In some embodiments, the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L. In some embodiments, the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 110 mmol/L. In some embodiments, the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 120 mmol/L. In some embodiments, the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 130 mmol/L.
  • the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 140 mmol/L. In some embodiments, the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 150 mmol/L. In some embodiments, the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 160 mmol/L. In some embodiments, the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 170 mmol/L. In some embodiments, the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 180 mmol/L.
  • the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 190 mmol/L. In some embodiments, the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 200 mmol/L. In some embodiments, the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 210 mmol/L. In some embodiments, the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 220 mmol/L. In some embodiments, the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 250 mmol/L.
  • the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 300 mmol/L. In some embodiments, the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 400 mmol/L. In some embodiments, the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 500 mmol/L. In some embodiments, the pharmaceutical composition comprises glutamate, or a pharmaceutically acceptable salt thereof, at a concentration of about 600 mmol/L.
  • the pharmaceutical composition comprises histidine buffer and additionally comprises glutamate.
  • anti-TSLP-R antibody compositions of the present disclosure comprise an uncharged excipient.
  • the uncharged excipient can assist in the prevention of denaturation or otherwise assist in stabilizing the antibody, or antigen-binding fragment thereof. Examples of excipients are known in the art. Examples can be taken, e.g., from the handbook: Gennaro, Alfonso R.: "Remington's Pharmaceutical Sciences” , Mack Publishing Company, Easton, Pa., 1990.
  • the uncharged excipient is fructose, glucose, mannose, sorbose, xylose, lactose, maltose, sucrose, dextran, pullulan, dextrin, cyclodextrins, soluble starch, trehalose, sorbitol, erythritol, isomalt, lactitol, maltitol, xylitol, glycerol, lactitol, hydroxyethyl starch, water-soluble glucans, or a combination thereof.
  • the uncharged excipient is sucrose.
  • the uncharged excipient is trehaolse.
  • the uncharged excipient is mannitol.
  • the pharmaceutical composition comprises an excipient, wherein the excipient is glycine, glutamate, arginine, histidine, or proline, or a pharmaceutically acceptable salt thereof, or any combination thereof, wherein the pharmaceutical composition additionally comprises an excipient, wherein the excipient is sodium chloride and/or sucrose.
  • the pharmaceutical composition comprises an excipient, wherein the excipient is sodium chloride and/or sucrose.
  • the pharmaceutical composition comprises sodium chloride, wherein the sodium chloride is present at a concentration of about 1 mmol/L to about 200 mmol/L. In some embodiments, the pharmaceutical composition comprises sodium chloride, wherein the sodium chloride is present at a concentration of about 10 mmol/L to about 150 mmol/L. In some embodiments, the pharmaceutical composition comprises sodium chloride, wherein the sodium chloride is present at a concentration of about 25 mmol/L to about 125 mmol/L. In some embodiments, the pharmaceutical composition comprises sodium chloride, wherein the sodium chloride is present at a concentration of about 50 mmol/L to about 120 mmol/L.
  • the pharmaceutical composition comprises sodium chloride, wherein the sodium chloride is present at a concentration of about 10 mmol/L. In some embodiments, the pharmaceutical composition comprises sodium chloride, wherein the sodium chloride is present at a concentration of about 20 mmol/L. In some embodiments, the pharmaceutical composition comprises sodium chloride, wherein the sodium chloride is present at a concentration of about 30 mmol/L. In some embodiments, the pharmaceutical composition comprises sodium chloride, wherein the sodium chloride is present at a concentration of about 40 mmol/L. In some embodiments, the pharmaceutical composition comprises sodium chloride, wherein the sodium chloride is present at a concentration of about 50 mmol/L.
  • the pharmaceutical composition comprises sodium chloride, wherein the sodium chloride is present at a concentration of about 60 mmol/L. In some embodiments, the pharmaceutical composition comprises sodium chloride, wherein the sodium chloride is present at a concentration of about 70 mmol/L. In some embodiments, the pharmaceutical composition comprises sodium chloride, wherein the sodium chloride is present at a concentration of about 80 mmol/L. In some embodiments, the pharmaceutical composition comprises sodium chloride, wherein the sodium chloride is present at a concentration of about 90 mmol/L. In some embodiments, the pharmaceutical composition comprises sodium chloride, wherein the sodium chloride is present at a concentration of about 100 mmol/L.
  • the pharmaceutical composition comprises sodium chloride, wherein the sodium chloride is present at a concentration of about 110 mmol/L. In some embodiments, the pharmaceutical composition comprises sodium chloride, wherein the sodium chloride is present at a concentration of about 120 mmol/L. In some embodiments, the pharmaceutical composition comprises sodium chloride, wherein the sodium chloride is present at a concentration of about 130 mmol/L. In some embodiments, the pharmaceutical composition comprises sodium chloride, wherein the sodium chloride is present at a concentration of about 140 mmol/L. In some embodiments, the pharmaceutical composition comprises sodium chloride, wherein the sodium chloride is present at a concentration of about 150 mmol/L.
  • the pharmaceutical composition comprises sodium chloride, wherein the sodium chloride is present at a concentration of about 160 mmol/L. In some embodiments, the pharmaceutical composition comprises sodium chloride, wherein the sodium chloride is present at a concentration of about 170 mmol/L. In some embodiments, the pharmaceutical composition comprises sodium chloride, wherein the sodium chloride is present at a concentration of about 180 mmol/L. In some embodiments, the pharmaceutical composition comprises sodium chloride, wherein the sodium chloride is present at a concentration of about 190 mmol/L. In some embodiments, the pharmaceutical composition comprises sodium chloride, wherein the sodium chloride is present at a concentration of about 200 mmol/L.
  • the pharmaceutical composition comprises sucrose, wherein the sucrose is present at a concentration of about 1% (w/v) to about 15% (w/v) . In some embodiments, the pharmaceutical composition comprises sucrose, wherein the sucrose is present at a concentration of about 1% (w/v) to about 10% (w/v) . In some embodiments, the pharmaceutical composition comprises sucrose, wherein the sucrose is present at a concentration of about 1% (w/v) to about 5% (w/v) . In some embodiments, the pharmaceutical composition comprises sucrose, wherein the sucrose is present at a concentration of about 2% (w/v) to about 4% (w/v) .
  • the pharmaceutical composition comprises sucrose, wherein the sucrose is at a concentration of about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, or about 15% (w/v) .
  • the pharmaceutical composition comprises sucrose, wherein the sucrose is at a concentration of about 1% (w/v) .
  • the pharmaceutical composition comprises sucrose, wherein the sucrose is at a concentration of about 2% (w/v) .
  • the pharmaceutical composition comprises sucrose, wherein the sucrose is at a concentration of about 3% (w/v) .
  • the pharmaceutical composition comprises sucrose, wherein the sucrose is at a concentration of about 4% (w/v) . In some embodiments, the pharmaceutical composition comprises sucrose, wherein the sucrose is at a concentration of about 5% (w/v) . In some embodiments, the pharmaceutical composition comprises sucrose, wherein the sucrose is at a concentration of about 6% (w/v) . In some embodiments, the pharmaceutical composition comprises sucrose, wherein the sucrose is at a concentration of about 7% (w/v) . In some embodiments, the pharmaceutical composition comprises sucrose, wherein the sucrose is at a concentration of about 8% (w/v) .
  • the pharmaceutical composition comprises sucrose, wherein the sucrose is at a concentration of about 9% (w/v) . In some embodiments, the pharmaceutical composition comprises sucrose, wherein the sucrose is at a concentration of about 10% (w/v) . In some embodiments, the pharmaceutical composition comprises sucrose, wherein the sucrose is at a concentration of about 11% (w/v) . In some embodiments, the pharmaceutical composition comprises sucrose, wherein the sucrose is at a concentration of about 12% (w/v) . In some embodiments, the pharmaceutical composition comprises sucrose, wherein the sucrose is at a concentration of about 13% (w/v) .
  • the pharmaceutical composition comprises sucrose, wherein the sucrose is at a concentration of about 14% (w/v) . In some embodiments, the pharmaceutical composition comprises sucrose, wherein the sucrose is at a concentration of about 15% (w/v) .
  • the pharmaceutical composition is described in Table 5.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of 180 mg/mL to 220 mg/mL; (ii) sodium acetate buffer at a concentration of 18 mmol/L to 22 mmol/L; and (iii) a pH of 4.4 to 5.7, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain CDRl, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 10, the light chain C
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of 180 mg/mL to 220 mg/mL; (ii) sodium acetate buffer at a concentration of 18 mmol/L to 22 mmol/L; and (iii) a pH of 4.4 to 4.6, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain CDRl, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 10, the light chain C
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of 180 mg/mL to 220 mg/mL; (ii) sodium acetate buffer at a concentration of 18 mmol/L to 22 mmol/L; and (iii) a pH of 4.9 to 5.1, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain CDRl, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 10, the light chain C
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of 180 mg/mL to 220 mg/mL; (ii) sodium acetate buffer at a concentration of 18 mmol/L to 22 mmol/L; and (iii) a pH of 5.4 to 5.6, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain CDRl, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 10, the light chain C
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 200 mg/mL; (ii) sodium acetate buffer at a concentration of about 20 mmol/L; and (iii) a pH of about 4.5, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain CDRl, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 10, the light chain CDR2 has the amino acid sequence of SEQ ID NO: 11,
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 200 mg/mL; (ii) sodium acetate buffer at a concentration of about 20 mmol/L; and (iii) a pH of about 5.0, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain CDRl, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 10, the light chain CDR2 has the amino acid sequence of SEQ ID NO: 11,
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 200 mg/mL; (ii) sodium acetate buffer at a concentration of about 20 mmol/L; and (iii) a pH of about 5.5, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain CDRl, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 10, the light chain CDR2 has the amino acid sequence of SEQ ID NO: 11,
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of 180 mg/mL to 220 mg/mL; (ii) sodium succinate buffer at a concentration of 18 mmol/L to 22 mmol/L; and (iii) a pH of 4.9 to 6.1, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain CDRl, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 10, the light chain CDR
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of 180 mg/mL to 220 mg/mL; (ii) sodium succinate buffer at a concentration of 18 mmol/L to 22 mmol/L; and (iii) a pH of 4.9 to 5.1, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain CDRl, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 10, the light chain CDR
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of 180 mg/mL to 220 mg/mL; (ii) sodium succinate buffer at a concentration of 18 mmol/L to 22 mmol/L; and (iii) a pH of 5.4 to 5.6, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain CDRl, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 10, the light chain CDR
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of 180 mg/mL to 220 mg/mL; (ii) sodium succinate buffer at a concentration of 18 mmol/L to 22 mmol/L; and (iii) a pH of 5.9 to 6.1, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain CDRl, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 10, the light chain CDR
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 200 mg/mL; (ii) sodium succinate buffer at a concentration of about 20 mmol/L; and (iii) a pH of about 5.0, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain CDRl, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 10, the light chain CDR2 has the amino acid sequence of SEQ ID NO: 11, and
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 200 mg/mL; (ii) sodium succinate buffer at a concentration of about 20 mmol/L; and (iii) a pH of about 5.5, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain CDRl, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 10, the light chain CDR2 has the amino acid sequence of SEQ ID NO: 11, and
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 200 mg/mL; (ii) sodium succinate buffer at a concentration of about 20 mmol/L; and (iii) a pH of about 6.0, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain CDRl, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 10, the light chain CDR2 has the amino acid sequence of SEQ ID NO: 11, and
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of 180 mg/mL to 220 mg/mL; (ii) sodium phosphate buffer at a concentration of 18 mmol/L to 22 mmol/L; and (iii) a pH of 6.4 to 7.6, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain CDRl, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 10, the light chain CDR
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of 180 mg/mL to 220 mg/mL; (ii) sodium phosphate buffer at a concentration of 18 mmol/L to 22 mmol/L; and (iii) a pH of 6.4 to 6.6, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain CDRl, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 10, the light chain C
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of 180 mg/mL to 220 mg/mL; (ii) sodium phosphate buffer at a concentration of 18 mmol/L to 22 mmol/L; and (iii) a pH of 6.9 to 7.1, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain CDRl, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 10, the light chain C
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of 180 mg/mL to 220 mg/mL; (ii) sodium phosphate buffer at a concentration of 18 mmol/L to 22 mmol/L; and (iii) a pH of 7.4 to 7.6, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain CDRl, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 10, the light chain CDR
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 200 mg/mL; (ii) sodium phosphate buffer at a concentration of about 20 mmol/L; and (iii) a pH of about 6.5, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain CDRl, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 10, the light chain CDR2 has the amino acid sequence of SEQ ID NO: 11,
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 200 mg/mL; (ii) sodium phosphate buffer at a concentration of about 20 mmol/L; and (iii) a pH of about 7.0, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain CDRl, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 10, the light chain CDR2 has the amino acid sequence of SEQ ID NO: 11,
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 200 mg/mL; (ii) sodium phosphate buffer at a concentration of about 20 mmol/L; and (iii) a pH of about 7.5, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain CDRl, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 10, the light chain CDR2 has the amino acid sequence of SEQ ID NO: 11,
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of 180 mg/mL to 220 mg/mL; (ii) histidine buffer at a concentration of 18 mmol/L to 22 mmol/L; and (iii) a pH of 5.4 to 6.6, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain CDRl, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 10, the light chain CDR
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of 180 mg/mL to 220 mg/mL; (ii) histidine buffer at a concentration of 18 mmol/L to 22 mmol/L; and (iii) a pH of 5.4 to 5.6, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain CDRl, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 10, the light chain CDR
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of 180 mg/mL to 220 mg/mL; (ii) histidine buffer at a concentration of 18 mmol/L to 22 mmol/L; and (iii) a pH of 5.9 to 6.1, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain CDRl, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 10, the light chain CDR
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of 180 mg/mL to 220 mg/mL; (ii) histidine buffer at a concentration of 18 mmol/L to 22 mmol/L; and (iii) a pH of 6.4 to 6.6, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain CDRl, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 10, the light chain CDR
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 200 mg/mL; (ii) histidine buffer at a concentration of about 20 mmol/L; and (iii) a pH of about 5.5, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain CDRl, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 10, the light chain CDR2 has the amino acid sequence of SEQ ID NO: 11, and
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 200 mg/mL; (ii) histidine buffer at a concentration of about 20 mmol/L; and (iii) a pH of about 6.0, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain CDRl, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 10, the light chain CDR2 has the amino acid sequence of SEQ ID NO: 11, and
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 200 mg/mL; (ii) histidine buffer at a concentration of about 20 mmol/L; and (iii) a pH of about 6.5, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain CDRl, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 10, the light chain CDR2 has the amino acid sequence of SEQ ID NO: 11, and
  • a pharmaceutical composition comprising: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) a pharmaceutically acceptable buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (i) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7; the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8; and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; or variants of any of the foregoing; and (ii) a light chain variable region comprising light chain CDR1, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence has the amino acid sequence SEQ ID NO: 10; the light chain CDR2 sequence has the amino acid sequence of SEQ ID NO: 11; and the light chain CDR3 sequence
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%identical to the sequence of SEQ ID NO: 5.
  • the pharmaceutical composition comprises the anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%identical to the sequence of SEQ ID NO: 5, provided that the heavy chain polypeptide comprises the amino acid sequences of SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 90%identical to the sequence of SEQ ID NO: 5.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 91%identical to the sequence of SEQ ID NO: 5.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 92%identical to the sequence of SEQ ID NO: 5.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 93%identical to the sequence of SEQ ID NO: 5.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 94%identical to the sequence of SEQ ID NO: 5.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 95%identical to the sequence of SEQ ID NO: 5.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 96%identical to the sequence of SEQ ID NO: 5.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 97%identical to the sequence of SEQ ID NO: 5.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 98%identical to the sequence of SEQ ID NO: 5.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 99%identical to the sequence of SEQ ID NO: 5.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 90%identical to the sequence of SEQ ID NO: 5, provided that the heavy chain polypeptide comprises the amino acid sequences of SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 91%identical to the sequence of SEQ ID NO: 5, provided that the heavy chain polypeptide comprises the amino acid sequences of SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 92%identical to the sequence of SEQ ID NO: 5, provided that the heavy chain polypeptide comprises the amino acid sequences of SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 93%identical to the sequence of SEQ ID NO: 5, provided that the heavy chain polypeptide comprises the amino acid sequences of SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 94%identical to the sequence of SEQ ID NO: 5, provided that the heavy chain polypeptide comprises the amino acid sequences of SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 95%identical to the sequence of SEQ ID NO: 5, provided that the heavy chain polypeptide comprises the amino acid sequences of SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 96%identical to the sequence of SEQ ID NO: 5, provided that the heavy chain polypeptide comprises the amino acid sequences of SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 97%identical to the sequence of SEQ ID NO: 5, provided that the heavy chain polypeptide comprises the amino acid sequences of SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 98%identical to the sequence of SEQ ID NO: 5, provided that the heavy chain polypeptide comprises the amino acid sequences of SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 99%identical to the sequence of SEQ ID NO: 5, provided that the heavy chain polypeptide comprises the amino acid sequences of SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%identical to the sequence of SEQ ID NO: 6.
  • the pharmaceutical composition comprises the anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%identical to the sequence of SEQ ID NO: 6, provided that the light chain polypeptide comprises the amino acid sequences of SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 90%identical to the sequence of SEQ ID NO: 6.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 91%identical to the sequence of SEQ ID NO: 6.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 92%identical to the sequence of SEQ ID NO: 6.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 93%identical to the sequence of SEQ ID NO: 6.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 94%identical to the sequence of SEQ ID NO: 6.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 95%identical to the sequence of SEQ ID NO: 6.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 96%identical to the sequence of SEQ ID NO: 6.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 97%identical to the sequence of SEQ ID NO: 6.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 98%identical to the sequence of SEQ ID NO: 6.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 99%identical to the sequence of SEQ ID NO: 6.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 90%identical to the sequence of SEQ ID NO: 6, provided that the light chain polypeptide comprises the amino acid sequences of SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 91%identical to the sequence of SEQ ID NO: 6, provided that the light chain polypeptide comprises the amino acid sequences of SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 92%identical to the sequence of SEQ ID NO: 6, provided that the light chain polypeptide comprises the amino acid sequences of SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 93%identical to the sequence of SEQ ID NO: 6, provided that the light chain polypeptide comprises the amino acid sequences of SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 94%identical to the sequence of SEQ ID NO: 6, provided that the light chain polypeptide comprises the amino acid sequences of SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 95%identical to the sequence of SEQ ID NO: 6, provided that the light chain polypeptide comprises the amino acid sequences of SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 96%identical to the sequence of SEQ ID NO: 6, provided that the light chain polypeptide comprises the amino acid sequences of SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 97%identical to the sequence of SEQ ID NO: 6, provided that the light chain polypeptide comprises the amino acid sequences of SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 98%identical to the sequence of SEQ ID NO: 6, provided that the light chain polypeptide comprises the amino acid sequences of SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 99%identical to the sequence of SEQ ID NO: 6, provided that the light chain polypeptide comprises the amino acid sequences of SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (i) a variable heavy chain polypeptide having a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%identical to the sequence of SEQ ID NO: 5; and (ii) a variable light chain polypeptide having a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%identical to the sequence of SEQ ID NO: 6.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (i) a variable heavy chain polypeptide having a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%identical to the sequence of SEQ ID NO: 5, provided that the heavy chain polypeptide comprises the amino acid sequences of SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9; and (ii) a variable light chain polypeptide having a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%identical to the sequence of SEQ ID NO: 6, provided that the light chain polypeptide comprises the amino acid sequences of SEQ ID NO:
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence of SEQ ID NO: 5.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence of SEQ ID NO: 6.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (i) a variable heavy chain polypeptide having a sequence of SEQ ID NO: 5; and (ii) a variable light chain polypeptide having a sequence of SEQ ID NO: 6.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the concentration of the antibody, or antigen-binding fragment thereof, is present at a concentration from about 1 mg/mL to about 300 mg/mL, from about 50 mg/mL to about 250 mg/mL, from about 100 mg/mL to about 200 mg/mL, or from about 150 mg/mL to about 200 mg/mL.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the concentration of the antibody, or antigen-binding fragment thereof, is present at a concentration from about 1 mg/mL to about 300 mg/mL.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the concentration of the antibody, or antigen- binding fragment thereof, is present at a concentration from about 50 mg/mL to about 250 mg/mL.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the concentration of the antibody, or antigen-binding fragment thereof, is present at a concentration from about 100 mg/mL to about 200 mg/mL.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the concentration of the antibody, or antigen-binding fragment thereof, is present at a concentration from about 150 mg/mL to about 200 mg/mL.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the concentration of the antibody, or antigen-binding fragment thereof, is present at a concentration from about 25 mg/mL, about 50 mg/mL, about 100 mg/mL, about 125 mg/mL, about 150 mg/mL, about 175 mg/mL, about 200 mg/mL, about 225 mg/mL, about 250 mg/mL, about 275 mg/mL, or about 300 mg/mL.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the concentration of the antibody, or antigen-binding fragment thereof, is present at a concentration from about 25 mg/mL.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the concentration of the antibody, or antigen-binding fragment thereof, is present at a concentration from about 50 mg/mL.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the concentration of the antibody, or antigen-binding fragment thereof, is present at a concentration from about 100 mg/mL.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the concentration of the antibody, or antigen-binding fragment thereof, is present at a concentration from about 125 mg/mL.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the concentration of the antibody, or antigen-binding fragment thereof, is present at a concentration from about 150 mg/mL.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the concentration of the antibody, or antigen-binding fragment thereof, is present at a concentration from about 175 mg/mL.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the concentration of the antibody, or antigen-binding fragment thereof, is present at a concentration from about 200 mg/mL.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the concentration of the antibody, or antigen-binding fragment thereof, is present at a concentration from about 225 mg/mL.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the concentration of the antibody, or antigen-binding fragment thereof, is present at a concentration from about 250 mg/mL.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the concentration of the antibody, or antigen-binding fragment thereof, is present at a concentration from about 275 mg/mL.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; glycine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the concentration of the antibody, or antigen-binding fragment thereof, is present at a concentration from about 300 mg/mL.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) a pharmaceutically acceptable buffer at a concentration of about 5 mmol/L to about 100 mmol/L; glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) , wherein the pharmaceutically acceptable buffer is phosphoric acid buffer, citric acid buffer, acetic acid buffer, succinic acid buffer, histidine buffer, phosphate buffer, acetate buffer, citrate buffer, succinate buffer, ascorbic acid buffer, glutamic acid buffer, lactic acid buffer, maleic acid buffer, trometamol buffer, and gluconic acid buffer.
  • the pharmaceutically acceptable buffer is phosphoric acid buffer, citric acid buffer, acetic acid
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) a pharmaceutically acceptable buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) , wherein the pharmaceutically acceptable buffer is histidine buffer.
  • the histidine buffer is present at a concentration of about 5 mmol/L to about 100 mmol/L, about 5 mmol/L to about 70 mmol/L, about 5 mmol/L to about 60 mmol/L, about 10 mmol/L to about 60 mmol/L, about 10 mmol/L to about 50 mmol/L, about 10 mmol/L to about 40 mmol/L, about 15 mmol/L to about 30 mmol/L, or about 15 mmol/L to about 25 mmol/L.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 700 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 60 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 10 mmol/L to about 60 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 10 mmol/L to about 50 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 10 mmol/L to about 40 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 15 mmol/L to about 30 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 15 mmol/L to about 25mmol; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 20 mmol; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the glycine, or pharmaceutically acceptable salt thereof is present at a concentration of about 1 mmol/L to about 600 mmol/L, about 50 mmol/L to about 300 mmol/L, about 100 mmol/L to about 250 mmol/L, about 120 mmol/L to about 200 mmol/L, about 130 mmol/L to about 200 mmol/L, about 140 mmol/L to about 200 mmol/L, about 150 mmol/L to about 200 mmol/L, about 160 mmol/L to about 200 mmol/L, about 170 mmol/L to about 200 mmol/L, or about 180 mmol/L to about 200 mmol/L.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 50 mmol/L to about 300 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 250 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 120 mmol/L to about 200 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 130 mmol/L to about 200 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 140 mmol/L to about 200 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 150 mmol/L to about 200 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 160 mmol/L to about 200 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 170 mmol/L to about 200 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 180 mmol/L to about 200 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the glycine, or pharmaceutically acceptable salt thereof is present at a concentration of about 50 mmol/L, about 75 mmol/L, about 100 mmol/L, about 120 mmol/L, about 130 mmol/L, about 140 mmol/L, about 150 mmol/L, about 160 mmol/L, about 170 mmol/L, about 180 mmol/L, about 190 mmol/L, about 200 mmol/L, about 250 mmol/L, or about 300 mmol/L.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 50 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 75 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 120 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 130 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 140 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 150 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 160 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 170 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 180 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 190 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 200 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 250 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 300 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the glycine, or a pharmaceutically acceptable salt thereof is glycine hydrochloride.
  • the glycine hydrochloride is present at a concentration of about 50 mmol/L, about 75 mmol/L, about 100 mmol/L, about 120 mmol/L, about 130 mmol/L, about 140 mmol/L, about 150 mmol/L, about 160 mmol/L, about 170 mmol/L, about 180 mmol/L, about 190 mmol/L, about 200 mmol/L, about 250 mmol/L, or about 300 mmol/L.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine hydrochloride at a concentration of about 50 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine hydrochloride at a concentration of about 75 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine hydrochloride at a concentration of about 100 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine hydrochloride at a concentration of about 120 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine hydrochloride at a concentration of about 130 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine hydrochloride at a concentration of about 140 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine hydrochloride at a concentration of about 150 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine hydrochloride at a concentration of about 160 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine hydrochloride at a concentration of about 170 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine hydrochloride at a concentration of about 180 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine hydrochloride at a concentration of about 190 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine hydrochloride at a concentration of about 200 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine hydrochloride at a concentration of about 250 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine hydrochloride at a concentration of about 300 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the surfactant is a polysorbate or a poloxamer.
  • the polysorbate is polysorbate 20 (PS20) or polysorbate 80 (PS80) .
  • the polysorbate is polysorbate 20 (PS20) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine, or pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) PS20 at a concentration of about 0.001%to about 1% (w/v) .
  • the polysorbate is polysorbate 80 (PS80) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine, or pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) PS80 at a concentration of about 0.001%to about 1% (w/v) .
  • the poloxamer is poloxamer 188.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine, or pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) poloxamer 188 at a concentration of about 0.001%to about 1% (w/v) .
  • the surfactant is present at a concentration of about 0.001%to about 1%, about 0.01%to about 0.5%, about 0.01%to about 0.1%, or about 0.02%to about 0.05% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine, or pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.01%to about 0.5% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine, or pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.01%to about 0.1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine, or pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.02%to about 0.05% (w/v) .
  • the surfactant is present at a concentration of about 0.01%, about 0.02%, about 0.03%, about 0.04%, or about 0.05% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine, or pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.01% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine, or pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.02% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine, or pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.03% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine, or pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.04% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine, or pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.05% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine, or pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) PS80 at a concentration of about 0.01% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine, or pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) PS80 at a concentration of about 0.02% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine, or pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) PS80 at a concentration of about 0.03% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine, or pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) PS80 at a concentration of about 0.04% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine, or pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) PS80 at a concentration of about 0.05% (w/v) .
  • the pH of the pharmaceutical composition is from about 4.9 to about 6.6. In some embodiments, the pH of the pharmaceutical composition is from about 5.0 to about 6.5. In some embodiments, the pH of the pharmaceutical composition is about 5.0, about 5.1, about 5.2, about 5.3, about 5.4, about 5.5, about 5.6, about 5.7, about 5.8, about 5.9, about 6.0, about 6.1, about 6.2, about 6.3, about 6.4, or about 6.5.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; (iv) a surfactant at a concentration of about 0.01%to about 0.5% (w/v) ; and (v) a pH of about 5.0.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; (iv) a surfactant at a concentration of about 0.01%to about 0.5% (w/v) ; and (v) a pH of about 5.1.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; (iv) a surfactant at a concentration of about 0.01%to about 0.5% (w/v) ; and (v) a pH of about 5.2.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; (iv) a surfactant at a concentration of about 0.01%to about 0.5% (w/v) ; and (v) a pH of about 5.3.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; (iv) a surfactant at a concentration of about 0.01%to about 0.5% (w/v) ; and (v) a pH of about 5.4.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; (iv) a surfactant at a concentration of about 0.01%to about 0.5% (w/v) ; and (v) a pH of about 5.5.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; (iv) a surfactant at a concentration of about 0.01%to about 0.5% (w/v) ; and (v) a pH of about 5.6.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; (iv) a surfactant at a concentration of about 0.01%to about 0.5% (w/v) ; and (v) a pH of about 5.7.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; (iv) a surfactant at a concentration of about 0.01%to about 0.5% (w/v) ; and (v) a pH of about 5.8.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; (iv) a surfactant at a concentration of about 0.01%to about 0.5% (w/v) ; and (v) a pH of about 5.9.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; (iv) a surfactant at a concentration of about 0.01%to about 0.5% (w/v) ; and (v) a pH of about 6.0.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; (iv) a surfactant at a concentration of about 0.01%to about 0.5% (w/v) ; and (v) a pH of about 6.1.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; (iv) a surfactant at a concentration of about 0.01%to about 0.5% (w/v) ; and (v) a pH of about 6.2.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; (iv) a surfactant at a concentration of about 0.01%to about 0.5% (w/v) ; and (v) a pH of about 6.3.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; (iv) a surfactant at a concentration of about 0.01%to about 0.5% (w/v) ; and (v) a pH of about 6.4.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; (iv) a surfactant at a concentration of about 0.01%to about 0.5% (w/v) ; and (v) a pH of about 6.5.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 150 mg/mL to about 250 mg/mL; (ii) histidine buffer at a concentration of about 10 mmol/L to about 30 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 150 mmol/L to about 200 mmol/L; (iv) polysorbate 80 at a concentration of about 0.01-0.2% (w/v) ; and (v) a pH of about 5.7.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of 135 mg/mL to 220 mg/mL; (ii) histidine buffer at a concentration of 18 mmol/L to 22 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of 160 mmol/L to 200 mmol/L; (iv) polysorbate 80 at a concentration of 0.01% (w/v) to 0.05% (w/v) ; and (v) a pH of 5.6 to 5.8, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of 180 mg/mL to 220 mg/mL; (ii) histidine buffer at a concentration of 18 mmol/L to 22 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of 160 mmol/L to 200 mmol/L; (iv) polysorbate 80 at a concentration of 0.01% (w/v) to 0.05% (w/v) ; and (v) a pH of 5.6 to 5.8, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of 180 mg/mL to 220 mg/mL; (ii) histidine buffer at a concentration of 18 mmol/L to 22 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of 160 mmol/L to 200 mmol/L; (iv) polysorbate 80 at a concentration of 0.018% (w/v) to 0.022% (w/v) ; and (v) a pH of 5.6 to 5.8, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 200 mg/mL; (ii) histidine buffer at a concentration of about 20 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 180 mmol/L; (iv) polysorbate 80 at a concentration of about 0.02% (w/v) ; and (v) a pH of about 5.7, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of 180 mg/mL to 220 mg/mL; (ii) histidine buffer at a concentration of 18 mmol/L to 22 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of 160 mmol/L to 200 mmol/L; (iv) polysorbate 80 at a concentration of 0.027% (w/v) to 0.033% (w/v) ; and (v) a pH of 5.6 to 5.8, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 200 mg/mL; (ii) histidine buffer at a concentration of about 20 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 180 mmol/L; (iv) polysorbate 80 at a concentration of about 0.03% (w/v) ; and (v) a pH of about 5.7, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain
  • the pharmaceutical composition comprises: (i) anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 135 mg/mL to about 165 mg/mL; (ii) histidine buffer at a concentration of about 18 mmol/L to about 22 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 160 mmol/L to about 200 mmol/L; (iv) polysorbate 80 at a concentration of about 0.01-0.05% (w/v) , and (v) a pH of about 5.6 to 5.8, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of 135 mg/mL to 165 mg/mL; (ii) histidine buffer at a concentration of 18 mmol/L to 22 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of 160 mmol/L to 200 mmol/L; (iv) polysorbate 80 at a concentration of 0.027% (w/v) to 0.033% (w/v) ; and (v) a pH of 5.6 to 5.8, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 150 mg/mL; (ii) histidine buffer at a concentration of about 20 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 180 mmol/L; (iv) polysorbate 80 at a concentration of about 0.03% (w/v) ; and (v) a pH of about 5.7, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of 135 mg/mL to 165 mg/mL; (ii) histidine buffer at a concentration of 18 mmol/L to 22 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of 160 mmol/L to 200 mmol/L; (iv) polysorbate 80 at a concentration of 0.018% (w/v) to 0.022% (w/v) ; and (v) a pH of 5.6 to 5.8, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 150 mg/mL; (ii) histidine buffer at a concentration of about 20 mmol/L; (iii) glycine, or a pharmaceutically acceptable salt thereof, at a concentration of about 180 mmol/L; (iv) polysorbate 80 at a concentration of about 0.02% (w/v) ; and (v) a pH of about 5.7, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain
  • a pharmaceutical composition comprising: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) a pharmaceutically acceptable buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (i) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7; the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8; and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; or variants of any of the foregoing; and (ii) a light chain variable region comprising light chain CDR1, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence has the amino acid sequence SEQ ID NO: 10; the light chain CDR2 sequence has the amino acid sequence of SEQ ID NO: 11; and the light chain CDR3 sequence
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%identical to the sequence of SEQ ID NO: 5.
  • the pharmaceutical composition comprises the anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%identical to the sequence of SEQ ID NO: 5, provided that the heavy chain polypeptide comprises the amino acid sequences of SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 90%identical to the sequence of SEQ ID NO: 5.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 91%identical to the sequence of SEQ ID NO: 5.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 92%identical to the sequence of SEQ ID NO: 5.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 93%identical to the sequence of SEQ ID NO: 5.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 94%identical to the sequence of SEQ ID NO: 5.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 95%identical to the sequence of SEQ ID NO: 5.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 96%identical to the sequence of SEQ ID NO: 5.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 97%identical to the sequence of SEQ ID NO: 5.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 98%identical to the sequence of SEQ ID NO: 5.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 99%identical to the sequence of SEQ ID NO: 5.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 90%identical to the sequence of SEQ ID NO: 5, provided that the heavy chain polypeptide comprises the amino acid sequences of SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 91%identical to the sequence of SEQ ID NO: 5, provided that the heavy chain polypeptide comprises the amino acid sequences of SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 92%identical to the sequence of SEQ ID NO: 5, provided that the heavy chain polypeptide comprises the amino acid sequences of SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 93%identical to the sequence of SEQ ID NO: 5, provided that the heavy chain polypeptide comprises the amino acid sequences of SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 94%identical to the sequence of SEQ ID NO: 5, provided that the heavy chain polypeptide comprises the amino acid sequences of SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 95%identical to the sequence of SEQ ID NO: 5, provided that the heavy chain polypeptide comprises the amino acid sequences of SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 96%identical to the sequence of SEQ ID NO: 5, provided that the heavy chain polypeptide comprises the amino acid sequences of SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 97%identical to the sequence of SEQ ID NO: 5, provided that the heavy chain polypeptide comprises the amino acid sequences of SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 98%identical to the sequence of SEQ ID NO: 5, provided that the heavy chain polypeptide comprises the amino acid sequences of SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 99%identical to the sequence of SEQ ID NO: 5, provided that the heavy chain polypeptide comprises the amino acid sequences of SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%identical to the sequence of SEQ ID NO: 6.
  • the pharmaceutical composition comprises the anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the anti-TSLP-R antibody, or antigen- binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%identical to the sequence of SEQ ID NO: 6, provided that the light chain polypeptide comprises the amino acid sequences of SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 90%identical to the sequence of SEQ ID NO: 6.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 91%identical to the sequence of SEQ ID NO: 6.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 92%identical to the sequence of SEQ ID NO: 6.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 93%identical to the sequence of SEQ ID NO: 6.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 94%identical to the sequence of SEQ ID NO: 6.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 95%identical to the sequence of SEQ ID NO: 6.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 96%identical to the sequence of SEQ ID NO: 6.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 97%identical to the sequence of SEQ ID NO: 6.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 98%identical to the sequence of SEQ ID NO: 6.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 99%identical to the sequence of SEQ ID NO: 6.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 90%identical to the sequence of SEQ ID NO: 6, provided that the light chain polypeptide comprises the amino acid sequences of SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 91%identical to the sequence of SEQ ID NO: 6, provided that the light chain polypeptide comprises the amino acid sequences of SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 92%identical to the sequence of SEQ ID NO: 6, provided that the light chain polypeptide comprises the amino acid sequences of SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 93%identical to the sequence of SEQ ID NO: 6, provided that the light chain polypeptide comprises the amino acid sequences of SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 94%identical to the sequence of SEQ ID NO: 6, provided that the light chain polypeptide comprises the amino acid sequences of SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 95%identical to the sequence of SEQ ID NO: 6, provided that the light chain polypeptide comprises the amino acid sequences of SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 96%identical to the sequence of SEQ ID NO: 6, provided that the light chain polypeptide comprises the amino acid sequences of SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12.
  • the pharmaceutical composition comprises: an anti-TSLP- R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 97%identical to the sequence of SEQ ID NO: 6, provided that the light chain polypeptide comprises the amino acid sequences of SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 98%identical to the sequence of SEQ ID NO: 6, provided that the light chain polypeptide comprises the amino acid sequences of SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 99%identical to the sequence of SEQ ID NO: 6, provided that the light chain polypeptide comprises the amino acid sequences of SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (i) a variable heavy chain polypeptide having a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%identical to the sequence of SEQ ID NO: 5; and (ii) a variable light chain polypeptide having a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%identical to the sequence of SEQ ID NO: 6.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (i) a variable heavy chain polypeptide having a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%identical to the sequence of SEQ ID NO: 5, provided that the heavy chain polypeptide comprises the amino acid sequences of SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9; and (ii) a variable light chain polypeptide having a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%identical to the sequence of SEQ ID NO: 6, provided that the light chain polypeptide comprises the amino acid sequences of SEQ ID NO:
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence of SEQ ID NO: 5.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence of SEQ ID NO: 6.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (i) a variable heavy chain polypeptide having a sequence of SEQ ID NO: 5; and (ii) a variable light chain polypeptide having a sequence of SEQ ID NO: 6.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the concentration of the antibody, or antigen-binding fragment thereof, is present at a concentration from about 1 mg/mL to about 300 mg/mL, from about 50 mg/mL to about 250 mg/mL, from about 100 mg/mL to about 200 mg/mL, or from about 150 mg/mL to about 200 mg/mL.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the concentration of the antibody, or antigen-binding fragment thereof, is present at a concentration from about 1 mg/mL to about 300 mg/mL.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the concentration of the antibody, or antigen-binding fragment thereof, is present at a concentration from about 50 mg/mL to about 250 mg/mL.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the concentration of the antibody, or antigen-binding fragment thereof, is present at a concentration from about 100 mg/mL to about 200 mg/mL.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the concentration of the antibody, or antigen-binding fragment thereof, is present at a concentration from about 150 mg/mL to about 200 mg/mL.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the concentration of the antibody, or antigen-binding fragment thereof, is present at a concentration from about 25 mg/mL, about 50 mg/mL, about 100 mg/mL, about 125 mg/mL, about 150 mg/mL, about 175 mg/mL, about 200 mg/mL, about 225 mg/mL, about 250 mg/mL, about 275 mg/mL, or about 300 mg/mL.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the concentration of the antibody, or antigen-binding fragment thereof, is present at a concentration from about 25 mg/mL.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the concentration of the antibody, or antigen-binding fragment thereof, is present at a concentration from about 50 mg/mL.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the concentration of the antibody, or antigen-binding fragment thereof, is present at a concentration from about 100 mg/mL.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the concentration of the antibody, or antigen-binding fragment thereof, is present at a concentration from about 125 mg/mL.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the concentration of the antibody, or antigen-binding fragment thereof, is present at a concentration from about 150 mg/mL.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the concentration of the antibody, or antigen-binding fragment thereof, is present at a concentration from about 175 mg/mL.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the concentration of the antibody, or antigen-binding fragment thereof, is present at a concentration from about 200 mg/mL.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the concentration of the antibody, or antigen-binding fragment thereof, is present at a concentration from about 225 mg/mL.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the concentration of the antibody, or antigen-binding fragment thereof, is present at a concentration from about 250 mg/mL.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the concentration of the antibody, or antigen-binding fragment thereof, is present at a concentration from about 275 mg/mL.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; arginine, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the concentration of the antibody, or antigen-binding fragment thereof, is present at a concentration from about 300 mg/mL.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) a pharmaceutically acceptable buffer at a concentration of about 5 mmol/L to about 100 mmol/L; arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) , wherein the pharmaceutically acceptable buffer is phosphoric acid buffer, citric acid buffer, acetic acid buffer, succinic acid buffer, histidine buffer, phosphate buffer, acetate buffer, citrate buffer, succinate buffer, ascorbic acid buffer, glutamic acid buffer, lactic acid buffer, maleic acid buffer, trometamol buffer, and gluconic acid buffer.
  • the pharmaceutically acceptable buffer is phosphoric acid buffer, citric acid buffer, acetic acid
  • the pharmaceutically acceptable buffer is sodium phosphate.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of 135 mg/mL to 220 mg/mL; (ii) sodium phosphate buffer at a concentration of 18 mmol/L to 22 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of 125 mmol/L to 155 mmol/L; (iv) polysorbate 80 at a concentration of 0.01% (w/v) to 0.05% (w/v) ; and (v) a pH of 5.6 to 5.8, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain
  • the pharmaceutical composition comprises histidine, and additionally comprises arginine.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of 135 mg/mL to 220 mg/mL; (ii) sodium phosphate buffer at a concentration of 18 mmol/L to 22 mmol/L; (iii) arginine hydrochloride at a concentration of 125 mmol/L to 155 mmol/L; (iv) polysorbate 80 at a concentration of 0.01% (w/v) to 0.05% (w/v) ; and (v) a pH of 5.6 to 5.8, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of 180 mg/mL to 220 mg/mL; (ii) sodium phosphate buffer at a concentration of 18 mmol/L to 22 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of 125 mmol/L to 155 mmol/L; (iv) polysorbate 80 at a concentration of 0.018% (w/v) to 0.022% (w/v) ; and (v) a pH of 5.6 to 5.8, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain C
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of 135 mg/mL to 165 mg/mL; (ii) sodium phosphate buffer at a concentration of 18 mmol/L to 22 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of 125 mmol/L to 155 mmol/L; (iv) polysorbate 80 at a concentration of 0.018% (w/v) to 0.022% (w/v) ; and (v) a pH of 5.6 to 5.8, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of 180 mg/mL to 220 mg/mL; (ii) sodium phosphate buffer at a concentration of 18 mmol/L to 22 mmol/L; (iii) arginine hydrochloride at a concentration of 125 mmol/L to 155 mmol/L; (iv) polysorbate 80 at a concentration of 0.018% (w/v) to 0.022% (w/v) ; and (v) a pH of 5.6 to 5.8, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of 135 mg/mL to 165 mg/mL; (ii) sodium phosphate buffer at a concentration of 18 mmol/L to 22 mmol/L; (iii) arginine hydrochloride at a concentration of 125 mmol/L to 155 mmol/L; (iv) polysorbate 80 at a concentration of 0.018% (w/v) to 0.022% (w/v) ; and (v) a pH of 5.6 to 5.8, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 200 mg/mL; (ii) sodium phosphate buffer at a concentration of about 20 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 140 mmol/L; (iv) polysorbate 80 at a concentration of about 0.02% (w/v) ; and (v) a pH of about 5.7, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 150 mg/mL; (ii) sodium phosphate buffer at a concentration of about 20 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 140 mmol/L; (iv) polysorbate 80 at a concentration of about 0.02% (w/v) ; and (v) a pH of about 5.7, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 200 mg/mL; (ii) sodium phosphate buffer at a concentration of about 20 mmol/L; (iii) arginine hydrochloride at a concentration of about 140 mmol/L; (iv) polysorbate 80 at a concentration of about 0.02%(w/v) ; and (v) a pH of about 5.7, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain CDRl, C
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 150 mg/mL; (ii) sodium phosphate buffer at a concentration of about 20 mmol/L; (iii) arginine hydrochloride at a concentration of about 140 mmol/L; (iv) polysorbate 80 at a concentration of about 0.02%(w/v) ; and (v) a pH of about 5.7, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain CDRl, C
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) a pharmaceutically acceptable buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) , wherein the pharmaceutically acceptable buffer is histidine buffer.
  • the histidine buffer is present at a concentration of about 5 mmol/L to about 100 mmol/L, about 5 mmol/L to about 70 mmol/L, about 5 mmol/L to about 60 mmol/L, about 10 mmol/L to about 60 mmol/L, about 10 mmol/L to about 50 mmol/L, about 10 mmol/L to about 40 mmol/L, about 15 mmol/L to about 30 mmol/L, or about 15 mmol/L to about 25 mmol/L.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 700 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 60 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 10 mmol/L to about 60 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 10 mmol/L to about 50 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 10 mmol/L to about 40 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 15 mmol/L to about 30 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 15 mmol/L to about 25mmol; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 20 mmol; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the arginine, or pharmaceutically acceptable salt thereof is present at a concentration of about 1 mmol/L to about 600 mmol/L, about 50 mmol/L to about 300 mmol/L, about 100 mmol/L to about 250 mmol/L, about 100 mmol/L to about 200 mmol/L, about 100 mmol/L to about 190 mmol/L, about 100 mmol/L to about 180 mmol/L, about 100 mmol/L to about 175 mmol/L, about 100 mmol/L to about 150 mmol/L, about 100 mmol/L to about 130 mmol/L, or about 110 mmol/L to about 130 mmol/L.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 50 mmol/L to about 300 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 250 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 200 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 190 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 180 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 175 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about150 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 130 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 110 mmol/L to about 130 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the arginine, or pharmaceutically acceptable salt thereof is present at a concentration of about 50 mmol/L, about 75 mmol/L, about 100 mmol/L, about 110 mmol/L, about 120 mmol/L, about 130 mmol/L, about 140 mmol/L, about 150 mmol/L, about 160 mmol/L, about 170 mmol/L, about 180 mmol/L, about 190 mmol/L, about 200 mmol/L, about 250 mmol/L, or about 300 mmol/L.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 50 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 75 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 110 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 120 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 130 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 140 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 150 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 160 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 170 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 180 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 190 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 200 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 250 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 300 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the arginine, or a pharmaceutically acceptable salt thereof is arginine hydrochloride.
  • the arginine hydrochloride is present at a concentration of about 50 mmol/L, about 75 mmol/L, about 100 mmol/L, about 120 mmol/L, about 130 mmol/L, about 140 mmol/L, about 150 mmol/L, about 160 mmol/L, about 170 mmol/L, about 180 mmol/L, about 190 mmol/L, about 200 mmol/L, about 250 mmol/L, or about 300 mmol/L.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine hydrochloride at a concentration of about 50 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine hydrochloride at a concentration of about 75 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine hydrochloride at a concentration of about 100 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine hydrochloride at a concentration of about 120 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine hydrochloride at a concentration of about 130 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine hydrochloride at a concentration of about 140 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine hydrochloride at a concentration of about 150 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine hydrochloride at a concentration of about 160 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine hydrochloride at a concentration of about 170 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine hydrochloride at a concentration of about 180 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine hydrochloride at a concentration of about 190 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine hydrochloride at a concentration of about 200 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine hydrochloride at a concentration of about 250 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine hydrochloride at a concentration of about 300 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the surfactant is a polysorbate or a poloxamer.
  • the polysorbate is polysorbate 20 (PS20) or polysorbate 80 (PS80) .
  • the polysorbate is polysorbate 20 (PS20) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine hydrochloride at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) PS20 at a concentration of about 0.001%to about 1% (w/v) .
  • the polysorbate is polysorbate 80 (PS80) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine hydrochloride at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) PS80 at a concentration of about 0.001%to about 1% (w/v) .
  • the poloxamer is poloxamer 188.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine hydrochloride at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) poloxamer 188 at a concentration of about 0.001%to about 1% (w/v) .
  • the surfactant is present at a concentration of about 0.001%to about 1%, about 0.01%to about 0.5%, about 0.01%to about 0.1%, or about 0.02%to about 0.05% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine hydrochloride at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.01%to about 0.5% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine hydrochloride at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.01%to about 0.1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine hydrochloride at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.02%to about 0.05% (w/v) .
  • the surfactant is present at a concentration of about 0.01%, about 0.02%, about 0.03%, about 0.04%, or about 0.05% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine hydrochloride at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.01% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine hydrochloride at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.02% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine hydrochloride at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.03% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine hydrochloride at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.04% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine hydrochloride at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.05% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine hydrochloride at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) PS80 at a concentration of about 0.01% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine hydrochloride at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) PS80 at a concentration of about 0.02% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine hydrochloride at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) PS80 at a concentration of about 0.03% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine hydrochloride at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) PS80 at a concentration of about 0.04% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine hydrochloride at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) PS80 at a concentration of about 0.05% (w/v) .
  • the pH of the pharmaceutical composition is from about 4.9 to about 6.6. In some embodiments, the pH of the pharmaceutical composition is from about 5.0 to about 6.5. In some embodiments, the pH of the pharmaceutical composition is about 5.0, about 5.1, about 5.2, about 5.3, about 5.4, about 5.5, about 5.6, about 5.7, about 5.8, about 5.9, about 6.0, about 6.1, about 6.2, about 6.3, about 6.4, or about 6.5.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of 1 mmol/L to about 600 mmol/L; (iv) a surfactant at a concentration of about 0.01%to about 0.5% (w/v) ; and (v) a pH of about 5.0.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; (iv) a surfactant at a concentration of about 0.01%to about 0.5% (w/v) ; and (v) a pH of about 5.1.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; (iv) a surfactant at a concentration of about 0.01%to about 0.5% (w/v) ; and (v) a pH of about 5.2.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; (iv) a surfactant at a concentration of about 0.01%to about 0.5% (w/v) ; and (v) a pH of about 5.3.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; (iv) a surfactant at a concentration of about 0.01%to about 0.5% (w/v) ; and (v) a pH of about 5.4.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; (iv) a surfactant at a concentration of about 0.01%to about 0.5% (w/v) ; and (v) a pH of about 5.5.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; (iv) a surfactant at a concentration of about 0.01%to about 0.5% (w/v) ; and (v) a pH of about 5.6.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; (iv) a surfactant at a concentration of about 0.01%to about 0.5% (w/v) ; and (v) a pH of about 5.7.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; (iv) a surfactant at a concentration of about 0.01%to about 0.5% (w/v) ; and (v) a pH of about 5.8.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; (iv) a surfactant at a concentration of about 0.01%to about 0.5% (w/v) ; and (v) a pH of about 5.9.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; (iv) a surfactant at a concentration of about 0.01%to about 0.5% (w/v) ; and (v) a pH of about 6.0.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; (iv) a surfactant at a concentration of about 0.01%to about 0.5% (w/v) ; and (v) a pH of about 6.1.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; (iv) a surfactant at a concentration of about 0.01%to about 0.5% (w/v) ; and (v) a pH of about 6.2.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; (iv) a surfactant at a concentration of about 0.01%to about 0.5% (w/v) ; and (v) a pH of about 6.3.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; (iv) a surfactant at a concentration of about 0.01%to about 0.5% (w/v) ; and (v) a pH of about 6.4.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; (iv) a surfactant at a concentration of about 0.01%to about 0.5% (w/v) ; and (v) a pH of about 6.5.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine hydrochloride a concentration of 1 mmol/L to about 600 mmol/L; (iv) a surfactant at a concentration of about 0.01%to about 0.5% (w/v) ; and (v) a pH of about 5.0.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine hydrochloride at a concentration of about 1 mmol/L to about 600 mmol/L; (iv) a surfactant at a concentration of about 0.01%to about 0.5% (w/v) ; and (v) a pH of about 5.1.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine hydrochloride at a concentration of about 1 mmol/L to about 600 mmol/L; (iv) a surfactant at a concentration of about 0.01%to about 0.5% (w/v) ; and (v) a pH of about 5.2.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine hydrochloride at a concentration of about 1 mmol/L to about 600 mmol/L; (iv) a surfactant at a concentration of about 0.01%to about 0.5% (w/v) ; and (v) a pH of about 5.3.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine hydrochloride at a concentration of about 1 mmol/L to about 600 mmol/L; (iv) a surfactant at a concentration of about 0.01%to about 0.5% (w/v) ; and (v) a pH of about 5.4.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine hydrochloride at a concentration of about 1 mmol/L to about 600 mmol/L; (iv) a surfactant at a concentration of about 0.01%to about 0.5% (w/v) ; and (v) a pH of about 5.5.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine hydrochloride at a concentration of about 1 mmol/L to about 600 mmol/L; (iv) a surfactant at a concentration of about 0.01%to about 0.5% (w/v) ; and (v) a pH of about 5.6.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine hydrochloride a concentration of about 1 mmol/L to about 600 mmol/L; (iv) a surfactant at a concentration of about 0.01%to about 0.5% (w/v) ; and (v) a pH of about 5.7.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine hydrochloride at a concentration of about 1 mmol/L to about 600 mmol/L; (iv) a surfactant at a concentration of about 0.01%to about 0.5% (w/v) ; and (v) a pH of about 5.8.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine hydrochloride at a concentration of about 1 mmol/L to about 600 mmol/L; (iv) a surfactant at a concentration of about 0.01%to about 0.5% (w/v) ; and (v) a pH of about 5.9.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine hydrochloride at a concentration of about 1 mmol/L to about 600 mmol/L; (iv) a surfactant at a concentration of about 0.01%to about 0.5% (w/v) ; and (v) a pH of about 6.0.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine hydrochloride at a concentration of about 1 mmol/L to about 600 mmol/L; (iv) a surfactant at a concentration of about 0.01%to about 0.5% (w/v) ; and (v) a pH of about 6.1.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine hydrochloride at a concentration of about 1 mmol/L to about 600 mmol/L; (iv) a surfactant at a concentration of about 0.01%to about 0.5% (w/v) ; and (v) a pH of about 6.2.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine hydrochloride at a concentration of about 1 mmol/L to about 600 mmol/L; (iv) a surfactant at a concentration of about 0.01%to about 0.5% (w/v) ; and (v) a pH of about 6.3.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine hydrochloride at a concentration of about 1 mmol/L to about 600 mmol/L; (iv) a surfactant at a concentration of about 0.01%to about 0.5% (w/v) ; and (v) a pH of about 6.4.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine hydrochloride at a concentration of about 1 mmol/L to about 600 mmol/L; (iv) a surfactant at a concentration of about 0.01%to about 0.5% (w/v) ; and (v) a pH of about 6.5.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 150 mg/mL to about 250 mg/mL; (ii) histidine buffer at a concentration of about 10 mmol/L to about 30 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 150 mmol/L; (iv) a surfactant at a concentration of about 0.01%to about 0.2% (w/v) ; and (v) a pH of about 5.7.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 150 mg/mL to about 250 mg/mL; (ii) histidine buffer at a concentration of about 10 mmol/L to about 30 mmol/L; (iii) arginine hydrochloride at a concentration of about 100 mmol/L to about 150 mmol/L; (iv) a surfactant at a concentration of about 0.01%to about 0.05% (w/v) ; and (v) a pH of about 5.7.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of 135 mg/mL to 220 mg/mL; (ii) histidine buffer at a concentration of 18 mmol/L to 22 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of 105 mmol/L to 145 mmol/L; (iv) polysorbate 80 at a concentration of 0.01% (w/v) to 0.05% (w/v) ; and (v) a pH of 5.6 to 5.8, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain C
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of 135 mg/mL to 220 mg/mL; (ii) histidine buffer at a concentration of 18 mmol/L to 22 mmol/L; (iii) arginine hydrochloride at a concentration of 105 mmol/L to 145 mmol/L; (iv) polysorbate 80 at a concentration of 0.01% (w/v) to 0.05% (w/v) ; and (v) a pH of 5.6 to 5.8, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of 180 mg/mL to 220 mg/mL; (ii) histidine buffer at a concentration of 18 mmol/L to 22 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of 105 mmol/L to 135 mmol/L; (iv) polysorbate 80 at a concentration of 0.01% (w/v) to 0.05% (w/v) ; and (v) a pH of 5.6 to 5.8, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR
  • the pharmaceutical composition comprises: (i) anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 135 mg/mL to about 165 mg/mL; (ii) histidine buffer at a concentration of about 18 mmol/L to about 22 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 105 mmol/L to 135 mmol/L; (iv) polysorbate 80 at a concentration of about 0.01-0.05% (w/v) , and (v) a pH of about 5.6 to 5.8, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of 180 mg/mL to 220 mg/mL; (ii) histidine buffer at a concentration of 18 mmol/L to 22 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of 105 mmol/L to 135 mmol/L; (iv) polysorbate 80 at a concentration of 0.036% (w/v) to 0.044% (w/v) ; and (v) a pH of 5.6 to 5.8, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 200 mg/mL; (ii) histidine buffer at a concentration of about 20 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 120 mmol/L; (iv) polysorbate 80 at a concentration of about 0.04% (w/v) ; and (v) a pH of about 5.7, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of 180 mg/mL to 220 mg/mL; (ii) histidine buffer at a concentration of 18 mmol/L to 22 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of 105 mmol/L to 135 mmol/L; (iv) polysorbate 80 at a concentration of 0.018% (w/v) to 0.022% (w/v) ; and (v) a pH of 5.6 to 5.8, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 200 mg/mL; (ii) histidine buffer at a concentration of about 20 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 120 mmol/L; (iv) polysorbate 80 at a concentration of about 0.02% (w/v) ; and (v) a pH of about 5.7, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of 135 mg/mL to 165 mg/mL; (ii) histidine buffer at a concentration of 18 mmol/L to 22 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of 115 mmol/L to 145 mmol/L; (iv) polysorbate 80 at a concentration of 0.018% (w/v) to 0.022% (w/v) ; and (v) a pH of 5.6 to 5.8, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain C
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 150 mg/mL; (ii) histidine buffer at a concentration of about 20 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 130 mmol/L; (iv) polysorbate 80 at a concentration of about 0.02% (w/v) ; and (v) a pH of about 5.7, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of 135 mg/mL to 165 mg/mL; (ii) histidine buffer at a concentration of 18 mmol/L to 22 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of 105 mmol/L to 135 mmol/L; (iv) polysorbate 80 at a concentration of 0.036% (w/v) to 0.044% (w/v) ; and (v) a pH of 5.6 to 5.8, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain C
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 150 mg/mL; (ii) histidine buffer at a concentration of about 20 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 120 mmol/L; (iv) polysorbate 80 at a concentration of about 0.04% (w/v) ; and (v) a pH of about 5.7, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of 180 mg/mL to 220 mg/mL; (ii) histidine buffer at a concentration of 18 mmol/L to 22 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of 105 mmol/L to 135 mmol/L; (iv) polysorbate 80 at a concentration of 0.027% (w/v) to 0.033% (w/v) ; and (v) a pH of 5.6 to 5.8, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 200 mg/mL; (ii) histidine buffer at a concentration of about 20 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 120 mmol/L; (iv) polysorbate 80 at a concentration of about 0.03% (w/v) ; and (v) a pH of about 5.7, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of 135 mg/mL to 165 mg/mL; (ii) histidine buffer at a concentration of 18 mmol/L to 22 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of 105 mmol/L to 135 mmol/L; (iv) polysorbate 80 at a concentration of 0.027% (w/v) to 0.033% (w/v) ; and (v) a pH of 5.6 to 5.8, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain C
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 150 mg/mL; (ii) histidine buffer at a concentration of about 20 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 120 mmol/L; (iv) polysorbate 80 at a concentration of about 0.03% (w/v) ; and (v) a pH of about 5.7, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 150 mg/mL; (ii) histidine buffer at a concentration of about 20 mmol/L; (iii) arginine, or a pharmaceutically acceptable salt thereof, at a concentration of about 120 mmol/L; (iv) polysorbate 80 at a concentration of about 0.02% (w/v) ; and (v) a pH of about 5.7, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of 180 mg/mL to 220 mg/mL; (ii) histidine buffer at a concentration of 18 mmol/L to 22 mmol/L; (iii) arginine hydrochloride at a concentration of 105 mmol/L to 135 mmol/L; (iv) polysorbate 80 at a concentration of 0.036% (w/v) to 0.044% (w/v) ; and (v) a pH of 5.6 to 5.8, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 200 mg/mL; (ii) histidine buffer at a concentration of about 20 mmol/L; (iii) arginine hydrochloride at a concentration of about 120 mmol/L; (iv) polysorbate 80 at a concentration of about 0.04% (w/v) ; and (v) a pH of about 5.7, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain CDRl, CDR
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of 180 mg/mL to 220 mg/mL; (ii) histidine buffer at a concentration of 18 mmol/L to 22 mmol/L; (iii) arginine hydrochloride at a concentration of 105 mmol/L to 135 mmol/L; (iv) polysorbate 80 at a concentration of 0.018% (w/v) to 0.022% (w/v) ; and (v) a pH of 5.6 to 5.8, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 200 mg/mL; (ii) histidine buffer at a concentration of about 20 mmol/L; (iii) arginine hydrochloride at a concentration of about 120 mmol/L; (iv) polysorbate 80 at a concentration of about 0.02% (w/v) ; and (v) a pH of about 5.7, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain CDRl, CDR
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of 135 mg/mL to 165 mg/mL; (ii) histidine buffer at a concentration of 18 mmol/L to 22 mmol/L; (iii) arginine hydrochloride at a concentration of 117 mmol/L to 143 mmol/L; (iv) polysorbate 80 at a concentration of 0.018% (w/v) to 0.022% (w/v) ; and (v) a pH of 5.6 to 5.8, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 150 mg/mL; (ii) histidine buffer at a concentration of about 20 mmol/L; (iii) arginine hydrochloride at a concentration of about 130 mmol/L; (iv) polysorbate 80 at a concentration of about 0.02% (w/v) ; and (v) a pH of about 5.7, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain CDRl, CDR
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of 135 mg/mL to 165 mg/mL; (ii) histidine buffer at a concentration of 18 mmol/L to 22 mmol/L; (iii) arginine hydrochloride at a concentration of 105 mmol/L to 135 mmol/L; (iv) polysorbate 80 at a concentration of 0.036% (w/v) to 0.044% (w/v) ; and (v) a pH of 5.6 to 5.8, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 150 mg/mL; (ii) histidine buffer at a concentration of about 20 mmol/L; (iii) arginine hydrochloride at a concentration of about 120 mmol/L; (iv) polysorbate 80 at a concentration of about 0.04% (w/v) ; and (v) a pH of about 5.7, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain CDRl, CDR
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of 180 mg/mL to 220 mg/mL; (ii) histidine buffer at a concentration of 18 mmol/L to 22 mmol/L; (iii) arginine hydrochloride at a concentration of 105 mmol/L to 135 mmol/L; (iv) polysorbate 80 at a concentration of 0.027% (w/v) to 0.033% (w/v) ; and (v) a pH of 5.6 to 5.8, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 200 mg/mL; (ii) histidine buffer at a concentration of about 20 mmol/L; (iii) arginine hydrochloride at a concentration of about 120 mmol/L; (iv) polysorbate 80 at a concentration of about 0.03% (w/v) ; and (v) a pH of about 5.7, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain CDRl, CDR
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of 135 mg/mL to 165 mg/mL; (ii) histidine buffer at a concentration of 18 mmol/L to 22 mmol/L; (iii) arginine hydrochloride at a concentration of 105 mmol/L to 135 mmol/L; (iv) polysorbate 80 at a concentration of 0.027% (w/v) to 0.033% (w/v) ; and (v) a pH of 5.6 to 5.8, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 150 mg/mL; (ii) histidine buffer at a concentration of about 20 mmol/L; (iii) arginine hydrochloride at a concentration of about 120 mmol/L; (iv) polysorbate 80 at a concentration of about 0.03% (w/v) ; and (v) a pH of about 5.7, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain CDRl, CDR
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 150 mg/mL; (ii) histidine buffer at a concentration of about 20 mmol/L; (iii) arginine hydrochloride at a concentration of about 120 mmol/L; (iv) polysorbate 80 at a concentration of about 0.02% (w/v) ; and (v) a pH of about 5.7, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (a) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8, and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; and (b) a light chain variable region comprising light chain CDRl, CDR
  • a pharmaceutical composition comprising: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) a pharmaceutically acceptable buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (i) a heavy chain variable region comprising heavy chain CDRl, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 7; the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 8; and the heavy chain CDR3 sequence has the amino acid sequence of SEQ ID NO: 9; or variants of any of the foregoing; and (ii) a light chain variable region comprising light chain CDR1, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence has the amino acid sequence SEQ ID NO: 10; the light chain CDR2 sequence has the amino acid sequence of SEQ ID NO: 11; and the light chain CDR3 sequence has the
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%identical to the sequence of SEQ ID NO: 5.
  • the pharmaceutical composition comprises the anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%identical to the sequence of SEQ ID NO: 5, provided that the heavy chain polypeptide comprises the amino acid sequences of SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 90%identical to the sequence of SEQ ID NO: 5.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 91%identical to the sequence of SEQ ID NO: 5.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 92%identical to the sequence of SEQ ID NO: 5.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 93%identical to the sequence of SEQ ID NO: 5.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 94%identical to the sequence of SEQ ID NO: 5.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 95%identical to the sequence of SEQ ID NO: 5.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 96%identical to the sequence of SEQ ID NO: 5.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 97%identical to the sequence of SEQ ID NO: 5.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 98%identical to the sequence of SEQ ID NO: 5.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 99%identical to the sequence of SEQ ID NO: 5.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 90%identical to the sequence of SEQ ID NO: 5, provided that the heavy chain polypeptide comprises the amino acid sequences of SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 91%identical to the sequence of SEQ ID NO: 5, provided that the heavy chain polypeptide comprises the amino acid sequences of SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 92%identical to the sequence of SEQ ID NO: 5, provided that the heavy chain polypeptide comprises the amino acid sequences of SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 93%identical to the sequence of SEQ ID NO: 5, provided that the heavy chain polypeptide comprises the amino acid sequences of SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 94%identical to the sequence of SEQ ID NO: 5, provided that the heavy chain polypeptide comprises the amino acid sequences of SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 95%identical to the sequence of SEQ ID NO: 5, provided that the heavy chain polypeptide comprises the amino acid sequences of SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 96%identical to the sequence of SEQ ID NO: 5, provided that the heavy chain polypeptide comprises the amino acid sequences of SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 97%identical to the sequence of SEQ ID NO: 5, provided that the heavy chain polypeptide comprises the amino acid sequences of SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 98%identical to the sequence of SEQ ID NO: 5, provided that the heavy chain polypeptide comprises the amino acid sequences of SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence that is at least 99%identical to the sequence of SEQ ID NO: 5, provided that the heavy chain polypeptide comprises the amino acid sequences of SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%identical to the sequence of SEQ ID NO: 6.
  • the pharmaceutical composition comprises the anti-TSLP-R antibody, or antigen-binding fragment thereof, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%identical to the sequence of SEQ ID NO: 6, provided that the light chain polypeptide comprises the amino acid sequences of SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 90%identical to the sequence of SEQ ID NO: 6.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 91%identical to the sequence of SEQ ID NO: 6.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 92%identical to the sequence of SEQ ID NO: 6.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 93%identical to the sequence of SEQ ID NO: 6.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 94%identical to the sequence of SEQ ID NO: 6.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 95%identical to the sequence of SEQ ID NO: 6.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 96%identical to the sequence of SEQ ID NO: 6.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 97%identical to the sequence of SEQ ID NO: 6.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 98%identical to the sequence of SEQ ID NO: 6.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 99%identical to the sequence of SEQ ID NO: 6.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 90%identical to the sequence of SEQ ID NO: 6, provided that the light chain polypeptide comprises the amino acid sequences of SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 91%identical to the sequence of SEQ ID NO: 6, provided that the light chain polypeptide comprises the amino acid sequences of SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 92%identical to the sequence of SEQ ID NO: 6, provided that the light chain polypeptide comprises the amino acid sequences of SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 93%identical to the sequence of SEQ ID NO: 6, provided that the light chain polypeptide comprises the amino acid sequences of SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 94%identical to the sequence of SEQ ID NO: 6, provided that the light chain polypeptide comprises the amino acid sequences of SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 95%identical to the sequence of SEQ ID NO: 6, provided that the light chain polypeptide comprises the amino acid sequences of SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 96%identical to the sequence of SEQ ID NO: 6, provided that the light chain polypeptide comprises the amino acid sequences of SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 97%identical to the sequence of SEQ ID NO: 6, provided that the light chain polypeptide comprises the amino acid sequences of SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 98%identical to the sequence of SEQ ID NO: 6, provided that the light chain polypeptide comprises the amino acid sequences of SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence that is at least 99%identical to the sequence of SEQ ID NO: 6, provided that the light chain polypeptide comprises the amino acid sequences of SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (i) a variable heavy chain polypeptide having a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%identical to the sequence of SEQ ID NO: 5; and (ii) a variable light chain polypeptide having a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%identical to the sequence of SEQ ID NO: 6.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (i) a variable heavy chain polypeptide having a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%identical to the sequence of SEQ ID NO: 5, provided that the heavy chain polypeptide comprises the amino acid sequences of SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9; and (ii) a variable light chain polypeptide having a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%identical to the sequence of SEQ ID NO: 6, provided that the light chain polypeptide comprises the amino acid sequences of SEQ ID NO: 10, SEQ ID NO:
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable heavy chain polypeptide having a sequence of SEQ ID NO: 5.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises a variable light chain polypeptide having a sequence of SEQ ID NO: 6.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the anti-TSLP-R antibody, or antigen-binding fragment thereof, comprises: (i) a variable heavy chain polypeptide having a sequence of SEQ ID NO: 5; and (ii) a variable light chain polypeptide having a sequence of SEQ ID NO: 6.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the concentration of the antibody, or antigen-binding fragment thereof, is present at a concentration from about 1 mg/mL to about 300 mg/mL, from about 50 mg/mL to about 250 mg/mL, from about 100 mg/mL to about 200 mg/mL, or from about 150 mg/mL to about 200 mg/mL.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the concentration of the antibody, or antigen-binding fragment thereof, is present at a concentration from about 1 mg/mL to about 300 mg/mL.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the concentration of the antibody, or antigen-binding fragment thereof, is present at a concentration from about 50 mg/mL to about 250 mg/mL.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the concentration of the antibody, or antigen-binding fragment thereof, is present at a concentration from about 100 mg/mL to about 200 mg/mL.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the concentration of the antibody, or antigen-binding fragment thereof, is present at a concentration from about 150 mg/mL to about 200 mg/mL.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the concentration of the antibody, or antigen-binding fragment thereof, is present at a concentration from about 25 mg/mL, about 50 mg/mL, about 100 mg/mL, about 125 mg/mL, about 150 mg/mL, about 175 mg/mL, about 200 mg/mL, about 225 mg/mL, about 250 mg/mL, about 275 mg/mL, or about 300 mg/mL.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the concentration of the antibody, or antigen-binding fragment thereof, is present at a concentration from about 25 mg/mL.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the concentration of the antibody, or antigen-binding fragment thereof, is present at a concentration from about 50 mg/mL.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the concentration of the antibody, or antigen-binding fragment thereof, is present at a concentration from about 100 mg/mL.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the concentration of the antibody, or antigen-binding fragment thereof, is present at a concentration from about 125 mg/mL.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the concentration of the antibody, or antigen-binding fragment thereof, is present at a concentration from about 150 mg/mL.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the concentration of the antibody, or antigen-binding fragment thereof, is present at a concentration from about 175 mg/mL.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the concentration of the antibody, or antigen-binding fragment thereof, is present at a concentration from about 200 mg/mL.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the concentration of the antibody, or antigen-binding fragment thereof, is present at a concentration from about 225 mg/mL.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the concentration of the antibody, or antigen-binding fragment thereof, is present at a concentration from about 250 mg/mL.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the concentration of the antibody, or antigen-binding fragment thereof, is present at a concentration from about 275 mg/mL.
  • the pharmaceutical composition comprises: an anti-TSLP-R antibody, or antigen-binding fragment thereof; a pharmaceutically acceptable buffer; proline, or a pharmaceutically acceptable salt thereof; and a surfactant, wherein the concentration of the antibody, or antigen-binding fragment thereof, is present at a concentration from about 300 mg/mL.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) a pharmaceutically acceptable buffer at a concentration of about 5 mmol/L to about 100 mmol/L; proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) , wherein the pharmaceutically acceptable buffer is phosphoric acid buffer, citric acid buffer, acetic acid buffer, succinic acid buffer, histidine buffer, phosphate buffer, acetate buffer, citrate buffer, succinate buffer, ascorbic acid buffer, glutamic acid buffer, lactic acid buffer, maleic acid buffer, trometamol buffer, and gluconic acid buffer.
  • the pharmaceutically acceptable buffer is phosphoric acid buffer, citric acid buffer, acetic acid buffer,
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) a pharmaceutically acceptable buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) , wherein the pharmaceutically acceptable buffer is histidine buffer.
  • the histidine buffer is present at a concentration of about 5 mmol/L to about 100 mmol/L, about 5 mmol/L to about 70 mmol/L, about 5 mmol/L to about 60 mmol/L, about 10 mmol/L to about 60 mmol/L, about 10 mmol/L to about 50 mmol/L, about 10 mmol/L to about 40 mmol/L, about 15 mmol/L to about 30 mmol/L, or about 15 mmol/L to about 25 mmol/L.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 700 mmol/L; (iii) proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 60 mmol/L; (iii) proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 10 mmol/L to about 60 mmol/L; (iii) proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 10 mmol/L to about 50 mmol/L; (iii) proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 10 mmol/L to about 40 mmol/L; (iii) proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 15 mmol/L to about 30 mmol/L; (iii) proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 15 mmol/L to about 25mmol; (iii) proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 20 mmol; (iii) proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the proline, or pharmaceutically acceptable salt thereof is present at a concentration of about 1 mmol/L to about 600 mmol/L, about 50 mmol/L to about 300 mmol/L, about 100 mmol/L to about 250 mmol/L, about 120 mmol/L to about 200 mmol/L, about 130 mmol/L to about 200 mmol/L, about 140 mmol/L to about 200 mmol/L, about 150 mmol/L to about 200 mmol/L, about 160 mmol/L to about 200 mmol/L, about 170 mmol/L to about 200 mmol/L, or about 180 mmol/L to about 200 mmol/L.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 1 mmol/L to about 600 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 50 mmol/L to about 300 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L to about 250 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 120 mmol/L to about 200 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 140 mmol/L to about 200 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 150 mmol/L to about 200 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 160 mmol/L to about 200 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 170 mmol/L to about 200 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 180 mmol/L to about 200 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 110 mmol/L to about 130 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the proline, or pharmaceutically acceptable salt thereof is present at a concentration of about 50 mmol/L, about 75 mmol/L, about 100 mmol/L, about 110 mmol/L, about 120 mmol/L, about 130 mmol/L, about 140 mmol/L, about 150 mmol/L, about 160 mmol/L, about 170 mmol/L, about 180 mmol/L, about 190 mmol/L, about 200 mmol/L, about 250 mmol/L, or about 300 mmol/L.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 50 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 75 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 100 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 110 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 120 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 130 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 140 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 150 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 160 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 170 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 180 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 190 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 200 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 250 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) proline, or a pharmaceutically acceptable salt thereof, at a concentration of about 300 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the proline, or a pharmaceutically acceptable salt thereof is proline hydrochloride.
  • the proline hydrochloride is present at a concentration of about 50 mmol/L, about 75 mmol/L, about 100 mmol/L, about 120 mmol/L, about 130 mmol/L, about 140 mmol/L, about 150 mmol/L, about 160 mmol/L, about 170 mmol/L, about 180 mmol/L, about 190 mmol/L, about 200 mmol/L, about 250 mmol/L, or about 300 mmol/L.
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) proline hydrochloride at a concentration of about 50 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) proline hydrochloride at a concentration of about 75 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) proline hydrochloride at a concentration of about 100 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) proline hydrochloride at a concentration of about 120 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) proline hydrochloride at a concentration of about 130 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) proline hydrochloride at a concentration of about 140 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) proline hydrochloride at a concentration of about 150 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) proline hydrochloride at a concentration of about 160 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) proline hydrochloride at a concentration of about 170 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) proline hydrochloride at a concentration of about 180 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) proline hydrochloride at a concentration of about 190 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) proline hydrochloride at a concentration of about 200 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) proline hydrochloride at a concentration of about 250 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the pharmaceutical composition comprises: (i) an anti-TSLP-R antibody, or antigen-binding fragment thereof, at a concentration of about 1 mg/mL to about 300 mg/mL; (ii) histidine buffer at a concentration of about 5 mmol/L to about 100 mmol/L; (iii) proline hydrochloride at a concentration of about 300 mmol/L; and (iv) a surfactant at a concentration of about 0.001%to about 1% (w/v) .
  • the surfactant is a polysorbate or a poloxamer.
  • the polysorbate is polysorbate 20 (PS20) or polysorbate 80 (PS80) .

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des compositions pharmaceutiques d'anticorps anti-TSLP-R, et leurs utilisations.
PCT/CN2022/130252 2020-06-16 2022-11-07 Compositions pharmaceutiques comprenant des anticorps anti-récepteur tslp humain et leurs procédés d'utilisation Ceased WO2024098180A1 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
PCT/CN2022/130252 WO2024098180A1 (fr) 2022-11-07 2022-11-07 Compositions pharmaceutiques comprenant des anticorps anti-récepteur tslp humain et leurs procédés d'utilisation
ARP230102991A AR130993A1 (es) 2020-06-16 2023-11-07 Composiciones farmacéuticas que comprenden anticuerpos anti-receptor tslp humano y métodos de uso de las mismas
KR1020257018074A KR20250120995A (ko) 2022-11-07 2023-11-07 항-인간 tslp 수용체 항체를 포함하는 약제학적 조성물 및 이를 사용하는 방법
AU2023375895A AU2023375895A1 (en) 2022-11-07 2023-11-07 Pharmaceutical compositions comprising anti-human tslp receptor antibodies and methods of using the same
US18/503,245 US12150991B2 (en) 2022-11-07 2023-11-07 Pharmaceutical compositions comprising anti-human TSLP receptor antibodies and methods of using the same
EP23889566.8A EP4615502A1 (fr) 2022-11-07 2023-11-07 Compositions pharmaceutiques comprenant des anticorps anti-récepteur de la tslp humaine et procédés d'utilisation de celles-ci
TW112142818A TW202432601A (zh) 2022-11-07 2023-11-07 包含抗人類ｔｓｌｐ受體抗體之醫藥組成物及其使用方法
JP2025526206A JP2025538151A (ja) 2022-11-07 2023-11-07 抗ヒトｔｓｌｐ受容体抗体を含む医薬組成物及びその使用方法
PCT/US2023/078873 WO2024102675A1 (fr) 2022-11-07 2023-11-07 Compositions pharmaceutiques comprenant des anticorps anti-récepteur de la tslp humaine et procédés d'utilisation de celles-ci
CN202380090775.XA CN120548195A (zh) 2022-11-07 2023-11-07 包含抗人类tslp受体抗体的药物组合物和其使用方法
US18/916,566 US20250064929A1 (en) 2022-11-07 2024-10-15 Pharmaceutical compositions comprising anti-human tslp receptor antibodies and methods of using the same
IL320555A IL320555A (en) 2022-11-07 2025-04-29 Pharmaceutical compositions containing anti-human TSLP receptor antibodies and methods of using them
MX2025005271A MX2025005271A (es) 2022-11-07 2025-05-06 Composiciones farmaceuticas que comprenden anticuerpos anti-receptor tslp humano y metodos de uso de las mismas

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2022/130252 WO2024098180A1 (fr) 2022-11-07 2022-11-07 Compositions pharmaceutiques comprenant des anticorps anti-récepteur tslp humain et leurs procédés d'utilisation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US18/503,245 Continuation-In-Part US12150991B2 (en) 2022-11-07 2023-11-07 Pharmaceutical compositions comprising anti-human TSLP receptor antibodies and methods of using the same

Publications (1)

Publication Number Publication Date
WO2024098180A1 true WO2024098180A1 (fr) 2024-05-16

Family

ID=91031673

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/130252 Ceased WO2024098180A1 (fr) 2020-06-16 2022-11-07 Compositions pharmaceutiques comprenant des anticorps anti-récepteur tslp humain et leurs procédés d'utilisation

Country Status (1)

Country Link
WO (1) WO2024098180A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102159204A (zh) * 2008-09-19 2011-08-17 辉瑞公司 稳定的液体抗体制剂
WO2014068021A1 (fr) * 2012-10-31 2014-05-08 Takeda Gmbh Procédé de préparation d'une formulation liquide à concentration élevée d'un anticorps
CN108430507A (zh) * 2015-12-18 2018-08-21 安斯泰来制药株式会社 含有抗人tslp受体抗体的药物组合物
WO2018193471A1 (fr) * 2017-04-18 2018-10-25 Dr. Reddy's Laboratories Limited Composition pharmaceutique liquide stable
WO2019198100A1 (fr) * 2018-04-10 2019-10-17 Dr. Reddy's Laboratories Limited Formulation d'anticorps
CN112292146A (zh) * 2018-04-10 2021-01-29 雷迪博士实验室有限公司 治疗性抗体的稳定的制剂

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102159204A (zh) * 2008-09-19 2011-08-17 辉瑞公司 稳定的液体抗体制剂
WO2014068021A1 (fr) * 2012-10-31 2014-05-08 Takeda Gmbh Procédé de préparation d'une formulation liquide à concentration élevée d'un anticorps
CN108430507A (zh) * 2015-12-18 2018-08-21 安斯泰来制药株式会社 含有抗人tslp受体抗体的药物组合物
WO2018193471A1 (fr) * 2017-04-18 2018-10-25 Dr. Reddy's Laboratories Limited Composition pharmaceutique liquide stable
WO2019198100A1 (fr) * 2018-04-10 2019-10-17 Dr. Reddy's Laboratories Limited Formulation d'anticorps
CN112292146A (zh) * 2018-04-10 2021-01-29 雷迪博士实验室有限公司 治疗性抗体的稳定的制剂

Similar Documents

Publication Publication Date Title
US12054555B2 (en) Anti-BAFFR antibody formulations and methods of use thereof
US11612659B2 (en) Anti-CD40 antibody formulation delivery device
US10689451B2 (en) Anti-BAFFR antibody therapeutic formulations
CN111315411B (zh) 高浓度抗c5抗体制剂
US20160279258A1 (en) Antibody-drug conjugate lyophilised formulation
US20210087267A1 (en) Liquid formulations of anti-cd200 antibodies
US20240277839A1 (en) High concentration formulation and uses thereof
WO2024098180A1 (fr) Compositions pharmaceutiques comprenant des anticorps anti-récepteur tslp humain et leurs procédés d'utilisation
US12150991B2 (en) Pharmaceutical compositions comprising anti-human TSLP receptor antibodies and methods of using the same
CN114786717A (zh) 稳定的水性抗-tfpi抗体制剂
US20250282882A1 (en) Pharmaceutical formulation comprising anti-ox40 monoclonal antibody
WO2025137473A1 (fr) Compositions pharmaceutiques comprenant des anticorps pour le traitement de troubles médiés par c1s et leurs procédés d'utilisation
WO2025129535A1 (fr) Compositions pharmaceutiques comprenant des anticorps pour le traitement de troubles médiés par c1s et leurs méthodes d'utilisation
HK40023281A (en) Lyophilised and aqueous anti-cd40 antibody formulations
HK1202050B (en) Lyophilised and aqueous anti-cd40 antibody formulations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22964659

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22964659

Country of ref document: EP

Kind code of ref document: A1